Compounds > mirtazapine
Page last updated: 2024-09-20

mirtazapine

Description

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4205
CHEMBL ID654
CHEBI ID6950
SCHEMBL ID35408
MeSH IDM0107850

Synonyms (156)

Synonym
AC-15480
HMS3268F21
HMS3394H03
BRD-A64977602-001-01-9
pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
org-3770
remergon
remeron soltab
pyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
zispin
mirtazapina [inn-spanish]
6-azamianserin
remergil
me-2040
azamianserin
mirtazapinum [inn-latin]
remeron
1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
org 3770
61337-67-5
2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
mirtazapine, >=98% (hplc)
einecs 288-060-6
(1)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
mirtazipine
mepirzapin
mepirzepine
promyrtil
rexer
NCGC00025346-01
PDSP1_001529
PDSP2_001513
mirtazapinum
CHEBI:6950 ,
mirtazapina
mirtazapine
C07570
85650-52-8
smr000466347
MLS000759460
mepirzapine
DB00370
NCGC00025346-02
D00563
mirtazapine (jan/usp/inn)
remeron (tn)
reflex (tn)
MLS001076676
norset
HMS2052H03
mirataz
mirtazapine anhydrous
avanza
mirtazapin
CHEMBL654 ,
bdbm50115644
2-methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene
(+/-)-12-methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene
L001294
STK711107
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene
EN300-49851
1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
M2151
MLS001424294
dtxsid0023325 ,
cas-61337-67-5
dtxcid503325
tox21_110965
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene
mirtazapine [usan:ban:inn]
mirtazepine
HMS2233K03
CCG-101154
AKOS005530681
BCP9000930
FT-0672414
unii-a051q2099q
smilon
a051q2099q ,
mirtazapine [usan:usp:inn:ban]
FT-0628951
FT-0601544
S2016
gtpl7241
HMS3370B05
HMS3374J01
mirtazapine, (+/-)-
mirtazapine [vandf]
mirtazapine [usp monograph]
mirtazapine [usan]
mirtazapine [orange book]
mirtazapine [ep monograph]
mirtazapine [mi]
mirtazapine [green book]
mirtazapine [inn]
mirtazapine [who-dd]
mirtazapine [usp-rs]
mirtazapine [jan]
1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c]benzazepine
CCG-220556
HY-B0352
MLS006011449
NC00404
SCHEMBL35408
KS-1086
mianserin, 6-aza-
2-methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine
pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (.+/-.)-
1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c](2)benzazepine
AB00698265_08
mfcd00865427
5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
(14br)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
org3770
SR-01000597530-4
sr-01000597530
SR-01000597530-1
mirtazapine, united states pharmacopeia (usp) reference standard
HMS3657M13
mirtazapine for system suitability, european pharmacopoeia (ep) reference standard
mirtazapine, european pharmacopoeia (ep) reference standard
mirtazapine 1.0 mg/ml in methanol
HMS3713P13
SW197784-4
A914630
BCP22244
Q421930
Z905065772
mirtazapine (remeron, avanza)
HMS3677C11
BCP14560
HMS3413C11
BRD-A64977602-001-04-3
2-methyl-1,2,3,4,10,14b-hexahydrobenzo-[c]pyrazino[1,2-a]pyrido[3,2-f]azepine
HMS3884O18
(s)-org3770;(s)-6-azamianserin
NCGC00025346-08
M-130
6 azamianserin
1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine.
5-methyl-2,5,19-triazatetracyclo[13.4.0.0?,?.0?,??]nonadeca-1(15),8,10,12,16,18-hexaene
mirtazapine- bio-x
BM164672
ps11 - mirtazapine/normirtazapine
mirtazapine (usp monograph)
mirtazapina (inn-spanish)
mirtazapinum (inn-latin)
mirtazapine (ep monograph)
2-methyl-1,2,3,4,10,14b-hexahydropyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
mirtazapine (usp-rs)
mirtazapine (usan:usp:inn:ban)
(14brs)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
n06ax11
remeronsoltab
mirtazapine, 1mg/ml in methanol

Research Excerpts

Overview

ExcerptReference
"Mirtazapine (MRT) is a well-known antidepressant that was proven to have anti-inflammatory activity; however, to date, its role has not been investigated in UC."( Abdel-Gaber, SA; Gad, AA; Hafez, HM; Ibrahim, MA; Mohammed Naguib Abdel Hafez, S; Yehia Abdelzaher, W, 2021)
"Mirtazapine (MIRT) is a multi-target antidepressant used in treatment of severe depression with promising efficacy, but also with important side effects, mainly sedation and weight gain. "( Chaves Filho, AJM; Cunha, NL; De Oliveira, GMF; Gadelha Filho, CVJ; Jucá, PM; Macedo, DS; Oliveira, TQ; Soares, MVR; Vasconcelos, SMM; Viana, GA; Vieira, CFX, 2022)
"Mirtazapine is an antidepressant drug that has been proven to possess a cognitive enhancer efficiency. "( Li, R; Ma, M; Wang, Q; Yu, H; Zhang, S, 2022)
"Mirtazapine is an option for treating children and adolescents with functional nausea and nausea associated with functional dyspepsia post-prandial distress syndrome, especially for a select group of patients with concurrent weight loss, anxiety, and insomnia."( Hyman, PE; Iglesias-Escabi, IM; Kleesattel, D; LeBlanc, C; McDaniel, LS; Reuther, E; Santucci, NR, 2022)
"Mirtazapine (MRT) is a tetracyclic antidepressant with poor water solubility (BCS Class II), which was recently approved as a potent drug used to treat severe depression."( Aldeeb, RA; Elnahas, HM; Mahdy, MA; Musallam, AA, 2022)
"Mirtazapine is a tetracyclic anti-depressant with poor water solubility. "( Abbas, M; Chan, SY; Goh, KW; Hamdullah, H; Khan, A; Khuda, F; Ming, LC; Muhammad, S; Mushtaq, M; Naureen, F; Rehman, IU; Shah, SI; Shah, Y, 2022)
"Mirtazapine (MRT) is an atypical antidepressant used to treat severe depression."( Aldeeb, RAE; El-Nahas, HM; Mahdy, MAE; Musallam, AA, 2023)
"Mirtazapine is a Food and Drug Administration-approved atypical antidepressant used off-label for insomnia. "( Hawkins, M, 2023)
"Mirtazapine is a frequently prescribed psychotropic drug for depression in older age. "( Kirk, C; Maidwell-Smith, A, 2023)
"Mirtazapine (MZP) is a central presynaptic α2 receptor antagonist used effectively in treating several neurological disorders."( Alamri, T; Alghamdi, BS; Alharthi, S; Alharthy, SA; Almashjary, MN; Althagafy, HS; Azhari, SA; Farsi, RM; Harakeh, S; Hassanein, EHM; Tabrez, S; Vij, P; Zughaibi, TA, 2023)
"Mirtazapine is an atypical antidepressant with antagonist activity for serotonin and histamine receptors. "( Almishri, W; Davis, RP; Jenne, CN; Swain, MG, 2020)
"Mirtazapine (MTZ) is a noradrenergic and specific serotonergic antidepressant. "( Aoyama, T; Katsuyama, M; Kawano, Y; Mano, Y; Mori, A; Nagata, M; Nakamatsu, S; Negishi, K; Obana, M; Sakamoto, N; Shimada, S, 2021)
"Mirtazapine is an antidepressant drug, used to treat depression, but also, in some specific conditions, to treat obsessive-compulsive disorder and anxiety. "( Ameline, A; Kintz, P; Raul, JS, 2021)
"Mirtazapine is a commonly used drug indicated for the treatment of severe depression. "( Ch'ng, CL; Haboubi, H; Lloyd, A; Thomas, E; Williams, N, 2017)
"Mirtazapine is an antidepressant implicated in reducing behavioral alterations induced by drugs of abuse."( Barbosa-Méndez, S; Flores-Zamora, A; Jurado, N; Matus-Ortega, M; Salazar-Juárez, A, 2017)
"Mirtazapine is a noradrenergic and specific serotoninergic antidepressant agent that stimulates norepinephrine and serotonin release while also blocking serotonin receptors (5-HT2 and 5-HT3). "( Avato, FM; Brandolini, F; Gaudio, RM; Groppi, A; Morini, L; Talarico, A; Vignali, C, 2017)
"Mirtazapine is an antidepressant with prominent antioxidant effects. "( Abdelsalam, NM; El-Sayad, ME; El-Sisi, AE, 2017)
"Mirtazapine is an antagonist of α"( Barbosa-Méndez, S; Salazar-Juárez, A, 2018)
"Mirtazapine is a widely-used antidepressant with a multimodal mechanism of action."( Papazisis, G; Siafis, S; Tzachanis, D, 2018)
"Mirtazapine is an antidepressant drug that when taken in addition to an antipsychotic may offer some benefit for negative symptoms."( Perry, LA; Ramson, D; Stricklin, S, 2018)
"Mirtazapine (Remeron™) is an antidepressant indicated for the treatment of episodes of major depression, which was originally approved in 1994 without a thorough QT study."( Chain, A; Gurkan, S; Gutstein, DE; Liu, F, 2019)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant; its pharmacological profile indicates a low risk for dopaminergic adverse effects. "( Hirabayashi, N; Nakagome, K; Okazaki, M; Satake, N; Takano, H; Yamada, M; Yamada, Y, 2018)
"Mirtazapine is a promising candidate to pursue, with definitive randomized controlled trials required to determine its efficacy and safety in this setting."( Bajwah, S; Etkind, SN; Higginson, IJ; Jolley, CJ; Lovell, N; Maddocks, M; Wilcock, A, 2019)
"Mirtazapine is an antidepressant, which is used primarily in the treatment of depression and other anxiety disorders."( Awny, MM; Fekry, E; Makary, S; Rahman, AA, 2019)
"Mirtazapine is an effective appetite stimulant and anti-emetic for cats with CKD and could be a useful adjunct to the nutritional management of these cases."( Lunn, KF; Quimby, JM, 2013)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant. "( Chen, JD; Lei, Y; Song, J; Xu, X; Yin, J, 2014)
"Mirtazapine is a commonly prescribed antidepressant drug, which is also metabolized through and may modulate the CYP4502D6 pathway leading to altered metabolism of propafenone and possible adverse effects."( Aryal, SR; Khan, MA; Rajpurohit, N; Stys, AT; Stys, TP, 2014)
"Mirtazapine is an antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission. "( Jang, JH; Kim, DK; Lee, SY; Myung, W; Yoon, H, 2014)
"Mirtazapine is an a2A antagonist and mixed 5-HT2/5-HT3 antagonist that has been proposed as a potential treatment for obstructive sleep apnea (OSA). "( Buchanan, PR; Crompton, R; Desai, AV; Gendreau, RM; Grunstein, RR; Kranzler, J; Marshall, NS; Melehan, KL; Rao, SG; Wong, KK; Yee, BJ; Zack, N, 2008)
"Mirtazapine is a racemic antidepressant with a multireceptor profile. "( Ashkanian, M; Audrain, H; Bender, D; Hall, H; Hansen, SB; Jakobsen, S; Minuzzi, L; Rosenberg, R; Smith, DF; Stork, BS, 2008)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant. "( Andrzejczak, D; Kocon, K; Zieba, R, 2008)
"Mirtazapine is a new antidepressant that selectively blocks 5-HT(2) and 5-HT(3) receptors."( Chang, FL; Ho, ST; Huang, ST; Lee, CH; Sheen, MJ; Tsung, YC, 2008)
"Mirtazapine is a clinically established antidepressant with complex actions involving blockade of noradrenaline alpha(2)-adrenoceptors as well as a number of 5-HT receptor subtypes."( Arnone, D; Cowen, PJ; Harmer, CJ; Horder, J, 2009)
"Mirtazapine is a tetracyclic antidepressant drug available as a racemic mixture of S(+)- and R(-)-mirtazapine. "( Ahlner, J; Baumann, P; Bengtsson, F; Dahl, ML; Jonzier-Perey, M; Lind, AB; Powell Golay, K; Reis, M, 2009)
"Mirtazapine is a pharmacologically unique agent among antidepressant drugs."( Howland, RH, 2008)
"Mirtazapine is an antidepressant with a unique mechanism of action and has been categorized as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). "( Imanishi, T; Inoue, T; Kakui, N; Kitamura, K; Koyama, T; Yamauchi, M; Yokoyama, F, 2009)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant(NaSSA). "( Ito, T; Okubo, Y; Roth, A, 2009)
"Mirtazapine is an antagonist of alpha2, 5-HT2A, and 5-HT2C receptors and promotes releases of NA, 5-HT, and DA."( Nakayama, K, 2009)
"Mirtazapine is an effective antidepressant with unique and special mechanism of action characterized by high response and remission rates, relatively early onest of action and favourable side-effect profile. "( Purebl, G; Rihmer, Z, 2009)
"Mirtazapine is a promising agent for the treatment of CRCA."( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010)
"Mirtazapine is an established antidepressant with well-documented efficacy demonstrated in controlled clinical trials. "( Adomaitiene, V; Danileviciūte, V; Fokas, V; Gumbrevicius, G; Sveikata, A; Sveikatiene, R, 2009)
"Mirtazapine is a novel antidepressant and a potent 5-HT(2) receptor antagonistic."( Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2010)
"Mirtazapine is a clinically established antidepressant with different pharmacological actions from monoamine reuptake inhibitors, involving blockade of noradrenaline α(2)-adrenoceptors and multiple 5-HT receptor subtypes."( Cowen, PJ; Harmer, CJ; Norbury, R; Rawlings, NB, 2010)
"Mirtazapine (Remeron) is an atypical antidepressant that antagonizes activated norepinephrine(α)₂, histamine₁ serotonin (5-HT)₂(A/C), and 5-HT₃ receptors."( Graves, SM; Napier, TC, 2011)
"Mirtazapine is a new antidepressant used in last years, however experience with it during pregnancy is unsatisfactory on the present. "( Hubickova, L; Kostalova, J; Manakova, E; Zemanova, Z, 2010)
"Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors."( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011)
"Mirtazapine is a novel antidepressant and a potent 5-HT(2A) receptor antagonist."( Iwamura, T; Kasai, M; Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2011)
"Mirtazapine is a medication unlike other agents used for depression both in its mechanism of action as well as its side effects. "( Benjamin, S; Doraiswamy, PM, 2011)
"Mirtazapine (MRT) is a human antidepressant drug mainly metabolised by the cytochrome P450 enzyme system to 8-OH mirtazapine (8-OH) and dimetilmirtazapine (DMR). "( Giorgi, M; Yun, H, 2012)
"Mirtazapine (MTZ) is an antidepressant, which is considered to enhance noradrenergic and serotonergic neurotransmission via antagonistic action at central α2-adrenergic autoreceptors and heteroreceptors."( Enomoto, T; Hirayama, S; Horiuchi, H; Ikegami, D; Inada, E; Iseki, M; Nagase, H; Nakahara, K; Narita, M; Sakai, H; Suzuki, T; Torigoe, K; Yamashita, A; Yanase, M, 2012)
"Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea."( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012)
"Mirtazapine is a tetracyclic antidepressant which works relating to noradrenergic and elective serotoninergic receptors. "( Miao, J; Xiang, J; Xu, N; Yu, Q; Zheng, L, 2012)
"Mirtazapine is an atypical antidepressant receiving attention for substance abuse pharmacotherapy, and its action includes alterations in monoaminergic transmission."( Graves, SM; Napier, TC; Persons, AL; Riddle, JL, 2012)
"Mirtazapine is a commonly used antidepressant with a well-known ability to produce sedation. "( Dolder, CR; Iler, CA; Nelson, MH, 2012)
"Mirtazapine is an antidepressant with sleep-promoting effects significantly greater than placebo, similar to tricyclic antidepressants, and somewhat similar to selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. "( Dolder, CR; Iler, CA; Nelson, MH, 2012)
"Mirtazapine (Remeron®) is a unique FDA-approved antidepressant, with negligible affinity for reuptake proteins, indirectly augments monoamine transmission presumably through antagonist activity at multiple receptors including the norepinephrine (NE)(α2), and serotonin (5-HT)(2A/C) receptors."( Graves, SM; Napier, TC; Rafeyan, R; Watts, J, 2012)
"Mirtazapine is an antidepressant approved for the treatment of major depressive disorder. "( Avena-Woods, C; Hilas, O, 2012)
"Mirtazapine is a new centrally acting noradrenergic and specific serotonin antidepressant, with an active demethyl metabolite. "( Begaud, B; Jarry, C; Matoga, M; Pehourcq, F; Romiguieres, T, 2002)
"Mirtazapine acts as an antagonist at presynaptic alpha(2)-receptors and at postsynaptic 5-hydroxytryptamine (5-HT)(2), 5-HT(3) and histamine H(1) receptors."( Baghai, T; Ella, R; Eser, D; Möller, HJ; Padberg, F; Rupprecht, R; Schüle, C; Zwanzger, P, 2003)
"Mirtazapine is a novel antidepressant that increases the synaptic concentrations of both noradrenaline and serotonin; moreover, it is an antagonist at 5-HT(2C) receptors, whose activation is considered to be responsible for some typical effects of serotonin on the ejaculation process (retardation of ejaculation, anorgasmia)."( Benelli, A; Bertolini, A; Frigeri, C; Genedani, S, 2004)
"Mirtazapine is a novel antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission. "( Härtter, S; Hiemke, C; Shams, M, 2004)
"Mirtazapine is a safe medication without serious side effects and may be an effective alternative for the treatment of nocturnal pruritus."( Hundley, JL; Yosipovitch, G, 2004)
"Mirtazapine is a relatively new so-called noradrenergic and specific serotonergic antidepressant, which is more specific and therefore generally better tolerated."( Bendtsen, L; Jensen, R, 2004)
"Mirtazapine is an antidepressant that acts specifically on noradrenergic and sertonergic receptors. "( Baumann, P; Cochard, N; Eap, CB; Jonzier-Perey, M; Paus, E, 2004)
"Mirtazapine appeared to be an effective and well-tolerated treatment for PTSD in Korean veterans."( Chung, MY; Jun, EM; Jun, YJ; Kim, SS; Kim, WC; Min, KH, 2004)
"Mirtazapine is a recent noradrenergic and specific serotonergic antidepressant drug. "( Bartoletti, C; Fanali, S; Mandrioli, R; Pucci, V; Raggi, MA; Sabbioni, C, 2004)
"Mirtazapine is a widely used antidepressant and the aim of this study was to further investigate its antidepressant activity in rats. "( Cassanelli, A; Gambarana, C; Raone, A; Rauggi, R; Tagliamonte, A, 2005)
"The mirtazapine dose is a weak predictor of mirtazapine plasma concentrations. "( Dragicevic, A; Frahnert, C; Grasmäder, K; Hiemke, C; Kühn, KU; Maier, W; Rao, ML; Verwohlt, PL; von Widdern, O; Zobel, A, 2005)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant, which blocks the 5HT3 receptor, leading to an antiemetic effect."( Breda, MF; Novaretti, TM; Pereira, PG; Pilon, B; Teixeira, FV, 2005)
"Mirtazapine seems to be an effective treatment modality in patients with severe hyperemesis gravidarum who do not respond to conventional anti-emesis treatment regimens. "( Dogan, E; Gol, M; Guclu, S; Saygili, U, 2005)
"Mirtazapine appears to be an effective agent in the treatment of social phobia in women and in the improvement of their health-related quality of life."( Anvar, J; Bachler, E; Egger, C; Fartacek, R; Kaplan, P; Kettler, C; Lahmann, C; Leiberich, PK; Loew, TH; Mitterlehner, F; Muehlbacher, M; Nickel, C; Nickel, MK; Pedrosa Gil, F; Rother, N; Rother, WK; Tritt, K, 2005)
"Mirtazapine is a third-generation antidepressant with a dual mode of action. "( Egger, C; Eichberger, G; Hinterhuber, H; Hofmann, P; Kasper, S; Konstantinidis, A; Mühlbacher, M; Nickel, M; Nimmerrichter, A; Schubert, H; Stuppaeck, C, 2006)
"Mirtazapine is a potent antagonist of central alpha(2) auto- and hetero-adrenergic receptors, as well as an antagonist of 5-HT(2A/2C), 5-HT(3), and histaminergic H(1) postsynaptic receptors. "( Chandra, PS; Chaturvedi, SK; Gupta, A; Prabhu, SC; Ranjan, S, 2006)
"Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants. "( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006)
"Mirtazapine is a mixed noradrenergic serotoninergic antidepressant used as a racemate."( Brockmöller, J; Kirchheiner, J; Meineke, I, 2007)
"Mirtazapine is a comparatively new antidepressant that selectively blocks central alpha2-adrenergic autoreceptors and postsynaptic 5-HT2 and 5-HT3 receptors, causing reduced neuronal norepinephrine and serotonin reuptake. "( Bateman, DN; Good, AM; Waring, WS, 2007)
"Mirtazapine is an antidepressant exhibiting both noradrenergic and serotonergic activity. "( Kayir, H; Sezer, Z; Uzbay, TI; Yilmaz, I, 2007)
"Mirtazapine (Remeron) is a newly approved medication for the treatment of depression. "( Brown, M; LoVecchio, F; Pizon, A; Riley, B, 2008)
"Mirtazapine (MIRT) is an antidepressant with mixed noradrenergic and serotonergic effects in central nervous system. "( Anderson, JJ; Berry, RB; Chou, YL; Davenport, PW; Hayward, LF; Stanley, JT; Vujisic, K, 2008)
"Mirtazapine is a new antidepressant that blocks 5-HT2 and 5-HT3 receptors. "( Chen, CC; Hsu, YW; Hung, YC; Ko, YP; Lao, HC; Lin, CS, 2008)
"Mirtazapine (MTZ) is a new and well-tolerated tricyclic antidepressants with both monoaminergic and opioid properties that might favorably influence pain."( Arnold, P; Deriaz, O; Gobelet, C; Kuntzer, T; Vuadens, P, 2008)
"Mirtazapine augmentation is a good choice for the treatment of SSRI-induced sexual dysfunction, and the results are typically seen later after 4-8 weeks."( Bozkurt, A; Cansever, A; Doruk, A; Karlidere, T; Ozgen, F; Ozmenler, NK; Ozsahin, A; Sutcigil, L; Uzun, O; Yetkin, S, 2008)
"Mirtazapine (Org 3770) is a new antidepressant with prominent alpha 2-adrenergic auto- and heteroreceptor antagonistic properties and no effect on monoamine reuptake. "( de Boer, T, 1996)
"Mirtazapine is a new antidepressant with a unique mode of action: it preferentially blocks the noradrenergic alpha2-auto- and heteroreceptors held responsible for controlling noradrenaline and serotonin release. "( de Boer, T, 1995)
"Mirtazapine is a novel antidepressant with a unique mode of action, which can be best summarized as a noradrenaline and specific serotonin antidepressant. "( Kasper, S, 1995)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety. "( Burrows, GD; Kremer, CM, 1997)
"Mirtazapine is a new antidepressant that falls into the general class of receptor-blocking drugs rather than being an uptake or enzyme inhibitor. "( Nutt, D, 1997)
"Mirtazapine is a new anti-depressant that blocks presynaptic alpha 2-adrenergic receptors and postsynaptic serotonin type 2 and type 3 receptors."( Puzantian, T, 1998)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a novel mode of action that differs from other antidepressants that are currently available. "( Nutt, DJ, 1998)
"Mirtazapine seems to be a safe compound in overdose. "( Holzbach, R; Jahn, H; Mähne, C; Pajonk, FG, 1998)
"Mirtazapine is a new antidepressant with a specific pharmacological profile which is different from all other currently available antidepressants. "( Bailer, U; Kasper, S; Pezawas, L; Praschak-Rieder, N, 1998)
"Mirtazapine is a newer antidepressant that exhibits both noradrenergic and serotonergic activity. "( Hartmann, PM, 1999)
"Mirtazapine is a noradrenergic with specific selective serotoninergic antidepressant."( Aschauer, HN; de Zwaan, M; Kasper, S; Pezawas, L; Stamenkovic, M, 1998)
"Mirtazapine is a novel antidepressant which has a mechanism that involves the enhancement of noradrenergic and serotonergic neurotransmission via blockade of alpha2-adrenergic autoreceptors and heteroreceptors without activity at the serotonin transporter."( Carpenter, LL; Hall, JM; Jocic, Z; Price, LH; Rasmussen, SA, 1999)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) which has predominantly been evaluated in the treatment of major depression. "( Holm, KJ; Markham, A, 1999)
"Mirtazapine is a presynaptic alpha-2 antagonist that has dual action by increasing noradrenergic and serotonergic neurotransmission. "( Barkin, RL; Fawcett, J, 1998)
"Mirtazapine is an atypical antidepressant with alpha 2 adrenergic antagonist and serotonin 5-HT2 and 5-HT3 receptor-blocking activity."( Boyarsky, BK; Haque, W; Hirschfeld, RM; Rouleau, MR, 1999)
"Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants."( Falkai, P, 1999)
"Mirtazapine is a new antidepressant agent which does not inhibit the reuptake of norepinephrine or serotonin but is an antagonist of presynaptic and, presumably, postsynaptic alpha 2-receptors as well as an antagonist of postsynaptic 5-HT2 and 5-HT3-receptors."( Baghai, T; Laakmann, G; Schüle, C; Waldvogel, E, 1999)
"Mirtazapine (Remeron) is a member of the relatively new class of tetracyclic antidepressants. "( Levine, B; Moore, KA; Saki, S; Schames, J; Smialek, JE; Smith, ML, 1999)
"Mirtazapine is a new antidepressant agent that entered the United States market in April 1996. "( Anderson, DT; Fritz, KL; Muto, JJ, 1999)
"Mirtazapine is an antidepressant which has been recently released on the U.S."( Bea, C; Budech, CB; Dunner, DL; Hendrickson, HE; O'Connor, E, 1999)
"Mirtazapine is a potent antagonist of central 2alpha-adrenergic autoreceptors, and heteroreceptors and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors."( Kent, JM, 2000)
"Mirtazapine is a new antidepressant with a tetracyclic chemical structure that is not related to selective serotonin reuptake inhibitors, tricyclic antidepressants, or monoamine oxidase inhibitors. "( Abo-Zena, RA; Bobek, MB; Dweik, RA, 2000)
"Mirtazapine is an effective antidepressant for many patients experiencing SSRI-induced sexual dysfunction."( Delgado, P; Gelenberg, AJ; Laukes, C; McGahuey, C; Moreno, F; Okayli, G; Zentner, L, 2000)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). "( Foster, RH; Holm, KJ; Jarvis, B, 2000)
"Mirtazapine (MIR) is a novel antidepressant, reported to raise extracellular noradrenaline (NA) through blockade of alpha2-autoreceptors and serotonin (5-HT) output via (1) indirect activation of facilitatory alpha1-adrenoceptors on the cell bodies of ascending 5-HT neurones and (2) blockade of presynaptic release-modulating alpha2-heteroreceptors on 5-HT terminals in the forebrain. "( Bengtsson, HJ; Hjorth, S; Johansson, J; Kele, J, 2000)
"Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects."( Berk, M; Brook, S; Ichim, C, 2001)
"Mirtazapine is an antidepressant that has a receptor-binding profile that may suit it for use in controlling the nausea and insomnia of highly emetic cancer chemotherapy. "( Kast, RE, 2001)
"Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder. "( Busnello, EA; Busnello, JV; Kapczinski, F; Kauer-Sant'Anna, M; Madruga, M; Quevedo, J; Ribeiro, L, 2001)
"Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated."( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001)
"Mirtazapine is a novel antidepressant with a noradrenergic and specific serotonergic mode of action. "( Barnas, C; Hilger, E; Kasper, S; Konstantinidis, A; Neumeister, A; Ptak-Butta, J; Stastny, J; Winkler, D, 2002)
"Mirtazapine (MIR) is an antidepressant which enhances noradrenergic and serotonergic 5-HT1A neurotransmission via antagomism of central alpha2-adrenergic autoreceptors and heteroreceptors. "( Dlaboga, D; Dziedzicka-Wasylewska, M; Maj, J; Rogoz, Z; Wrobel, A, 2002)

Effects

ExcerptReference
"Mirtazapine has a specific pharmacodynamics, blocking not only post-synaptic serotonergic receptors but also α2-presynaptic adrenergic receptors."( Abreu, T; Barranha, R; Freitas, C; Von Doellinger, O, 2019)
"Mirtazapine has a good tolerability and safety profile that demonstrates several benefits over other antidepressants and it is associated with few fatalities. "( Matsukawa, T; Nagasawa, H; Nakanishi, H; Saito, K; Yanagawa, Y; Yokoyama, K, 2019)
"Mirtazapine has a unique mechanism of antidepressant action, and thus is thought to have a different profile of adverse events from that of other antidepressants."( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; McGuire, H; Nakagawa, A; Omori, IM; Watanabe, N, 2010)
"Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice."( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Nakagawa, A; Omori, IM; Watanabe, N, 2011)
"Mirtazapine has a low affinity for 5-HT(1A) receptors but shows 5-HT(1A)-agonistic-like effects in behavioral pharmacology test. "( Katsu, H; Nakayama, K; Sakurai, T, 2004)
"Mirtazapine has a pharmacological profile expected to result in a lack of sexual dysfunction."( Arias, F; Carrasco, JL; Díaz, M; Ferrando, L; Ibáñez, A; Montes, JM; Pelegrín, C; Saiz-Ruiz, J; Vicente, F; Viñas, R, 2005)
"Mirtazapine has a prophylactic and ibuprofen an acute effect in tension-type headache."( Ashina, S; Bendtsen, L; Buchgreitz, L; Jensen, R, 2007)
"Mirtazapine has a dual-action profile, combining the enhancement of the noradrenergic neurotransmitter system with specific actions on particular serotonergic receptor subtypes."( Choi, MJ; Kang, RH; Lee, MS; Paik, JW; Wong, ML, 2007)
"Mirtazapine has a low affinity for 5-HT1A receptors but shows 5-HT1A-agonistic-like effects in a conditioned taste aversion test and by causing lower lip retraction in rats."( de Boer, T, 1996)
"Mirtazapine has a very low seizure-inducing potential: only one case was recorded in a patient with a history of seizures during previous treatment with c"( Montgomery, SA, 1995)
"Mirtazapine has a unique tolerability profile, since the specific postsynaptic 5-HT2 and 5-HT3 receptor blockade of mirtazapine provides early antidepressant effects without causing unwanted serotonin-related side-effects."( Barkin, RL; Fawcett, J, 1998)
"Mirtazapine has a beneficial effect on sexual functioning in both depressed women and men. "( Boyarsky, BK; Haque, W; Hirschfeld, RM; Rouleau, MR, 1999)
"Mirtazapine has often been prescribed as add-on treatment for schizophrenia in patients with suboptimal response to conventional treatments. "( Joffe, G; Terevnikov, V, 2022)
"Mirtazapine has been associated with movement disorders in adults."( Hawkins, M, 2023)
"Mirtazapine has a specific pharmacodynamics, blocking not only post-synaptic serotonergic receptors but also α2-presynaptic adrenergic receptors."( Abreu, T; Barranha, R; Freitas, C; Von Doellinger, O, 2019)
"Esmirtazapine (1.5-4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. "( Braat, S; Chang, Q; Hajak, G; Ivgy-May, N; Roth, T; van Osta, G, 2020)
"Mirtazapine has been suggested for use in cancer-associated anorexia and cachexia."( Abdel-Aal, HH; Alsirafy, SA; Elsherief, WA; Farag, DE; Hunter, CN; Riad, NM, 2021)
"Mirtazapine has been shown in case reports to reduce symptoms in gastroparesis."( Kataria, R; Malamood, M; Parkman, HP; Roberts, A; Schey, R, 2017)
"Mirtazapine has been associated with increased serum cholesterol and serum triglyceride levels."( Bowers, RD; Holombo, AA; Valanejad, SM, 2019)
"Mirtazapine has a good tolerability and safety profile that demonstrates several benefits over other antidepressants and it is associated with few fatalities. "( Matsukawa, T; Nagasawa, H; Nakanishi, H; Saito, K; Yanagawa, Y; Yokoyama, K, 2019)
"Mirtazapine has traditionally been used for the treatment of major depressive disorder, with an added benefit in patients who have comorbid insomnia or anxiety. "( Chamseddin, BH; Fawaz, B; Griffin, JR, 2021)
"Mirtazapine has moderate efficacy for depression if sedation and weight gain side effects are tolerated and some small support for use in nausea and vomiting."( Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016)
"Mirtazapine has a unique mechanism of antidepressant action, and thus is thought to have a different profile of adverse events from that of other antidepressants."( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; McGuire, H; Nakagawa, A; Omori, IM; Watanabe, N, 2010)
"Mirtazapine in particular has been suggested to have a faster onset of action than reuptake inhibitors."( Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P, 2010)
"Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice."( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Nakagawa, A; Omori, IM; Watanabe, N, 2011)
"Mirtazapine has chemoprotective effects against cisplatin-induced oxidative stress and DNA damage in the rat brain, which may be attributed to its antioxidant capabilities. "( Akcay, F; Dursun, OB; Gulec, M; Hacimuftuoglu, A; Oral, E; Suleyman, H; Yucel, A, 2013)
"Mirtazapine has proved effective in the treatment of patients who were resistant or intolerant to selective serotonin reuptake inhibitors (SSRIs) and the switch to mirtazapine could be made immediately without the necessity for a taper period."( Hirschfeld, RM, 2002)
"Mirtazapine has significant adverse effects and should be used cautiously in ET patients."( Lyons, KE; Pahwa, R, 2003)
"Mirtazapine has been shown to acutely inhibit cortisol secretion in healthy subjects. "( Baghai, T; Laakmann, G; Rackwitz, C; Schule, C, 2003)
"Mirtazapine has a low affinity for 5-HT(1A) receptors but shows 5-HT(1A)-agonistic-like effects in behavioral pharmacology test. "( Katsu, H; Nakayama, K; Sakurai, T, 2004)
"Mirtazapine has been shown to acutely inhibit cortisol secretion in healthy subjects. "( Baghai, T; Hennig, J; Laakmann, G; Schüle, C, 2004)
"Mirtazapine has a pharmacological profile expected to result in a lack of sexual dysfunction."( Arias, F; Carrasco, JL; Díaz, M; Ferrando, L; Ibáñez, A; Montes, JM; Pelegrín, C; Saiz-Ruiz, J; Vicente, F; Viñas, R, 2005)
"Mirtazapine has no demonstrable serotonergic effects in humans and there is insufficient evidence to designate it as a dual-action drug."( Gillman, PK, 2006)
"Mirtazapine has a prophylactic and ibuprofen an acute effect in tension-type headache."( Ashina, S; Bendtsen, L; Buchgreitz, L; Jensen, R, 2007)
"Mirtazapine has a dual-action profile, combining the enhancement of the noradrenergic neurotransmitter system with specific actions on particular serotonergic receptor subtypes."( Choi, MJ; Kang, RH; Lee, MS; Paik, JW; Wong, ML, 2007)
"Mirtazapine has a low affinity for 5-HT1A receptors but shows 5-HT1A-agonistic-like effects in a conditioned taste aversion test and by causing lower lip retraction in rats."( de Boer, T, 1996)
"Mirtazapine has virtually no anticholinergic, adrenergic or typical selective serotonin reuptake inhibitor (SSRI) side effects."( Montgomery, SA, 1995)
"Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients."( Burrows, GD; Kremer, CM, 1997)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction."( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997)
"Mirtazapine has FDA-approved labeling for treatment of depression."( Puzantian, T, 1998)
"Mirtazapine has minimal inhibitory effects on CYP1A2, CYP3A4, and CYP2D6 in vitro."( Nemeroff, CB; Owen, JR, 1998)
"Mirtazapine has been evaluated in a worldwide clinical development program involving approximately 4500 patients."( Barkin, RL; Fawcett, J, 1998)
"Mirtazapine has a beneficial effect on sexual functioning in both depressed women and men. "( Boyarsky, BK; Haque, W; Hirschfeld, RM; Rouleau, MR, 1999)
"Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment."( Nutt, DJ, 1999)
"Mirtazapine has little inhibitory"( Delbressine, LP; Sitsen, JM; Timmer, CJ, 2000)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects."( Bailer, U; Fischer, P; Kasper, S; Küfferle, B; Stastny, J, 2000)
"Mirtazapine has generally shown similar efficacy to other antidepressants."( Foster, RH; Holm, KJ; Jarvis, B, 2000)
"Mirtazapine also has similar effects to SSRIs on quality of life with possibly a shorter time to onset of action, although published trial results are required to confirm these preliminary data."( Foster, RH; Holm, KJ; Jarvis, B, 2000)

Actions

ExcerptReference
"Mirtazapine plays a role in treatment for intra-thecel morphine-induced pruritis yet high-quality trials are needed to confirm its efficacy in other dermatologic conditions."( Chamseddin, BH; Fawaz, B; Griffin, JR, 2021)
"For mirtazapine, no increase of SGF was observed when the column ID was decreased."( de Jong, GJ; Kranendijk, M; Somsen, GW; Waterval, JC, 2005)
"Mirtazapine induced lower lip retraction in rats, as did the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)."( Berendsen, HH; Broekkamp, CL, 1997)

Treatment

ExcerptReference
"Mirtazapine treatment increased N3 sleep at week 1 compared with agomelatine treatment, but this difference disappeared at week 8."( Bao, YP; Du, LT; Fan, TT; Fu, Y; Gao, XJ; Guo, LH; Hao, XN; Li, LZ; Li, SX; Lin, X; Liu, L; Liu, Z; Lu, L; Mi, WF; Shi, Y; Si, TM; Sun, HQ; Tabarak, S; Wang, L; Wang, XQ; Zhang, HY; Zhang, SZ; Zhang, WH, 2020)
"Mirtazapine-treated neuron-conditioned medium (Mir-NCM) induced astrocyte proliferation and upregulated MT expression via 5-HT1A receptors on astrocytes."( Asanuma, M; Kagawa, D; Kikuoka, R; Kitamura, Y; Kubota, N; Maeda, M; Miyazaki, I; Moriyama, M; Murakami, S; Sato, A; Sendo, T, 2020)
"Mirtazapine treatment rapidly induced a significant reduction in total hepatic B cell numbers, paralleled by a compositional shift in the predominant hepatic B cell subtype from B2 to B1."( Almishri, W; Altonsy, MO; Davis, RP; Jenne, CN; Shaheen, AA; Swain, MG, 2021)
"Mirtazapine treatment rapidly alters hepatic B cell populations, enhancing hepatic retention of CXCR3-expressing innate-like B cells that generate a more anti-inflammatory cytokine profile. "( Almishri, W; Altonsy, MO; Davis, RP; Jenne, CN; Shaheen, AA; Swain, MG, 2021)
"Mirtazapine-treated patients had a 74% higher likelihood of achieving remission during the first 2 weeks of therapy compared with patients treated with SSRIs."( Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P, 2010)
"Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. "( Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R, 2012)
"Mirtazapine treatment resulted in a significant improvement in mean Hamilton Depression Rating Scale total score at the end of the study (P < 0.0001)."( Baumann, P; Brocard, M; Crettol, S; Eap, CB; Golay, KP; Harenberg, S; Hilleret, H; Jaquenoud Sirot, E; Jonzier-Perey, M; Kemmerling, K; Lima, CA; Perrenoud, P; Vandel, P; Zullino, DF, 2012)
"Mirtazapine treatment was associated with modest improvement of psychotic and parkinsonian symptoms."( Epshtein, S; Fuchs, C; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003)
"Mirtazapine treatment resulted in a statistically significantly greater improvement in quality of life than paroxetine at endpoint (P=0.021)."( Knapp, M; Patel, A; Romeo, R; Thomas, C, 2004)
"In mirtazapine-treated females homozygous for the A-allele compared to AG/GG-carriers, HAMD-17 scores during the study period were constantly and markedly lower, but not statistically different."( Dahmen, N; Kohnen, R; Müller, MJ; Rujescu, D; Stassen, HH; Szegedi, A; Tadić, A, 2007)
"Mirtazapine-treated patients demonstrated a statistically significant (p < or = .05) reduction in the sum of HAM-D items 9, 10, and 11 (anxiety/agitation) compared with placebo-treated patients at Weeks 1, 2, 4, and 6 and at the endpoint. "( Barkin, RL; Fawcett, J, 1998)
"Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points."( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999)
"Treatment with mirtazapine, a widely prescribed antidepressant, has been linked to weight gain and dyslipidemia. "( Dose, T; Fulda, S; Heel, S; Hennings, JM; Holsboer, F; Kloiber, S; Lechner, K; Lucae, S; Schaaf, L; Uhr, M, 2023)
"Treatment with mirtazapine, mefloquine and cidofovir did not affect the progression of the disease, which was fatal within 7 months of presentation."( Stacpoole, SRL; Zucker, BE, 2018)
"Cats treated with mirtazapine also gained significant bodyweight compared with placebo-treated cats (P=0.002) as determined by linear mixed model analysis."( Lunn, KF; Quimby, JM, 2013)
"Treatment with mirtazapine or placebo had no effect on cognitive and functional status as assessed by the Mini-Mental State Examination and the Katz scale, respectively. "( Camargos, EF; Louzada, LL; Naves, JO; Nóbrega, OT; Quintas, JL; Scoralick, FM, 2017)
"Treatment with mirtazapine 30 mg orally daily and mefloquine hydrochloride 250 mg orally for three days, then 250 mg weekly, was initiated."( Jett, RA; Moenster, RP, 2012)
"Pretreatment with mirtazapine 24h prior to the CPP test had no effect on CPP expression."( Graves, SM; Napier, TC; Persons, AL; Riddle, JL, 2012)
"Treatment with mirtazapine also restored the oestrogen withdrawal-induced disturbed tail-temperature."( Berendsen, HH; Kloosterboer, HJ, 2003)
"Treatment with mirtazapine resulted in a non-significant decrease in betaTG and PF4 and platelet 5-HT levels."( Crijns, H; Hamulyák, K; Honig, A; Lousberg, R; Scharpé, S; Schins, A; Van Melle, J, 2004)
"A treatment with mirtazapine improved the entire clinical autistic picture with the disappearance of masturbation."( Albertini, G; Di Gennaro, G; Onorati, P; Polito, E; Sarà, M, 2006)
"Treatment with mirtazapine was associated with significant reductions in clinical global impressions-severity of illness scale (CGI-S) score, the Hamilton rating scale for anxiety (HAM-A) total score, the 17-item Hamilton rating scale for depression (HAM-D) total score and the Beck depression inventory (BDI) total scores. "( Doraiswamy, PM; Gersing, K; Hellegers, C; Varia, I; Venkataraman, S, 2007)

Roles (6)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
histamine antagonistHistamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
oneirogenAny substance that produces or enhances dream-like states of consciousness.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzazepineA group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
tetracyclic antidepressantAn antidepressant whose molecular structure consists of four ring-like structures in a T-shape.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

mirtazapine is involved in 1 pathway(s), involving a total of 8 unique proteins and 7 unique compounds

PathwayProteinsCompounds
Mirtazapine H1-Antihistamine Action87

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
GLS proteinHomo sapiens (human)Potency25.11890.35487.935539.8107AID624170
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.84890.01237.983543.2770AID1346984
EWS/FLI fusion proteinHomo sapiens (human)Potency5.25760.001310.157742.8575AID1259255
pregnane X nuclear receptorHomo sapiens (human)Potency22.38720.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.83250.000229.305416,493.5996AID743075
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.50120.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.05010.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.05010.00636.904339.8107AID883
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.13170.000323.4451159.6830AID743065; AID743067
gemininHomo sapiens (human)Potency30.35790.004611.374133.4983AID624296; AID624297
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.05010.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
TAR DNA-binding protein 43Homo sapiens (human)Potency0.35481.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.01800.00010.532610.0000AID1570582; AID3855
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.00550.00020.667710.0000AID5739
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.08510.00001.44217.3470AID36067
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.02000.00010.807410.0000AID238989
D(2) dopamine receptorHomo sapiens (human)Ki5.45400.00000.651810.0000AID239052
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00200.00010.601710.0000AID5578
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.22390.00021.874210.0000AID35399
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.82900.00010.949010.0000AID238991; AID35426
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.22390.00001.23808.1590AID35399
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.19950.00001.47257.8980AID36530
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.01800.00030.483410.0000AID238990
DRattus norvegicus (Norway rat)Ki4.16700.00010.610010.0000AID238855
D(4) dopamine receptorHomo sapiens (human)Ki0.02500.00000.436210.0000AID63676
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.22390.00021.270410.0000AID35399
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.82900.00000.575110.0000AID238991; AID35426
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00070.97749.7000AID64685
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.03860.00000.385510.0000AID1570583; AID239010
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.03900.00010.954910.0000AID239069
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.70000.00030.81978.4900AID200771; AID204229
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.26500.00030.380610.0000AID239149
Alpha-1A adrenergic receptorHomo sapiens (human)IC50 (µMol)3.16230.00020.56145.4000AID36737
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)Ki0.01800.00010.01470.0316AID3855
Histamine H1 receptorHomo sapiens (human)Ki0.00160.00000.511010.0000AID239091
D(3) dopamine receptorHomo sapiens (human)Ki2.87150.00000.602010.0000AID239150; AID65283
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.22390.00001.819410.0000AID35399
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.82900.00000.965010.0000AID238991; AID35426
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki2.90000.00000.74119.9000AID775164
Angiotensin-converting enzymeRattus norvegicus (Norway rat)Ki0.01800.00011.96427.3000AID3855
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki1.46000.00000.437510.0000AID65901
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
TransporterRattus norvegicus (Norway rat)IC50 (µMol)0.50670.00081.95628.8000AID145389; AID147730
TransporterRattus norvegicus (Norway rat)Ki1.64000.00010.866710.0000AID238962
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Kd5.01190.00010.95285.0119AID438555
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (406)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (98)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (79)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (197)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID184276The increase in the extracellular levels of DOPAC in the rat ventral hippocampus at a dose of 5.0 mg/kg sc measured by in vivo microdialysis2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID3855The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID246883In vivo effective dose for reversal of tryptamine-induced cyanosis in rats2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID246985Effective dose for antagonistic activity against m-chlorophenyl-piperazine induced anxiety in rats2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1223477Total clearance in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID330660Effect on life span of Caenorhabditis elegans at 100 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1223486Intrinsic clearance in human hepatocytes from chimeric mouse with humanized liver assessed per 10'6 cells at 10 uM after 0.25 to 2 hrs by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1211297Drug recovery in plasma (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID87221The binding affinity at the Histamine H1 receptor determined using [3H]pyrilamine2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1223483Unbound fraction in iv dosed human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36067Binding affinity at human Alpha-2A adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID63676The binding affinity at the Dopamine receptor D4 determined using [3H]YM-09151-22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID238962Inhibition of [3H]nisoxetine binding to rat Norepinephrine transporter2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID238990Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1223475Elimination half life in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID238989Inhibition of [3H]rauwolscine binding to Alpha-2A adrenergic receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID343685Ratio of drug level in brain to blood in Wistar rat2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1223478Total clearance in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID145389The binding affinity at the Norepinephrine transporter reuptake sites determined using competition binding assay2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID35399Binding affinity at human Alpha-2B adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID171602Inhibition of Xylazine (15 mg/kg i.v.) induced loss of righting reflex in rats following i.v. administration.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID239010Inhibition of [125I]R91150 binding to human 5-hydroxytryptamine 2A receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID438555Binding affinity to 5HT1A receptor2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Physical binding pocket induction for affinity prediction.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID239069Inhibition of [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID5578The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID238991Inhibition of [3H]prazosin binding to rat Alpha-1 adrenergic receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID4541The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID238855Inhibition of [3H]SCH-23390 binding to rat Dopamine receptor D12005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID5739The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID65901The binding affinity at the Dopamine receptor D2 determined using [3H]spiperone2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1223481Elimination half life iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID246931In vivo effective dose for reversal of tryptamine-induced backward locomotion in rats2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID239150Inhibition of [125I]iodosulpiride binding to human Dopamine receptor D32005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID775164Displacement of [3H]GR65630 from human 5-HT3A receptor expressed in HEK293 cells by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID171612Inhibition of clonidine (0.04 mg/kg) induced anti diarrhoeal effects in rats following s.c. administration.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID147730Binding affinity against norepinephrine transporter (NET) by displacement of [3H]nisoxetine in male wistar rats2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1211298Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID204229Binding affinity against serotonin transporter (SERT) by displacement of [3H]paroxetine in male wistar rats2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID239149Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 7 receptor2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID247009In vivo effective dose to inhibit apomorphine induced agitation in rats upon subcutaneous administration2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID239052Inhibition of [3H]-spiperone binding to human Dopamine receptor D22005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID395326Fraction unbound in rat brain2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID246894In vivo effective dose for reversal of RO-4-1284 induced hypothermia in mouse2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID35426The binding affinity at Alpha-1 adrenergic receptor determined using [3H]prazosin2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID239091Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor 2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID246918In vivo effective dose to inhibit tryptamine-induced bilateral convulsions in rats2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
AID1570583Binding affinity to human 5HT2A receptor2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID184274The increase in the extracellular levels of 5-HT in the rat ventral hippocampus at a dose of 5.0 mg/kg sc measured by in vivo microdialysis2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID395329Dissociation constant, pKa by mass spectrometry2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID5907The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID1211294Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID88334The binding affinity at the Histamine H2 receptor determined using [3H]APT; Not tested2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1223482Ratio of drug level in blood to plasma in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID65283The binding affinity at the Dopamine receptor D3 determined using [3H]spiperone2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID311933Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1211296Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID35189The binding affinity at the Alpha-2 adrenergic receptor determined using [3H]RX-821002; Not tested2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID5513Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211295Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1211293Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID200771The binding affinity at the 5-HT reuptake sites determined using competition binding assay2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36530Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID36737Binding affinity at human Alpha-1A adrenergic receptor in CHO cells uby [3H]prazosin (0.25 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID1570582Binding affinity to human 5HT1A receptor2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID330659Effect on life span of Caenorhabditis elegans at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID64685Binding affinity against dopamine transporter (DAT) by displacement of [3H]WIN-35428 in male wistar rats2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID3719Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017Wombat Data for BeliefDocking2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,408)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (0.78)18.7374
1990's123 (8.74)18.2507
2000's565 (40.13)29.6817
2010's525 (37.29)24.3611
2020's184 (13.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials324 (21.07%)5.53%
Reviews196 (12.74%)6.00%
Case Studies418 (27.18%)4.05%
Observational7 (0.46%)0.25%
Other593 (38.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (108)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicentre Randomised Double-blind, Placebo-controlled 2x2 Factorial Trial Investigating the Effects of Adding Mirtazapine and Folic Acid to Existing Therapy for Patients With Schizophrenia[NCT01263080]Phase 4333 participants (Actual)Interventional2010-11-30Completed
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients[NCT01352572]300 participants (Anticipated)Interventional2002-01-31Active, not recruiting
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype[NCT01352559]1,000 participants (Anticipated)Interventional2001-11-30Active, not recruiting
Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering in Patients Undergoing Urological Surgeries: a Randomized Controlled Trial[NCT03679052]Phase 4300 participants (Actual)Interventional2018-03-01Completed
Clinical Psychopharmacology Division,Institute of Mental Health,Peking University[NCT03148522]120 participants (Anticipated)Interventional2017-06-01Recruiting
A Randomized, Double-Blind, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly-dosed Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New S[NCT03852160]Phase 30 participants (Actual)Interventional2019-12-01Withdrawn(stopped due to New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study)
Role of Mirtazapine in Ameliorating Sleep Disordered Breathing[NCT04799782]Phase 218 participants (Actual)Interventional2017-01-31Completed
Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder[NCT04614584]Phase 124 participants (Anticipated)Interventional2021-07-12Recruiting
A Relative Bioavailability Study of 15 mg Mirtazapine Orally Disintegrating Tablets Under Fasting Conditions[NCT00835575]Phase 132 participants (Actual)Interventional2003-07-31Completed
Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics[NCT03219008]Phase 4800 participants (Anticipated)Interventional2017-08-01Recruiting
Measurement-based Care vs. Standard Care for Major Depressive Disorder: a Randomized Controlled Trial With Masked Raters[NCT02191124]Phase 4164 participants (Actual)Interventional2011-06-30Completed
Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Gynecological Surgeries: a Randomized Controlled Trial[NCT03675555]Phase 4300 participants (Actual)Interventional2018-03-01Completed
Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488]Phase 252 participants (Actual)Interventional2019-03-26Completed
Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia: A 6-Week Pre and Post Intervention Study[NCT05978219]Phase 4135 participants (Anticipated)Interventional2023-05-25Recruiting
Predict Antidepressant Responsiveness Using Pharmacogenomics[NCT01228357]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
Strategic Use of New Generation Antidepressants for Depression[NCT01109693]Phase 42,011 participants (Actual)Interventional2010-12-31Completed
Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy[NCT03935685]Phase 2120 participants (Anticipated)Interventional2019-02-26Recruiting
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial[NCT01305707]Phase 4104 participants (Actual)Interventional2009-07-31Terminated(stopped due to Difficulties in recruiting)
Mirtazapine Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting After Lap Cholecystectomy a Comparative Study[NCT04547842]Early Phase 190 participants (Anticipated)Interventional2020-09-01Recruiting
A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients[NCT06054321]400 participants (Anticipated)Interventional2022-08-03Recruiting
Assessment of the Inter-patient Variability in Clinical Response and Correlated Genetic Variations in Substance Use Disorders[NCT05833399]200 participants (Anticipated)Observational2022-11-28Recruiting
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients[NCT00817375]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
The Effects of Mirtazapine vs Placebo on Alcohol Consumption in Male Alcohol High Consumers; a Randomized Controlled Trial[NCT00874003]Phase 259 participants (Actual)Interventional2004-04-30Completed
A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects[NCT02228239]Phase 126 participants (Actual)Interventional2014-09-30Completed
Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache Following Obstetric Surgery Under Spinal Anesthesia: A Randomized Controlled Trial[NCT05108688]Phase 4210 participants (Anticipated)Interventional2021-11-15Recruiting
Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia[NCT04155008]Phase 41 participants (Actual)Interventional2021-03-01Terminated(stopped due to The trial was closed after 4 months due to slow to accrual. Only 1 participant was enrolled.)
Clinical Psychopharmacology Division[NCT03294525]400 participants (Anticipated)Observational2016-01-31Recruiting
Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study[NCT04806230]81 participants (Actual)Observational2011-04-01Completed
Mirtazapine Reduces ICD Appropriate Shocks in Cardioverter Implanted Patients With Depression and Anxiety[NCT00960830]40 participants (Actual)Interventional2007-04-30Completed
Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine[NCT00782405]Phase 340 participants (Anticipated)Interventional2008-10-31Completed
A Randomized Double-blind, Placebo-controlled, 4-period Cross-over Study to Assess the Effect of Single and Multiple Doses of 1.5 mg and 4.5 mg Org 50081 and a Single Dose of 7.5 mg Zopiclone on Next-day Driving Ability and Psychomotor Performance in Heal[NCT00798395]Phase 132 participants (Actual)Interventional2007-10-31Completed
Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002.[NCT00610675]Phase 3346 participants (Actual)Interventional2006-12-07Completed
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause[NCT00560833]Phase 3943 participants (Actual)Interventional2004-10-15Completed
A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement[NCT02336750]Phase 3212 participants (Actual)Interventional2014-12-31Completed
Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine[NCT04908605]Phase 4165 participants (Actual)Interventional2021-06-15Completed
5-HT2AR: 5HT2CR Balance in Brain Connectivity in Cocaine Dependence[NCT03921151]Phase 1/Phase 290 participants (Actual)Interventional2014-05-13Completed
Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544]Phase 2236 participants (Anticipated)Interventional2015-12-31Active, not recruiting
Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)[NCT05452174]Phase 1/Phase 225 participants (Anticipated)Interventional2022-06-13Enrolling by invitation
Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients[NCT00488072]Phase 298 participants (Actual)Interventional2006-09-20Active, not recruiting
A Double-Blind, Randomized, Parallel Group, Placebo- Controlled Sleep Laboratory Efficacy and Safety Study With Org 50081 in Elderly Subjects With Chronic Primary Insomnia[NCT00561821]Phase 3538 participants (Actual)Interventional2007-11-20Completed
A Two-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Efficacy and Safety Out-Patient Trial With Org 50081 in Patients With Chronic Primary Insomnia[NCT00482612]Phase 3526 participants (Actual)Interventional2006-12-07Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness[NCT00817011]1,000 participants (Anticipated)Interventional2006-04-30Recruiting
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients: A Randomized, Double-Blind Trail.[NCT05380479]Phase 280 participants (Anticipated)Interventional2022-06-01Recruiting
Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting After Laparoscopic Sleeve Surgery: a Randomized Controlled Trial[NCT04013386]Phase 490 participants (Actual)Interventional2019-07-15Completed
A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081[NCT00561574]Phase 3259 participants (Actual)Interventional2008-01-09Completed
New Pharmacological Treatment for Obstructive Sleep Apnea[NCT00108498]Phase 10 participants Interventional2003-10-31Completed
Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients.[NCT00919295]Phase 280 participants (Actual)Interventional2008-12-31Completed
Phase 1 Study of Mirtazapine in Healthy Subjects[NCT00878540]Phase 112 participants (Anticipated)Interventional2008-09-30Completed
A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients[NCT00926835]Phase 4692 participants (Actual)Interventional2009-05-31Terminated(stopped due to due to patient recruitment difficulties)
A Twenty-six Weeks, Open-label Extension Trial to Evaluate Safety and Efficacy of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106[NCT00750919]Phase 3184 participants (Actual)Interventional2008-10-07Terminated(stopped due to This trial was stopped prematurely due to the Sponsor's decision not to continue the development of esmertazapine for this indication.)
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause[NCT00535288]Phase 3946 participants (Actual)Interventional2004-09-15Completed
Pharmacogenetic Study of Mirtazapine Response in Depressed Patients[NCT01039740]100 participants (Anticipated)Interventional2003-02-28Recruiting
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM: a 6-month Randomized Controlled Trial With 3 Months of Follow-up[NCT01888835]Phase 2120 participants (Actual)Interventional2013-08-31Completed
Phase II Clinical Studies on Anti-addictive Therapeutic Effects of Mirtazapine in Human Subjects Addicted to Cocaine.[NCT01949571]Phase 264 participants (Actual)Interventional2007-01-31Completed
Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD)[NCT01178671]Phase 438 participants (Actual)Interventional2010-07-31Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies[NCT02893371]1,037,352 participants (Actual)Observational2016-09-30Completed
A Relative Bioavailability Study of 15 mg Mirtazapine Tablets Under Non-Fasting Conditions[NCT00865384]Phase 124 participants (Actual)Interventional2001-09-30Completed
A Relative Bioavailability Study of 15 mg Mirtazapine Tablets Under Fasting Conditions[NCT00865696]Phase 132 participants (Actual)Interventional2001-09-30Completed
Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia[NCT02541526]Phase 380 participants (Anticipated)Interventional2013-05-31Recruiting
A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans[NCT00302107]Phase 478 participants (Actual)Interventional2006-04-30Completed
A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia[NCT00506389]Phase 3419 participants (Actual)Interventional2007-06-06Completed
[NCT02711215]Phase 480 participants (Anticipated)Interventional2015-05-31Active, not recruiting
Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523]86 participants (Actual)Interventional2018-08-29Completed
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study[NCT00177567]Phase 460 participants Interventional2001-07-31Completed
Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study[NCT01867775]Phase 330 participants (Anticipated)Interventional2012-05-31Recruiting
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study[NCT01488266]90 participants (Anticipated)Interventional2011-11-30Active, not recruiting
A Placebo Controlled Trial of Mirtazapine for Patients With Depression and Cocaine Dependence[NCT00249444]Phase 286 participants (Actual)Interventional2006-05-31Completed
A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer[NCT01725048]Early Phase 121 participants (Actual)Interventional2011-01-31Completed
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial[NCT05952713]73,336 participants (Actual)Observational2022-10-01Completed
Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss[NCT01240096]Phase 435 participants (Anticipated)Interventional2006-09-30Recruiting
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-blind, Placebo-controlled Trial[NCT00150839]Phase 480 participants (Actual)Interventional2006-03-31Completed
Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward[NCT00600145]0 participants (Actual)Interventional2007-09-30Withdrawn(stopped due to PI decision)
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders[NCT01302964]Phase 330 participants (Actual)Interventional2010-08-31Completed
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.[NCT02185131]Phase 216 participants (Actual)Interventional2013-09-30Completed
[NCT00080158]Phase 2/Phase 3120 participants Interventional2004-03-31Completed
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Phase 4 Open-labeled Study to Compare the Anti-depressive Efficacy Between Mirtazapine and Psychotherapy for Patients With Interferon-related Depression During Antiviral Therapy for Hepatitis C[NCT01465919]Phase 45 participants (Actual)Interventional2011-08-31Terminated(stopped due to Due to the recent change in standard of care for hepatitis C.)
The Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects[NCT00322309]Phase 224 participants (Actual)Interventional2005-09-30Completed
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors[NCT00497081]Phase 260 participants (Actual)Interventional2007-05-31Completed
Combining Medications to Enhance Depression Outcomes[NCT00590863]Phase 4665 participants (Actual)Interventional2008-03-31Completed
[NCT02655354]635 participants (Actual)Interventional2015-10-31Completed
Does LEPR Polymorphism Predict Variability in Weight Gain Induced by Mirtazapine in the Treatment of Late Life Depression?[NCT01601002]Phase 419 participants (Actual)Interventional2012-06-30Completed
Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans[NCT00288782]Phase 424 participants Interventional2006-02-28Completed
Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate[NCT01501396]Phase 20 participants (Actual)Interventional2013-09-30Withdrawn
Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study[NCT01505504]22 participants (Actual)Observational2004-01-31Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder[NCT01764867]Phase 41,080 participants (Anticipated)Interventional2012-06-30Recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial.[NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
A Double-blind, Active-controlled, Randomized Study Comparing Mirtazapine Combined With Paroxetine or Paroxetine Monotherapy in Patients With Major Depressive Patients Without Early Improvement in the First 2 Weeks[NCT01458626]Phase 4525 participants (Actual)Interventional2012-11-14Completed
A 6-Month, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Outpatient Trial, Investigating the Efficacy and Safety of Org 50081 in Adult Patients With Chronic Primary Insomnia[NCT00631657]Phase 3460 participants (Actual)Interventional2008-03-04Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression[NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
A Phase II/III Prospective Randomized Placebo-control Trail Compare Mirtazapine Plus Gemcitabine With Gemcitabine in Metastasis Pancreatic Cancer[NCT01598584]Phase 2/Phase 30 participants (Actual)Interventional2012-06-30Withdrawn(stopped due to Gemcitabine is not the first choice for most pancreatic cancer patients nowdays)
Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial[NCT03785691]Phase 258 participants (Actual)Interventional2019-03-01Terminated(stopped due to Recruiting difficulties)
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data[NCT04446039]405,349 participants (Actual)Observational2022-07-04Completed
Safety and Efficacy of Mirtazapine in the Treatment of Chronic Insomnia in Older Adults : The MIRAGE Study[NCT05247697]Phase 160 participants (Anticipated)Interventional2022-09-01Recruiting
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial[NCT02646449]Phase 211 participants (Actual)Interventional2015-06-30Completed
Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder[NCT00385437]Phase 216 participants Interventional2003-04-30Completed
INST 0816: Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight[NCT00832520]Phase 213 participants (Actual)Interventional2008-11-30Terminated(stopped due to Low accrual rate.)
Pharmacovigilance in Gerontopsychiatric Patients[NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers[NCT01165541]Phase 220 participants (Actual)Interventional2010-09-30Completed
A Pragmatic, Multi Centre, Double-blind, Placebo Controlled Randomised Trial to Assess the Safety, Clinical and Cost Effectiveness of Mirtazapine in Patients With Alzheimer's Disease (AD) and Agitated Behaviours[NCT03031184]Phase 3207 participants (Actual)Interventional2017-01-31Completed
A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis[NCT01943435]259 participants (Actual)Interventional2013-11-20Completed
Effects of Treatment on Decision-making in Major Depression[NCT01916824]Phase 453 participants (Actual)Interventional2013-08-31Completed
An Efficacy Study Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer[NCT05170919]Phase 2170 participants (Anticipated)Interventional2022-01-20Enrolling by invitation
What is the Effectiveness and Safety of Mirtazapine Versus Escitalopram in Alleviating Cancer-associated Poly-symptomatology (MIR-P)? A Mixed-method Randomized Controlled Trial Protocol[NCT04763135]Phase 31 participants (Actual)Interventional2021-12-15Terminated(stopped due to difficulties in recruiting)
Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain[NCT04747314]Phase 2/Phase 3300 participants (Anticipated)Interventional2021-03-31Recruiting
A Relative Bioavailability Study of 15 mg Mirtazapine Orally Disintegrating Tablets Under Non-Fasting Conditions[NCT00834197]Phase 132 participants (Actual)Interventional2003-07-31Completed
Mirtazapine and Quetiapine as Treatment for Postoperative Sleep Disturbance After Fast-track Knee Replacement[NCT04728581]165 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia : a Randomized Controlled Clinical Trial[NCT03254173]Phase 2/Phase 3120 participants (Actual)Interventional2018-03-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AHI (Apnea/Hypopnea Index)

AHI is an index that measures the severity of sleep apnea and is calculated by dividing the total number of apneas and hypopneas by the number of hours of sleep. Randomized placebo-controlled cross-over study. Each subject was studied on two separate occasions: (1) Mirtazapine vs. placebo for one week; After the one-week treatment a polysomnogram (PSG) study was performed to determine the AHI. (2) Cross over medication for one week was followed by a second PSG to determine the AHI. (NCT04799782)
Timeframe: One Week

InterventionEvents/Hour (Mean)
Mirtazapine46.4
Placebo47.8

CO2 Reserve (Delta-PETCO2-AT)

Randomized placebo-controlled cross-over study. Each subject was studied on two separate occasions: (1) Mirtazapine vs. placebo for one week; After the one-week treatment a physiological sleep study was performed to determine the CO2 reserve (Delta-PETCO2-AT) and hypocapnic apneic threshold. (2) Cross over medication for one week was followed by a second physiological sleep study to determine the CO2 reserve (Delta-PETCO2-AT) and hypocapnic apneic threshold. (NCT04799782)
Timeframe: One Week

InterventionmmHg (Mean)
Mirtazapine-3.8
Placebo-2.0

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00835575)
Timeframe: Blood samples collected over a 120 hour period.

Interventionpg*h/mL (Mean)
Test (Mirtazapine)327022.65
Reference (Remeron®)316863.06

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00835575)
Timeframe: Blood samples collected over a 120 hour period.

Interventionpg*h/mL (Mean)
Test (Mirtazapine)303749.52
Reference (Remeron®)294920.42

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax. (NCT00835575)
Timeframe: Blood samples collected over a 120 hour period.

Interventionpg/mL (Mean)
Test (Mirtazapine)32975.95
Reference (Remeron®)33122.52

Number of Participants Who Discontinued Treatment Due to an Adverse Event

An Adverse Event (AE) is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an IMP, whether or not it is related to the IMP. (NCT00610675)
Timeframe: Up to 52 weeks

InterventionParticipants (Number)
Esmirtazapine67

Number of Participants With an Adverse Event

An Adverse Event (AE) is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an investigational medicinal product (IMP), whether or not it is related to the IMP. (NCT00610675)
Timeframe: Up to 57 weeks

InterventionParticipants (Number)
Esmirtazapine235

Change From Baseline in Number of Awakenings at Week 52

Number of awakenings is a subjective number recorded by the participant in an electronic sleep diary. Baseline values were calculated by averaging baseline values from base trials P05706 and P05707. Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged. Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged. (NCT00610675)
Timeframe: Baseline and Week 52

InterventionAwakenings (Mean)
Baseline (n= 290)Change from Baseline (n= 285)
Esmirtazapine2.0-0.7

Change From Baseline in Quality of Sleep Scale at Week 52

Quality of Sleep is a subjective number on a Visual Analog Scale recorded by the participant in an electronic sleep diary. The scale ranges from 0 to 100, where very poor is rated at 0, up to excellent, rated at 100. Baseline values were calculated by averaging baseline values from base trials P05706 and P05707. Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged. Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged. (NCT00610675)
Timeframe: Baseline and Week 52

InterventionUnits on a scale (Mean)
Baseline (n= 290)Change from Baseline (n= 285)
Esmirtazapine43.917.3

Change From Baseline in Satisfaction With Sleep Duration Scale at Week 52

Satisfaction with Sleep Duration is a subjective number on a Visual Analog Scale recorded by the participant in an electronic sleep diary. The scale ranges from 0 to 100, where very unsatisfied is rated at 0, up to fully satisfied, rated at 100. Baseline values were calculated by averaging baseline values from base trials P05706 and P05707. Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged. Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged. (NCT00610675)
Timeframe: Baseline and Week 52

InterventionUnits on a scale (Mean)
Baseline (n= 290)Change from Baseline (n= 285)
Esmirtazapine41.319.2

Change From Baseline in Sleep Latency at Week 52

Sleep Latency (SL) is the time from when the participant went to bed up to the the time the participant actually fell asleep, recorded by the participant in an electronic sleep diary. Baseline values were calculated by averaging baseline values from base trials P05706 and P05707. Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged. Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged. (NCT00610675)
Timeframe: Baseline and Week 52

InterventionMinutes (Mean)
Baseline (n= 290)Change from Baseline (n= 285)
Esmirtazapine70.9-24.5

Change From Baseline in Total Sleep Time at Week 52

"Total Sleep Time (TST) is a subjective time recorded by the participant in an electronic sleep diary in response to the question How much time did you actually spend sleeping?. Baseline values were calculated by averaging baseline values from base trials P05706 and P05707. Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged. Missing values were imputed by the last observation carried forward (LOCF) method, where the last available assessments prior to the scheduled observation were averaged." (NCT00610675)
Timeframe: Baseline and Week 52

InterventionMinutes (Mean)
Baseline (n= 290)Change from Baseline (n= 285)
Esmirtazapine331.773.0

Change From Baseline in Wake Time After Sleep Onset at Week 52

Wake time after sleep onset (WASO) is, if the planned waking time is on or after the time of final awakening, as follows: total time from falling asleep to the time of planned wake up minus the total sleep time. If the planned waking time is before the time of final awakening then WASO is as follows: total time from falling asleep to the time of actual final awakening minus the total sleep time. All times were recorded by the participant in an electronic sleep diary. Baseline values were calculated by averaging baseline values from base trials P05706 and P05707. Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged. Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged. (NCT00610675)
Timeframe: Baseline and Week 52

InterventionMinutes (Mean)
Baseline (n= 290)Change from Baseline (n= 285)
Esmirtazapine85.0-34.8

Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 12

Participants recorded the frequency of vasomotor symptoms (hot flushes) on a LogPad on a daily basis during screening and treatment. Frequency score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00560833)
Timeframe: Baseline and Week 12

Interventionnumber of events (Mean)
Placebo-4.9
Esmirtazapine 2.25 mg-6.2
Esmirtazapine 4.5 mg-6.7
Esmirtazapine 9 mg-6.9
Esmirtazapine 18mg-6.5

Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4

Participants recorded the frequency of vasomotor symptoms (hot flushes) on an electronic diary card (LogPad®) on a daily basis during screening and treatment. Frequency score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00560833)
Timeframe: Baseline and Week 4

InterventionNumber of events (Mean)
Placebo-3.9
Esmirtazapine 2.25 mg-5.6
Esmirtazapine 4.5 mg-6.0
Esmirtazapine 9 mg-6.0
Esmirtazapine 18mg-6.0

Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 12

Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00560833)
Timeframe: Baseline and Week 12

Interventionscore on a scale (Mean)
Placebo-0.12
Esmirtazapine 2.25 mg-0.10
Esmirtazapine 4.5 mg-0.15
Esmirtazapine 9 mg-0.18
Esmirtazapine 18mg-0.17

Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 4

Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00560833)
Timeframe: Baseline and Week 4

Interventionscore on a scale (Mean)
Placebo-0.09
Esmirtazapine 2.25 mg-0.11
Esmirtazapine 4.5 mg-0.15
Esmirtazapine 9 mg-0.16
Esmirtazapine 18mg-0.15

Change From Baseline in Vasomotor Symptoms Score Per Women's Health Questionnaire (WHQ) at Week 12

The WHQ is a 36-item, user-friendly, and rapid way of assessing nine domains of physical and emotional health for mid-aged women. Participants self-administered the WHQ questionnaire; scoring is based on a 4-point scale as follows: 'Yes definitely=1', 'Yes sometimes=2', 'No not much=3' and 'No not at all=4'. Each score is transformed to a value '1' for scores '1' and '2' and to a value '0' for scores '3' and '4'. Vasomotor symptoms encompass Items 19 and 27 of the 36 total items. The transformed sums of items 19+27 are divided by 2 to get the score; therefore, the domain ranges from 0 to 1, where lower values are better. (NCT00560833)
Timeframe: Baseline and Week 12

,,,,
InterventionScore on a scale (Mean)
BaselineChange from baseline
Esmirtazapine 18mg0.985-0.246
Esmirtazapine 2.25 mg0.993-0.235
Esmirtazapine 4.5 mg0.985-0.256
Esmirtazapine 9 mg0.981-0.256
Placebo0.984-0.151

Change in Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR Antagonist on the Functional Circuitry Underlying Cue Reactivity

Change in fMRI activation during Attentional bias task with placebo dose vs Mirtazapine dose measured using whole brain blood oxygenation level dependent (BOLD) signal (NCT03921151)
Timeframe: Baseline to 1 week

Interventionpercent of BOLD signal (Mean)
Cocaine-dependent-0.135
Non-drug Using Healthy Controls0.2225

Change in Interaction of the Serotonin Receptor (5-HTR) Type-2C Cys23Ser Single Nucleotide Polymorphism (SNP) and a 5-HT2AR Antagonist on the Functional Circuitry Underlying Impulsive Action.

"Change in fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose.~Brain activation measured using blood-oxygen-level dependent (BOLD) contrast" (NCT03921151)
Timeframe: Baseline to 1 week

Interventionpercent of whole brain BOLD signal (Mean)
Cocaine-dependent0.6889
Non-drug Using Healthy Controls-1.1091

Average Latency to Persistent Sleep Measured by Polysomnography

Latency to Persistent Sleep (LPS) is the time from lights out to the first 20 consecutive epochs scored as sleep by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of LPS (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged. (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg32.3
Esmirtazapine 1.5 mg30.7
Esmirtazapine 3.0 mg29.3
Placebo37.1

Average Number of Awakenings Measured by Polysomnography

Number of awakenings (NAW) was measured by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of NAW (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged. (NCT00561821)
Timeframe: Up to Day 16

InterventionNumber of awakenings (Mean)
Esmirtazapine 0.5 mg13.5
Esmirtazapine 1.5 mg13.4
Esmirtazapine 3.0 mg13.5
Placebo12.1

Average Number of Stage Shifts to Stage 1 or Wake Measured by Polysomnography

Number of stage shifts to stage 1 of sleep or to awaken was measured by PSG. A stage shift is the transition measured by PSG between various sleep stages. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of the number of stage shifts (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged. (NCT00561821)
Timeframe: Up to Day 16

InterventionNumber of stage shifts (Mean)
Esmirtazapine 0.5 mg51.8
Esmirtazapine 1.5 mg50.6
Esmirtazapine 3.0 mg51.3
Placebo44.0

Average Subjective Number of Awakenings Based on Sleep Diary

Number of awakenings between sleep onset and final awakening (NAW) is a subjective number (observed data only) recorded daily by the participant in an electronic diary, that was averaged over the entire 16-day, double-blind treatment period. (NCT00561821)
Timeframe: Up to Day 16

InterventionNumber of Awakenings (Mean)
Esmirtazapine 0.5 mg1.9
Esmirtazapine 1.5 mg2.2
Esmirtazapine 3.0 mg2.1
Placebo1.9

Average Subjective Quality of Sleep Based on Sleep Diary

Quality of Sleep (QS) is a subjective number on a Visual Analog Scale ranging from 0 to 100, where very poor is rated at 0, up to excellent, rated at 100. Daily recordings by the participant in an electronic diary (observed data only) were averaged over the entire 16-day, double-blind treatment period. (NCT00561821)
Timeframe: Up to Day 16

InterventionUnits on a Scale (Mean)
Esmirtazapine 0.5 mg57.8
Esmirtazapine 1.5 mg56.7
Esmirtazapine 3.0 mg58.0
Placebo54.8

Average Subjective Satisfaction of Sleep Duration Based on Sleep Diary

Satisfaction of Sleep Duration (SSD) is a subjective number on a Visual Analog Scale ranging from 0 to 100, where very unsatisfied is rated at 0, up to fully satisfied, rated at 100. Daily recordings by the participant in an electronic diary (observed data only) were averaged over the entire 16-day, double-blind treatment period. (NCT00561821)
Timeframe: Up to Day 16

InterventionUnits on a Scale (Mean)
Esmirtazapine 0.5 mg57.8
Esmirtazapine 1.5 mg56.8
Esmirtazapine 3.0 mg58.1
Placebo54.0

Average Subjective Sleep Latency Based on Sleep Diary

Sleep latency (SL) is the time taken to fall asleep (observed data only) recorded daily by the participant in an electronic diary, that was averaged over the entire 16-day, double-blind treatment period. (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg51.6
Esmirtazapine 1.5 mg53.1
Esmirtazapine 3.0 mg50.5
Placebo46.5

Average Subjective Total Sleep Time Based on Sleep Diary

Total Sleep Time (TST) is a subjective time (observed data only) recorded daily by the participant in an electronic diary, that was averaged over the entire 16-day, double-blind treatment period. (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg364.4
Esmirtazapine 1.5 mg357.3
Esmirtazapine 3.0 mg368.8
Placebo339.9

Average Subjective Wake Time After Sleep Onset Based on Sleep Diary

Wake Time after Sleep Onset (WASO) is after falling asleep initially, the subjective time that the participant was awake during the night. Daily recordings by the participant in an electronic diary (observed data only), were averaged over the entire 16-day, double-blind treatment period. (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg58.4
Esmirtazapine 1.5 mg70.3
Esmirtazapine 3.0 mg62.2
Placebo81.7

Average Total Sleep Time Measured by Polysomnography

Total sleep time (TST) is the sleep time recorded by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of TST (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged. (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg374.1
Esmirtazapine 1.5 mg376.2
Esmirtazapine 3.0 mg383.4
Placebo338.7

Average Wake Time After Sleep Onset in the First Quarter of the Night Measured by Polysomnography

"Wake time after sleep onset (WASO) is the total time awake between sleep onset and lights on; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the first quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged." (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg34.5
Esmirtazapine 1.5 mg33.7
Esmirtazapine 3.0 mg31.2
Placebo40.6

Average Wake Time After Sleep Onset in the Fourth Quarter of the Night Measured by Polysomnography

"Wake time after sleep onset (WASO) is the total time awake between sleep onset and lights on; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the fourth quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged." (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg30.9
Esmirtazapine 1.5 mg29.7
Esmirtazapine 3.0 mg27.4
Placebo42.4

Average Wake Time After Sleep Onset in the Second Quarter of the Night Measured by Polysomnography

"Wake time after sleep onset (WASO) is the total time awake between sleep onset and lights on; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the second quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged." (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg20.1
Esmirtazapine 1.5 mg19.2
Esmirtazapine 3.0 mg18.9
Placebo25.9

Average Wake Time After Sleep Onset in the Third Quarter of the Night Measured by Polysomnography

"Wake time after sleep onset (WASO) is the total time awake between sleep onset and lights on; i.e. from the onset of persistent sleep until the end of the 8-hour PSG recording. WASO was recorded in the third quarter of the night, for at most 2 hours, by PSG. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged." (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg20.5
Esmirtazapine 1.5 mg21.3
Esmirtazapine 3.0 mg19.1
Placebo31.9

Average Wake Time After Sleep Onset Measured by Polysomnography

"Wake time after sleep onset (WASO) is the total time awake between sleep onset and lights on; i.e. from the onset of persistent sleep until the end of the 8-hour polysomnography (PSG) recording. PSG assesses the quality of sleep by monitoring brain waves, breathing, heart function, muscle activity and eye movement. PSG measurements of WASO (observed data only) taken during the 16-day double-blind treatment period, over days 1 and 2 and days 15 and 16, were averaged." (NCT00561821)
Timeframe: Up to Day 16

InterventionMinutes (Mean)
Esmirtazapine 0.5 mg80.3
Esmirtazapine 1.5 mg79.6
Esmirtazapine 3.0 mg74.8
Placebo109.8

Number of Participants Who Discontinued Treatment Due to an Adverse Event During the 16 Day, Double-blind Treatment Period

An AE is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an IMP, whether or not it is related to the IMP. (NCT00561821)
Timeframe: Up to Day 16

InterventionNumber of participants (Number)
Esmirtazapine 0.5 mg2
Esmirtazapine 1.5 mg3
Esmirtazapine 3.0 mg1
Placebo1

Number of Participants With an Adverse Event During the 16 Day, Double-blind Treatment Period

An Adverse Event (AE) is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an investigational medicinal product (IMP), whether or not it is related to the IMP. (NCT00561821)
Timeframe: Up to Day 16

InterventionNumber of participants (Number)
Esmirtazapine 0.5 mg48
Esmirtazapine 1.5 mg54
Esmirtazapine 3.0 mg56
Placebo40

Average Sleep Latency (SL) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period

SL was defined as the duration of time measured in minutes that it took a participant to fall asleep as recorded daily in the participant's sleep diary. SL values over the 14-day active treatment period were averaged for each participant, and average SL was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were present were used in the analysis. (NCT00482612)
Timeframe: Day 1 to Day 15

InterventionMinutes (Mean)
Esmirtazapine 1.5 mg48.93
Esmirtazapine 3.0 mg52.02
Esmirtazapine 4.5 mg50.80
Placebo60.13

Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period

TST was defined as the total amount of time (measured in minutes) that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 14-day active treatment period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were present was used in the analysis. (NCT00482612)
Timeframe: Day 1 to Day 15

InterventionMinutes (Mean)
Esmirtazapine 1.5 mg382.14
Esmirtazapine 3.0 mg382.77
Esmirtazapine 4.5 mg394.83
Placebo351.40

Number of Participants Experiencing an Adverse Event (AE) During the 14-day In-treatment Period

The total number of participants with an AE during the 14-day In-treatment Period was tallied for each treatment arm. An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT00482612)
Timeframe: Day 1 to Day 15

InterventionNumber of participants (Number)
Esmirtazapine 1.5 mg35
Esmirtazapine 3.0 mg41
Esmirtazapine 4.5 mg41
Placebo28

Number of Participants Who Discontinued From Study Treatment Due to an AE During the 14-day In-Treatment Period

The total number of participants discontinuing from study treatment due to experiencing an AE was tallied for each treatment arm. An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT00482612)
Timeframe: Day 1 to Day 15

InterventionNumber of participants (Number)
Esmirtazapine 1.5 mg4
Esmirtazapine 3.0 mg7
Esmirtazapine 4.5 mg9
Placebo0

Number of Participants Who Discontinue Study Drug Due to an AE

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug. (NCT00561574)
Timeframe: Up to 52 weeks

InterventionParticipants (Number)
Esmirtazapine 1.5 mg21
Esmirtazapine 3.0 mg24

Number of Participants Who Experience at Least One Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug. (NCT00561574)
Timeframe: Up to 53 weeks

InterventionParticipants (Number)
Esmirtazapine 1.5 mg115
Esmirtazapine 3.0 mg116

Change From Baseline in Ability to Work/Function

"Ability to work/function was assessed by participants using a 0-100 mm visual analog scale (VAS) in response to Weekly Sleep Diary question 8 How were you able to work or function over the past 7 days?. Scores could range from 0=Not at all to 100=Very well. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an OC approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionScore on a Scale (Mean)
BL (n=121, 123)Change from BL at Week 52 (n=61, 53)
Esmirtazapine 1.5 mg46.919.7
Esmirtazapine 3.0 mg45.921.7

Change From Baseline in Alertness at Awakening

"Alertness at awakening was assessed by participants using a 0-100 mm visual analog scale (VAS) in response to Weekly Sleep Diary question 6 How did you feel upon awakening over the past 7 days?. Scores could range from 0=Tired to 100=Alert. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an observed cases (OC) approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionScore on a Scale (Mean)
Baseline (BL) (n=121, 123)Change from BL at Week 52 (n=61, 53)
Esmirtazapine 1.5 mg38.325.6
Esmirtazapine 3.0 mg38.321.7

Change From Baseline in Feeling Full of Energy

"Feeling full of energy was assessed by participants using a 0-100 mm visual analog scale (VAS) in response to Weekly Sleep Diary question 7 How full of energy have you felt over the past 7 days?. Scores could range from 0=Terribly tired to 100=Full of energy. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an OC approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionScore on a Scale (Mean)
BL (n=121, 123)Change from BL at Week 52 (n=61, 53)
Esmirtazapine 1.5 mg42.620.1
Esmirtazapine 3.0 mg43.320.8

Change From Baseline in Number of Awakenings (NAW)

"NAW was defined as the time recorded by participants in response to Weekly Sleep Diary question 2a During the past 7 nights, how many times did you wake up, on average? Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a LOCF approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionNumber of Awakenings (Mean)
BL (n=118,114)Change from BL at Week 52 (n=114, 109)
Esmirtazapine 1.5 mg2.5-0.3
Esmirtazapine 3.0 mg2.6-0.4

Change From Baseline in Sleep Latency (SL)

"SL was defined as the time recorded by participants in response to Weekly Sleep Diary question 4 During the past 7 nights, how long did it take you to fall asleep, on average? Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a LOCF approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionMinutes (Mean)
BL (n=121,121)Change from BL at Week 52 (n=123,128)
Esmirtazapine 1.5 mg89.8-26.1
Esmirtazapine 3.0 mg92.5-22.2

Change From Baseline in Total Nap Time

"Total nap time was assessed by participants in response to Weekly Sleep Diary question 9a How much time per day did you nap, on average?. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an OC approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionMinutes (Mean)
BL (n=48, 45)Change from BL at Week 52 (n=18, 14)
Esmirtazapine 1.5 mg23.310.7
Esmirtazapine 3.0 mg30.52.9

Change From Baseline in Total Sleep Time (TST)

"TST was defined as the time recorded by participants in response to Weekly Sleep Diary question 4 During the past 7 nights, how much time did you actually spend sleeping, on average?. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a last observation carried forward (LOCF) approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionMinutes (Mean)
BL (n=121,121)Change from BL at Week 52 (n=123,128)
Esmirtazapine 1.5 mg294.388.3
Esmirtazapine 3.0 mg292.386.3

Change From Baseline in Wake Time After Sleep Onset (WASO)

"WASO was defined as the time recorded by participants in response to Weekly Sleep Diary question 4 During the past 7 nights, how much time were you awake, on average, after falling asleep initially? Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a LOCF approach." (NCT00561574)
Timeframe: Baseline and Week 52

,
InterventionMinutes (Mean)
BL (n=121,121)Change from BL at Week 52 (n=122,128)
Esmirtazapine 1.5 mg110.2-62.7
Esmirtazapine 3.0 mg102.4-47.2

Number of Participants Discontinuing Due to AEs

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. (NCT00750919)
Timeframe: Up to 26 weeks

InterventionParticipants (Number)
Esmirtazapine9

Number of Participants Experiencing Adverse Events (AEs)

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. (NCT00750919)
Timeframe: Up to 30 weeks

InterventionParticipants (Number)
Esmirtazapine127

Change From Baseline in Sleep Latency (SL)

"SL was defined as the time recorded for sleep diary question 3 how long did it take you to fall asleep', as reported by the participants using a LogPad (hand-held electronic data capture device). Baseline was defined as the SL from the last week of the base study. Daily diary data were converted to weekly averages. For each treatment week the non-missing diary data of that week were taken into account; if a treatment week had three non-missing morning diaries or less, the data of the previous week were taken into account, weighing the data of both weeks, using the number of observed diaries as weights (weighted mean); if no diary data were available for a treatment week the data were considered as missing and were not imputed." (NCT00750919)
Timeframe: Baseline and Week 26

InterventionMinutes per night (Mean)
Baseline measure (n=184)Change from baseline at Week 26 (n=123)
Esmirtazapine38.7-1.5

Change From Baseline in Total Sleep Time (TST)

"TST was defined as the time recorded for sleep diary question 6 how much time did you actually spend sleeping as reported by the participants using a LogPad (hand-held electronic data capture device). Baseline was defined as the TST from the last week of the base study. Daily diary data were converted to weekly averages. For each treatment week the non-missing diary data of that week were taken into account; if a treatment week had three non-missing morning diaries or less, the data of the previous week were taken into account, weighing the data of both weeks, using the number of observed diaries as weights (weighted mean); if no diary data were available for a treatment week the data were considered as missing and were not imputed." (NCT00750919)
Timeframe: Baseline and Week 26

InterventionMinutes per night (Mean)
Baseline measure (n=184)Change from baseline at Week 26 (n=123)
Esmirtazapine368.19.7

Change From Baseline in Wake Time After Sleep Onset (WASO)

"WASO was defined as the time recorded for sleep diary question 5 how much time were you awake, after falling asleep initially as reported by the participants using a LogPad (hand-held electronic data capture device). Baseline was defined as the WASO from the last week of the base study. Daily diary data were converted to weekly averages. For each treatment week the non-missing diary data of that week were taken into account; if a treatment week had three non-missing morning diaries or less, the data of the previous week were taken into account, weighing the data of both weeks, using the number of observed diaries as weights (weighted mean); if no diary data were available for a treatment week the data were considered as missing and were not imputed." (NCT00750919)
Timeframe: Baseline and Week 26

InterventionMinutes per night (Mean)
Baseline measure (n=184)Change from baseline at Week 26 (n=123)
Esmirtazapine40.0-5.4

Change From Baseline in Average Daily Frequency of Mild to Severe Vasomotor Symptoms (Frequency Score B) by Week

Participants recorded the frequency (number) of vasomotor symptoms (hot flushes) on a LogPad on a daily basis during screening and treatment. Frequency Score B was based on the number of mild hot flushes + the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and up to Week 12

,,,,
InterventionEvents per day (Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Esmirtazapine 18 mg13.00-4.16-5.50-5.79-5.85-5.90-5.89-6.15-6.03-6.26-6.35-6.28-6.32
Esmirtazapine 2.25 mg13.48-3.24-4.81-5.05-5.37-5.61-5.82-5.69-5.54-5.47-5.59-5.68-5.63
Esmirtazapine 4.5 mg13.66-3.81-5.19-5.66-6.01-6.13-6.32-6.47-6.51-6.59-6.36-6.45-6.45
Esmirtazapine 9 mg13.41-3.57-4.79-5.08-5.38-5.57-5.75-5.90-6.06-6.08-6.18-6.08-6.10
Placebo13.29-2.22-3.35-3.83-3.97-4.06-4.25-4.27-4.19-4.30-4.29-4.43-4.40

Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 12

Participants recorded the frequency (number) of vasomotor symptoms (hot flushes) on a LogPad on a daily basis during screening and treatment. Frequency Score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and Week 12

,,,,
InterventionEvents per day (Mean)
BaselineWeek 12
Esmirtazapine 18 mg11.5-6.0
Esmirtazapine 2.25 mg12.2-5.2
Esmirtazapine 4.5 mg12.6-6.0
Esmirtazapine 9 mg12.3-5.8
Placebo12.1-4.2

Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4

Participants recorded the frequency (number) of vasomotor symptoms (hot flushes) on an electronic diary card (LogPad®) on a daily basis during screening and treatment. Frequency Score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (last observation carried forward, or LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and Week 4

,,,,
InterventionEvents per day (Mean)
BaselineWeek 4
Esmirtazapine 18 mg11.5-5.6
Esmirtazapine 2.25 mg12.2-5.1
Esmirtazapine 4.5 mg12.6-5.7
Esmirtazapine 9 mg12.3-5.3
Placebo12.1-3.8

Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) by Week Excluding Weeks 4 and 12

Participants recorded the frequency (number) of vasomotor symptoms (hot flushes) on a LogPad on a daily basis during screening and treatment. Frequency Score A was based on the number of moderate hot flushes + the number of severe hot flushes in one day. Baseline average was derived from, at most, 7 completely observed pre-treatment days. Weekly averages during treatment were calculated if at least 4 days with non-missing data were completely observed; if less than 4 days were completely observed, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and Up to Week 12

,,,,
InterventionEvents per day (Mean)
BaselineWeek 1Week 2Week 3Week 5Week 6Week 7Week 8Week 9Week 10Week 11
Esmirtazapine 18 mg11.52-4.18-5.39-5.59-5.54-5.62-5.93-5.72-5.95-6.11-5.91
Esmirtazapine 2.25 mg12.19-3.20-4.72-4.82-5.29-5.41-5.33-5.19-5.15-5.18-5.30
Esmirtazapine 4.5 mg12.56-4.08-5.19-5.68-5.83-5.96-6.10-6.14-6.23-5.97-6.03
Esmirtazapine 9 mg12.30-3.63-4.88-5.13-5.50-5.58-5.69-5.86-5.96-6.00-5.86
Placebo12.10-2.21-3.25-3.71-3.90-4.02-4.11-4.04-4.11-4.11-4.20

Change From Baseline in Average Daily Mild to Severe Composite Symptoms Score (Composite Score B) by Week

Composite Score B was calculated as Severity Score B x Frequency Score B. (NCT00535288)
Timeframe: Baseline and up to Week 12

,,,,
InterventionComposite score (Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Esmirtazapine 18 mg29.35-10.61-13.64-14.09-14.01-14.08-14.21-14.93-14.40-14.98-15.32-14.95-15.04
Esmirtazapine 2.25 mg31.70-8.53-12.40-12.86-13.48-13.96-14.29-14.09-13.66-13.53-13.71-13.96-13.66
Esmirtazapine 4.5 mg32.13-10.01-12.98-14.40-14.69014.78-15.19-15.48-15.56-15.77-15.15-15.34-15.32
Esmirtazapine 9 mg31.51-9.37-12.60-13.34-13.75-14.22-14.40-14.63-14.92-15.05-15.21-14.79-14.71
Placebo31.39-5.66-8.38-9.57-9.93-10.12-10.45-10.58-10.34-10.49-10.44-10.76-10.66

Change From Baseline in Average Daily Moderate/Severe Composite Score (Composite Score A) by Week

Composite Score A was calculated as Severity Score A x Frequency Score A. (NCT00535288)
Timeframe: Baseline and up to Week 12

,,,,
InterventionComposite score (Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Esmirtazapine 18 mg27.87-10.63-13.54-13.89-13.72-13.72-13.95-14.72-14.08-14.67-15.0814.57-14.71
Esmirtazapine 2.25 mg30.41-8.48-12.32-12.63-13.18-13.65-13.89-13.73-13.31-13.20-13.30-13.58-13.25
Esmirtazapine 4.5 mg31.03-10.28-12.98-14.22-14.42-14.47-14.84-15.11-15.19-15.40-14.76-14.92-14.88
Esmirtazapine 9 mg30.40-9.43-12.70-13.39-13.70-14.16-14.24-14.42-14.73-14.93-15.03-14.58-14.36
Placebo30.19-5.65-8.28-9.46-9.79-9.96-10.22-10.42-10.20-10.30-10.26-10.53-10.42

Change From Baseline in Average Daily Severity of Mild to Severe Vasomotor Symptoms (Severity Score B) by Week

Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity Score B was calculated as the number of mild hot flushes + the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of all hot flushes per week. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and up to Week 12

,,,,
InterventionSeverity score (Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Esmirtazapine 18 mg2.270-0.192-0.250-0.272-0.273-0.266-0.275-0.287-0.273-0.292-0.307-0.308-0.280
Esmirtazapine 2.25 mg2.331-0.132-0.210-0.217-0.224-0.234-0.222-0.234-0.251-0.245-0.244-0.260-0.255
Esmirtazapine 4.5 mg2.349-0.167-0.223-0.246-0.240-0.228-0.214-0.232-0.234-0.256-0.257-0.245-0.240
Esmirtazapine 9 mg2.350-0.140-0.225-0.240-0.249-0.254-0.245-0.242-0.251-0.256-0.257-0.224-0.210
Placebo2.332-0.080-0.111-0.121-0.113-0.124-0.121-0.142-0.139-0.136-0.143-0.149-0.152

Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 12

Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity Score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes per week. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and Week 12

,,,,
InterventionSeverity score (Mean)
BaselineWeek 12
Esmirtazapine 18 mg2.40-0.15
Esmirtazapine 2.25 mg2.45-0.15
Esmirtazapine 4.5 mg2.45-0.13
Esmirtazapine 9 mg2.46-0.13
Placebo2.45-0.08

Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 4

Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity Score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes per week. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and Week 4

,,,,
InterventionSeverity score (Mean)
BaselineWeek 4
Esmirtazapine 18 mg2.40-0.15
Esmirtazapine 2.25 mg2.45-0.14
Esmirtazapine 4.5 mg2.45-0.13
Esmirtazapine 9 mg2.46-0.15
Placebo2.45-0.07

Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) by Week Excluding Weeks 4 and 12

Participants recorded the severity of hot flushes on a LogPad on a daily basis during screening and treatment. The severity of hot flushes was defined as: mild (sensation of heat without sweating); moderate (sensation of heat with sweating, able to continue activity); and severe (sensation of heat with sweating, causing cessation of activity). Severity Score A was calculated as the number of moderate hot flushes x 2 + the number of severe hot flushes x 3, divided by the total number of moderate and severe hot flushes per week. If no hot flushes were experienced, this was to be recorded as 'no sensation of heat'. Baseline values were based on, at most, 7 completely observed pre-treatment days. If less than 4 days were completely observed during treatment, the averages of the previous week were carried forward (LOCF). If the number of days observed in Week 1 were not sufficient, baseline values were carried forward. (NCT00535288)
Timeframe: Baseline and up to Week 12

,,,,
InterventionSeverity score (Mean)
BaselineWeek 1Week 2Week 3Week 5Week 6Week 7Week 8Week 9Week 10Week 11
Esmirtazapine 18 mg2.400-0.108-0.136-0.137-0.151-0.152-0.144-0.133-0.144-0.162-0.156
Esmirtazapine 2.25 mg2.451-0.081-0.117-0.133-0.141-0.136-0.144-0.142-0.142-0.147-0.159
Esmirtazapine 4.5 mg2.449-0.085-0.111-0.119-0.123-0.127-0.131-0.124-0.137-0.125-0.130
Esmirtazapine 9 mg2.460-0.085-0.140-0.150-0.154-0.140-0.140-0.139-0.130-0.141-0.124
Placebo2.447-0.045-0.063-0.071-0.080-0.075-0.088-0.082-0.083-0.084-0.078

Change From Baseline in WHQ Vasomotor Symptoms Domain Score at Week 12

The WHQ is a 36-item, user-friendly, and rapid way of assessing nine domains of physical and emotional health for mid-aged women. Participants self-administered the WHQ questionnaire; scoring is based on a 4-point scale as follows: 'Yes definitely=1', 'Yes sometimes=2', 'No not much=3' and 'No not at all=4'. Each score is transformed to a value '1' for scores '1' and '2' and to a value '0' for scores '3' and '4'. Vasomotor symptoms encompass Items 19 and 27 of the 36 total items. The transformed sums of items 19+27 are divided by 2 to get the score; therefore, the domain ranges from 0 to 1, where lower values are better. (NCT00535288)
Timeframe: Baseline and Week 12

,,,,
InterventionScore on a scale (Mean)
BaselineWeek 12
Esmirtazapine 18mg0.984-0.164
Esmirtazapine 2.25 mg0.989-0.196
Esmirtazapine 4.5 mg0.993-0.224
Esmirtazapine 9 mg0.984-0.117
Placebo0.983-0.085

Change From Baseline in Women's Health Questionnaire (WHQ) Sleep Problems Symptoms Domain Score at Week 12

The WHQ is a 36-item, user-friendly, and rapid way of assessing nine domains of physical and emotional health for mid-aged women. Participants self-administered the WHQ questionnaire; scoring is based on a 4-point scale as follows: 'Yes definitely=1', 'Yes sometimes=2', 'No not much=3' and 'No not at all=4'. Each score is transformed to a value '1' for scores '1' and '2' and to a value '0' for scores '3' and '4'. Sleep problems encompass Items 1, 11, and 29 of the 36 total items. The transformed sums of items 1, 11, and 29 were divided by 3 to get the score; therefore, the domain ranges from 0 to 1, where lower values are better. (NCT00535288)
Timeframe: Baseline and Week 12

,,,,
InterventionScore on a scale (Mean)
BaselineWeek 12
Esmirtazapine 18 mg0.693-0.195
Esmirtazapine 2.25 mg0.659-0.232
Esmirtazapine 4.5 mg0.684-0.251
Esmirtazapine 9 mg0.688-0.224
Placebo0.714-0.140

Total Number of Remitters by Week

A participant was defined as a (hot flush) remitter for a study week if at most one moderate/severe vasomotor symptom per day on average was recorded. A study week was taken into account if at least 4 days were completely observed. The last observation was carried forward if there were less than 4 complete days observed. In cases where Week 1 did not have 4 days that were completely observed, the participant was considered a non-remitter. (NCT00535288)
Timeframe: Up to 12 weeks

,,,,
InterventionParticipants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Esmirtazapine 18 mg21317171718212126252826
Esmirtazapine 2.25 mg21115151815191919192223
Esmirtazapine 4.5 mg71316181621222525252324
Esmirtazapine 9 mg287151213161819232120
Placebo368101315192324252527

Total Number of Responders by Week

A participant was defined as a (hot flush) responder for a study week if a reduction of at least 50% for average daily frequency of moderate/severe vasomotor symptoms (hot flushes) (Frequency Score A) compared to Baseline was recorded. A study week was taken into account if at least 4 days were completely observed. The last observation was carried forward if there were less than 4 complete days observed. In cases where Week 1 did not have 4 days that were completely observed, the participant was considered a non-responder. An LOCF approach was used. (NCT00535288)
Timeframe: Up to 12 weeks

,,,,
InterventionParticipants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Esmirtazapine 18 mg426572717169757275777277
Esmirtazapine 2.25 mg294953586367596567657070
Esmirtazapine 4.5 mg356063706570727374737875
Esmirtazapine 9 mg324847525655606668676565
Placebo375685767684899396979599

Adverse Effects

as assessed by Side Effect Checklist (NCT01178671)
Timeframe: up to 24 weeks

Interventionpercentage of subject dropped due to AEs (Number)
Sertraline and Mirtazapine22.2
Sertraline and Sugar Pill33.3

Alternative Measure of PTSD Severity

as measured by the Short Posttraumatic Stress Disorder Rating Interview, which rates severity of PTSD from 0 (least severe) to 32 (most severe) (NCT01178671)
Timeframe: up to 24 weeks

Interventionunits on a scale (Mean)
Sertraline and Mirtazapine3.4
Sertraline and Sugar Pill6.7

Depression Severity

as measured by the 17-item Hamilton Rating Scale for Depression, which rates severity of depression on a scale from 0 (least depression) to 50 (greatest depression). (NCT01178671)
Timeframe: up to 24 weeks

Interventionunits on a scale (Mean)
Sertraline and Mirtazapine6.4
Sertraline and Sugar Pill11.6

PTSD Self-rated Severity

as measured by the PTSD Checklist which rates severity of PTSD from 17 (least severe) to 85 (most severe). (NCT01178671)
Timeframe: up to 24 weeks

Interventionunits on a scale (Mean)
Sertraline and Mirtazapine33.2
Sertraline and Sugar Pill39.2

PTSD Severity

PTSD severity will be measured by the Clinician-Administered Posttraumatic Stress Disorder Scale, from 0 (least severe) to 136 (most severe). (NCT01178671)
Timeframe: up to 24 weeks

Interventionunits on a scale (Mean)
Sertraline and Mirtazapine23.8
Sertraline and Sugar Pill34.6

Remission Status

Remitter as defined by Clinician Administered Posttraumatic Stress Disorders Scale total score <20 at endpoint (NCT01178671)
Timeframe: up to 24 weeks

Interventionpercentage of subjects (Number)
Sertraline and Mirtazapine39
Sertraline and Sugar Pill11

Response Status

Responders defined by Clinician Administered Posttraumatic Stress Disorder Scale total score decreased by at least 30% compared with baseline and Clinical Global Impression improvement score of =1 or 2 at endpoint (NCT01178671)
Timeframe: up to 24 weeks

Interventionpercentage of subjects (Number)
Sertraline and Mirtazapine56
Sertraline and Sugar Pill22

Sexual Functioning

as measured by Arizona Sexual Experiences Scale, which rates impairment in sexual functioning from 5 (least impaired) to 30 (most impaired). (NCT01178671)
Timeframe: up to 24 weeks

Interventionunits on a scale (Mean)
Sertraline and Mirtazapine16.3
Sertraline and Sugar Pill17.4

Sleep Quality

as measured by Pittsburgh Sleep Quality Index, which rates severity of impairment in sleep quality from 0 (least impaired) to 21 (most impaired). (NCT01178671)
Timeframe: up to 24 weeks

Interventionunits on a scale (Mean)
Sertraline and Mirtazapine4.4
Sertraline and Sugar Pill9.1

Time to Discontinuation of Study Treatment

(NCT01178671)
Timeframe: up to 24 weeks

Interventiondays (Mean)
Sertraline and Mirtazapine95.2
Sertraline and Sugar Pill90.0

Structured Interview of Posttraumatic Stress Disorder (SIP)

Structured Interview of Posttraumatic Stress Disorder (SIP) is a 17-item clinician-administered scale for PTSD based on Diagnostic Statistical Manual-IV criteria. The SIP has excellent test-retest reliability (0.89; p=.00001), and internal consistency (Conbach α of 0.80). The SIP showed significant correlations with the DTS (r=0.67, p=.0001) and the Impact of Event Scale (r=0.49 p=.0001). Relative to the SCID diagnosis of PTSD, sensitivity, specificity, positive predictive value, negative predictive value, and efficiency values were 100% for all indices using a score of 20 on the SIP. Items are scored on a scale from 0-4 which are summed to yield a total score ranging from 0 to 68 (higher score means more symptomatic or worse outcome). A symptom is counted as positive if it is at least a 2 (moderate). (NCT00302107)
Timeframe: Primary outcome is measured at baseline and week 8 (primary endpoint) with primary outcome change scores calculated as week 8 minus baseline score.

Interventionunits on a scale (Mean)
Mirtazapine-7.61
Placebo-5.83

Average Latency to Persistent Sleep (LPS) During the In-Treatment Period

LPS was defined as the time in minutes from lights out to the first 20 consecutive epochs scored as sleep as measured by PSG. LPS was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36

InterventionMinutes (Mean)
Esmirtazapine 3.0 mg28.7
Esmirtazapine 4.5 mg26.1
Placebo40.5

Average Subjective Total Sleep Time (TST) During the In-Treatment Period

TST was defined as the total amount of time in minutes that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 6 week In-Treatment Period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were available was used in the analysis. (NCT00506389)
Timeframe: From Day 1 to Day 36

InterventionMinutes (Mean)
Esmirtazapine 3.0 mg384.6
Esmirtazapine 4.5 mg384.6
Placebo351.6

Average Wake Time After Sleep Onset (WASO) During the In-Treatment Period

WASO was defined as the total objective time awake after the onset of persistent sleep until the end of the 8-hour sleep cycle period as measured by polysomnography (PSG). WASO was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36

InterventionMinutes (Mean)
Esmirtazapine 3.0 mg45.6
Esmirtazapine 4.5 mg45.5
Placebo76.1

Cocaine Abstinence During Last Three Weeks of Study

measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation (NCT00249444)
Timeframe: measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation

Interventionparticipants (Number)
Mirtazapine5
Placebo9

Depression Score on Hamilton - Depression 25 Item

Participants those who had a 50% decrease in HAM-D scores from baseline at end of study. The outcome measured is 50% drop in Hamilton score at week 8 or last week of study participation compared to baseline. We looked at the difference between baseline score and score at week 8 or last week of study participation. (NCT00249444)
Timeframe: End of 8 week study or last week of participation

Interventionparticipants (Number)
Mirtazapine38
Placebo42

Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase

The Pediatric Anxiety Rating Scale (PARS) is a clinician-rated instrument that assesses anxiety symptoms that are commonly associated with social anxiety, separation anxiety, and generalized anxiety disorders. Scaled score ranges form 0-25 with higher scores indicating more severe anxiety symptoms. Means were estimated using a repeated measures linear regression model with treatment group, study week (in categories), and their interaction as covariates, and assuming a common mean between treatment groups at baseline. Confidence intervals reflect a Bonferroni multiple testing correction accounting for the selection of two primary outcomes. (NCT01302964)
Timeframe: Weeks Baseline, 2, 4, 6, and 10

Interventionscore on a scale (Mean)
Mirtazapine-4.9
Placebo-3.2

Proportion of Participants Who Responded to Treatment at 10 Weeks According to the Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or CGI-I=2)

The Clinical Global Impressions Global Improvement (CGI-I) is designed to take into account all factors to arrive at an assessment of response to treatment. The CGI-I scale ranges from 1 to 7 (1=very much improved; 2= much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse), with lower scores indicating improvement (1=very much improved and 2=much improved). In this study the CGI was focused on the target symptom of anxiety. Participants with a CGI-I score of 1 or 2 were classified as responders. The CGI-I was administered biweekly for 6 weeks and again at 10 weeks during the study. The participant who withdrew from the study before 10 weeks was not included in the calculations. (NCT01302964)
Timeframe: Screen (Visit 1) Baseline (Visit 2) and Endpoint (Week 10)

InterventionProportion of participants (Number)
Mirtazapine0.47
Placebo0.20

Drinks Per Drinking Day

Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02185131)
Timeframe: 12 Weeks

InterventionDrinks per drinking day (Mean)
Mirtazapine3.5
Placebo4.4

Level of Depressive Symptoms

Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02185131)
Timeframe: 12 Weeks

InterventionUnits on a scale (Mean)
Mirtazapine27.6
Placebo26.1

Hamilton Depression Rating Scale

Subjects are assessed on 24 characteristics of depressive disorders. Scale scores may range from 0 for no depressive symptoms to 75. (NCT00322309)
Timeframe: Week 11

InterventionScores on a scale (Mean)
Mirtazepine7.2
Placebo6.7

Ln Benzoylecgonine Concentration

(NCT00322309)
Timeframe: Week 11

Interventionln (ng/ml) (Mean)
Mirtazapine9.8
Placebo7.9

Percent Urines Positive for Riboflavin

This measure of adherence was determined by finding the percent of total urines examined that were positive for riboflavin, which had been added to each medication tablet. (NCT00322309)
Timeframe: Weeks 1-11

InterventionPercentage of total urines examined (Mean)
Mirtazapine93.5
Placebo93.5

Pill Count

Percentage of medication capsules administered based on the ratio of the number of capsules administered to the total number dispensed for entire period during which subjects were in treatment. (NCT00322309)
Timeframe: Weeks 1 to 11

InterventionPercentage of dispensed capsules (Mean)
Mirtazapine91
Placebo91

The Clinical Global Impression Observer (CGI-O)Comparison for Week 11

Clinician's overall assessment of the subjects global functioning including the severity of the subject's cocaine use, cocaine seeking, use of other drugs, psychiatric symptoms, medical problems, maladaptive family/social coping, and coping with issues related to employment, housing, and legal issues. Totals range between 7 (for none) to 56 for most severe. (NCT00322309)
Timeframe: Week 11

InterventionScores on a scale (Mean)
Mirtazapine29.9
Placebo23.1

Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12).

(NCT00497081)
Timeframe: Baseline (week 0) and Final Visit (week 12)

InterventionPercentage reduction (Number)
Active Comparator:40
Placebo Comparator:6

Frequency of Adverse Events Reported

(NCT00497081)
Timeframe: From Baseline (week 0) through Final Visit (week 12)

InterventionAdverse Events Reported (Number)
Active Comparator:109
Placebo Comparator:107

Proportion of Days With Recorded Pill Bottle Opening, as Determined by MEMS.

Proportion of days with recorded pill bottle opening, as determined by MEMS (medication event monitoring system). (NCT00497081)
Timeframe: Daily, from Baseline (week 0) through Final Visit (week 12)

InterventionPercentage of recorded openings (Mean)
Active Comparator:48.3
Placebo Comparator:48.7

Quality of Life Inventory

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Interventionunits on a scale (Mean)
Escitalopram + Bupropion SR0.6
Venlafaxine XR + Mirtazapine0.4
Escitalopram + Placebo0.4

Quick Inventory of Depressive Symptoms

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Interventionpercentage of participants (Number)
Escitalopram + Bupropion SR46.6
Venlafaxine XR + Mirtazapine41.8
Escitalopram + Placebo46.0

Brief Pain Inventory

A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention6.84.34.13.9
Usual Care6.74.74.53.8

Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury

The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-2.04-1.69-1.81
Usual Care-1.90-1.63-1.45

Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury

The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-0.79-1.17-1.84
Usual Care-0.50-0.90-2.16

Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury

The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-1.65-4.02-5.51
Usual Care0.08-1.44-4.25

Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury

The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-16.78-14.17-13.23
Usual Care-15.90-13.83-11.68

Cognitive Impairment Scale

The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention13.513.313.213.8
Usual Care13.413.213.414.2

Number of Participants Endorsing a Single Item That Assesses Marijuana Use

Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention125606051
Usual Care177728279

Number of Participants Endorsing a Single Item That Assesses Opioid Use

Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention18446
Usual Care4415206

Number of Participants Endorsing a Single Item That Assesses Stimulant Use

Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention58978
Usual Care77172216

Number of Participants With Suicidal Ideation

Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention67696351
Usual Care909910692

SF-36 Quality of Life

The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention44.338.338.439.2
Usual Care45.139.139.541.4

TSOS Patient Satisfaction: Mental Health Care

Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3 Month, 6 Month, 12 Month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.13.63.63.7
Usual Care4.03.53.43.5

TSOS Patient Satisfaction: Overall Health Care

Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.43.94.03.9
Usual Care4.43.83.83.8

Change From Baseline in Investigator Global Rating (IGR) - 6-Month Treatment Period

The IGR is a clinician-rated 7-point scale used to assess the severity of illness. Severity is rated on a scale from 1=Normal to 7=Extremely severe. Baseline was defined as the last non-missing value obtained during the Placebo Run-in Period. IGR assessments were done at Baseline of the 6-Month Treatment Period and and at the end of the 6-Month Treatment Period to assess the effects of treatment. (NCT00631657)
Timeframe: Baseline and Week 26

Interventionscore on a scale (Mean)
Esmirtazapine 4.5 mg-2.1
Placebo-1.4

Change From Baseline in Investigator Global Rating (IGR) - 7-Day Discontinuation Period

The IGR is a clinician-rated 7-point scale used to assess the severity of illness. Severity is rated on a scale from 1=Normal to 7=Extremely severe. Baseline was defined as the last non-missing value obtained during the Placebo Run-in Period. IGR assessments were done at Baseline of the 6-Month Treatment Period and and at the end of the 7-day Discontinuation Period to assess the effects of discontinuing treatment. (NCT00631657)
Timeframe: Baseline and End of 7-day Discontinuation Period

Interventionscore on a scale (Mean)
Esmirtazapine 4.5 mg/Esmirtazapine 4.5 mg0.3
Esmirtazapine 4.5 mg/Placebo0.5
Placebo/Placebo0.0

Change From Baseline in Number of Awakenings (NAW) - 6-Month Treatment Period

"NAW was defined as the number of times recorded for sleep diary question 4a How many times did you wake up during the night?, as reported by participants using a LogPad. Baseline was defined as the mean NAW from the Placebo Run-in Period. Change from Baseline was calculated as the mean of combined data from Weeks 14 through 26, using an LOCF approach." (NCT00631657)
Timeframe: Baseline and the Mean of Weeks 14-26

Interventionnumber of awakenings (Mean)
Esmirtazapine 4.5 mg-0.8
Placebo-0.5

Change From Baseline in Satisfaction With Sleep Duration - 6-Month Treatment Period

"Satifaction with Sleep Duration was assessed using a Visual Analog Scale (VAS) in response to the sleep diary question 8 How satisfied are you about your sleep duration of last night?, as reported by participants using a LogPad. Responses could range from 0=Very unsatisfied to 100=Fully satisfied, with a higher score indicating great satisfaction with sleep duration. Baseline was defined as the mean Satisfaction with Sleep Duration score from the Placebo Run-in Period. Change from Baseline was calculated as the mean of combined data from Weeks 14 through 26, using an LOCF approach." (NCT00631657)
Timeframe: Baseline and the Mean of Weeks 14-26

Interventionscore on a scale (Mean)
Esmirtazapine 4.5 mg18.3
Placebo7.2

Change From Baseline in Sleep Latency (SL) - 6-Month Treatment Period

"SL was defined as the time recorded for sleep diary question 3 How long did it take you to fall asllep?, as reported by participants using a LogPad. Baseline was defined as the mean SL from the Placebo Run-in Period. Change from Baseline was calculated as the mean of combined data from Weeks 14 through 26, using an LOCF approach." (NCT00631657)
Timeframe: Baseline and the Mean of Weeks 14-26

Interventionminutes (Mean)
Esmirtazapine 4.5 mg-29.7
Placebo-26.9

Change From Baseline in Sleep Quality - 6-Month Treatment Period

"Sleep Quality was assessed using a Visual Analog Scale (VAS) in response to the sleep diary question 7 Rate the quality of your sleep last night, as reported by participants using a LogPad. Responses could range from 0=Very poor to 100=Excellent, with a higher score indicating greater sleep quality. Baseline was defined as the mean Sleep Quality score from the Placebo Run-in Period. Change from Baseline was calculated as the mean of combined data from Weeks 14 through 26, using an LOCF approach." (NCT00631657)
Timeframe: Baseline and the Mean of Weeks 14-26

Interventionscore on a scale (Mean)
Esmirtazapine 4.5 mg16.1
Placebo5.8

Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period

"TST was defined as the time recorded for sleep diary question 6 How much time did you actually spend sleeping? as reported by participants using a LogPad (hand-held electronic data capture device). Baseline was defined as the mean TST from the Placebo Run-in Period. Change from Baseline was calculated as the mean of combined data from Weeks 14 through 26, using a last observation carried forward (LOCF) approach." (NCT00631657)
Timeframe: Baseline and the Mean of Weeks 14-26

Interventionminutes (Mean)
Esmirtazapine 4.5 mg65.9
Placebo19.3

Change From Baseline in Wake Time After Sleep Onset (WASO) - 6-Month Treatment Period

"WASO was defined as the time recorded for sleep diary question 5 How much time were you awake, after falling asleep initially?, as reported by participants using a LogPad. Baseline was defined as the mean WASO from the Placebo Run-in Period. Change from Baseline was calculated as the mean of combined data from Weeks 14 through 26, using an LOCF approach." (NCT00631657)
Timeframe: Baseline and the Mean of Weeks 14-26

Interventionminutes (Mean)
Esmirtazapine 4.5 mg-46.4
Placebo-20.8

Number of Participants Who Discontinued Study Drug Due to an AE

An AE is defined as any unfavorable and unintended change in the structure, function or chemistry of the body whether or not considered related to study drug. The number of participants who discontinued study drug due to an AE is combined for the 6-Month Treatment Period and the 7-Day Discontinuation Period. (NCT00631657)
Timeframe: Up to 27 weeks

Interventionparticipants (Number)
Esmirtazapine 4.5 mg47
Placebo7

Number of Participants Who Experienced Adverse Events (AEs)

An AE is defined as any unfavorable and unintended change in the structure, function or chemistry of the body whether or not considered related to study drug. The number of participants who experienced AEs is combined for the 6-Month Treatment Period and the 7-Day Discontinuation Period. (NCT00631657)
Timeframe: Up to 31 weeks

Interventionparticipants (Number)
Esmirtazapine 4.5 mg253
Placebo75

Change From Baseline in Two Aggregate Measures of Short Form 36 (SF-36) Health Survey Score - 6-Month Treatment Period

SF-36 is a participant-rated questionnaire that consists of 8 scaled scores: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each of the 8 questions carries equal weight. The SF-36 can be divided into 2 aggregate summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The scores can range from 0 to 100, with a lower score indicating more disability. Baseline was defined as the SF-36 score assessed at randomization. (NCT00631657)
Timeframe: Baseline and Week 26

,
Interventionscore on a scale (Mean)
Change from BL at Week 26 - PCSChange from BL at Week 26 - MCS
Esmirtazapine 4.5 mg1.64.6
Placebo-0.24.5

Drinks Per Drinking Day

Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02646449)
Timeframe: 12 Weeks

InterventionDrinks per drinking day (Mean)
Mirtazapine2.8
Placebo2.0

Level of Depressive Symptoms

Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02646449)
Timeframe: 12 Weeks

Interventionunits on a scale (Mean)
Mirtazapine8.0
Placebo3.3

Number of Very Heavy Drinking Days Per Week

"The number of very heavy drinking days (8 or more drinks per drinking day for men or 6 or more drinks per drinking day for women) per week" (NCT01165541)
Timeframe: 14 Weeks

Interventiondays (Mean)
Quetiapine Fumarate Extended Release (Quetiapine XR)2.1
Quetiapine XR Plus Mirtazapine1.3

Self Paced Walking Test (SPWT)

Our primary aim also included a performance-based outcome measure, which was the distance walked during the SPWT. The analysis was a comparison of between-group changes in SPWT between baseline and 8 weeks. The Self-Paced Walking Test (SPWT) is a validated objective measure of a patient's walking capacity, which is performed on a level walking surface. The patient is instructed to walk at their own pace and to stop when the symptoms are troublesome enough that s/he needs to sit down to rest. The total time and total distance walked are measured by the research assistant. Our unit of measure was the total distance walked, expressed in meters. (NCT01943435)
Timeframe: Primary end-point was 8 weeks ( 2 weeks after 6 week intervention is completed).

Interventionmeters (Mean)
Medical Care130.5
Group Exercise219.2
Manual Therapy and Exercise267.8

Sense Wear Armband

Our secondary aim was to measure the change in physical activity between baseline and 8 weeks using the Sense Wear armband (SWA). The outcome measure was the average number of minutes spent daily performing physical activities >1.5 metabolic equivalents (METs).The SWA is a small device that collects information from multiple sensors: a triaxial accelerometer, heat flux, skin temperature, and galvanic signal. The information is integrated and processed by software using proprietary algorithms utilizing subjects' demographic characteristics (gender, age, height, and weight) to provide minute-by-minute estimates of physical activity. The SWA has shown good reliability and validity. The research participants in our study will wear the SWA for a week before and after they complete the treatment interventions. (NCT01943435)
Timeframe: Primary End-Point was 8 weeks ( 2 weeks after completion of 6-week intervention).

Interventionminutes per day (Mean)
Medical Care-23.1
Group Exercise4.3
Manual Therapy and Exercise-6.0

Swiss Spinal Stenosis (SSS) Questionnaire Score

Our primary aim included a primary outcome measure of self-reported pain/function, which was the change in SSS total score between baseline and 8 weeks. The Swiss Spinal Stenosis Questionnaire (SSS) is a validated 12-item condition-specific instrument for patients with lumbar spinal stenosis. It provides a patient self-report measure of pain and physical function. Higher scores represent worse symptoms and less physical function. The 12-item SSS total score range is 12-55. For our analysis, we compared the change in the 12-item Total score from baseline to 8 weeks. (NCT01943435)
Timeframe: Primary End-Point was 8 weeks ( 2 weeks after completion of 6-week intervention).

Interventionunits on a scale (Mean)
Medical Care-2.0
Group Exercise-1.7
Manual Therapy and Exercise-4.1

Money Earned

"Change in amount of money earned between baseline and after 6 weeks of antidepressant treatment is determined through a summary score from a variety of decision-making tasks. Participants received between $5 and $40 per visit, depending on the outcomes of the decisions made on the computerized tasks. Variable payment ensured that the decision-making tasks were approached realistically, as opposed to using hypothetical points that do not have meaning in the real world. Greater earnings indicate better financial decision-making.~The specific tasks were:~risk task~balloon analogue risk task~temporal discounting task~ultimatum game~continuous performance task" (NCT01916824)
Timeframe: Baseline, Week 6

,
InterventionUS Dollars (Mean)
Baseline VisitAfter 6 Weeks of Treatment
Healthy Controls25.021.9
Participants With Major Depressive Disorder23.220.5

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00834197)
Timeframe: Blood samples collected over a 120 hour period.

Interventionpg*h/mL (Mean)
Test (Mirtazapine)380545.78
Reference (Remeron®)385738.84

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00834197)
Timeframe: Blood samples collected over a 120 hour period.

Interventionpg*h/mL (Mean)
Test (Mirtazapine)355137.72
Reference (Remeron®)359429

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax. (NCT00834197)
Timeframe: Blood samples collected over a 120 hour period.

Interventionpg/mL (Mean)
Test (Mirtazapine)26345.06
Reference (Remeron®)25942.77

SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
idazoxan[no description available]high80benzodioxine;
imidazolines		alpha-adrenergic antagonist
coumarin[no description available]medium20coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid[no description available]medium40monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
phenytoin[no description available]medium80imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
phenytoin[no description available]medium81imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
tacrine[no description available]medium90acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol[no description available]medium100aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen[no description available]medium100acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
albuterol[no description available]medium100phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alprazolam[no description available]high100organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol[no description available]medium80secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
amantadine[no description available]medium140adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
amantadine[no description available]medium141adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
theophylline[no description available]medium110dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amiodarone[no description available]medium1101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amitriptyline[no description available]medium690carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amitriptyline[no description available]medium6912carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlodipine[no description available]medium120dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amobarbital[no description available]medium30barbiturates
aspirin[no description available]medium100benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
atenolol[no description available]medium110ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
bepridil[no description available]medium40pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
betaxolol[no description available]medium80propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bevantolol[no description available]medium30propanolamineanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker
bisoprolol[no description available]medium90secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
brotizolam[no description available]medium30organic molecular entity
bumetanide[no description available]medium90amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
caffeine[no description available]medium120purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil[no description available]medium150aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbamazepine[no description available]medium140dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbamazepine[no description available]medium141dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carteolol[no description available]medium20quinolone;
secondary alcohol		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
carvedilol[no description available]medium90carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
chlorambucil[no description available]medium80aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlordiazepoxide[no description available]medium80benzodiazepine
chloroquine[no description available]medium100aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorothiazide[no description available]medium20benzothiadiazineantihypertensive agent;
diuretic
chlorpheniramine[no description available]medium110monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine[no description available]medium130organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide[no description available]medium70monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone[no description available]medium60isoindoles;
monochlorobenzenes;
sulfonamide
cifenline[no description available]medium50diarylmethane
cimetidine[no description available]medium100aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cimetidine[no description available]medium101aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cisapride[no description available]medium40benzamides
citalopram[no description available]medium11802-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
citalopram[no description available]medium118222-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clobazam[no description available]medium301,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clomipramine[no description available]high191dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clomipramine[no description available]high190dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam[no description available]high1201,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine[no description available]medium210clonidine;
imidazoline
clonidine[no description available]medium211clonidine;
imidazoline
desipramine[no description available]high230dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
nordazepam[no description available]medium301,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
diazepam[no description available]high2031,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazepam[no description available]high2001,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide[no description available]medium70benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
diclofenac[no description available]medium110amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
diflunisal[no description available]medium60monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
diphenhydramine[no description available]high100ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
disopyramide[no description available]medium90monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
valproic acid[no description available]medium160branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
valproic acid[no description available]medium161branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
domperidone[no description available]medium90benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
doxazosin[no description available]medium40aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin[no description available]medium210dibenzooxepine;
tertiary amino compound		antidepressant
doxepin[no description available]medium213dibenzooxepine;
tertiary amino compound		antidepressant
ethosuximide[no description available]medium30dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
etilefrine[no description available]medium40phenols
etodolac[no description available]medium40monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
felodipine[no description available]medium90dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fenfluramine[no description available]medium20(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
berotek[no description available]medium20resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
flecainide[no description available]medium100aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fluconazole[no description available]medium100conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine[no description available]medium80aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
flumazenil[no description available]medium100ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
flunitrazepam[no description available]medium401,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
fluorouracil[no description available]medium70nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine[no description available]medium920(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
fluoxetine[no description available]medium9211(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
flurbiprofen[no description available]medium60fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
furosemide[no description available]medium100chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gemfibrozil[no description available]medium50aromatic etherantilipemic drug
glipizide[no description available]medium80aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glyburide[no description available]medium90monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
haloperidol[no description available]high242aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
haloperidol[no description available]high240aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
hexobarbital[no description available]medium40barbiturates
hydralazine[no description available]medium50azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydrochlorothiazide[no description available]medium60benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
ibuprofen[no description available]medium120monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
ibuprofen[no description available]medium121monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
lidocaine[no description available]medium130benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
imipramine[no description available]medium400dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
imipramine[no description available]medium406dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone[no description available]medium70bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indomethacin[no description available]medium120aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
isoniazid[no description available]medium70carbohydrazideantitubercular agent;
drug allergen
isoproterenol[no description available]medium50catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isradipine[no description available]medium70benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
ketamine[no description available]medium90cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketamine[no description available]medium91cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketoprofen[no description available]medium100benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac[no description available]medium90amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
labetalol[no description available]medium90benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine[no description available]medium1701,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lamotrigine[no description available]medium1711,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole[no description available]medium90benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lofepramine[no description available]medium50aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
lorazepam[no description available]medium150benzodiazepine
lorazepam[no description available]medium152benzodiazepine
mabuterol[no description available]medium10(trifluoromethyl)benzenes
maprotiline[no description available]medium100anthracenes
mebendazole[no description available]medium90aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
meperidine[no description available]medium80ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
metaproterenol[no description available]medium20aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
methadone[no description available]medium110benzenes;
diarylmethane;
ketone;
tertiary amino compound
metoclopramide[no description available]medium150benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metoprolol[no description available]medium160aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole[no description available]medium100C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
mexiletine[no description available]medium80aromatic ether;
primary amino compound		anti-arrhythmia drug
mianserin[no description available]high1,229272dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
mianserin[no description available]high1,2290dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
midazolam[no description available]high150imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
milrinone[no description available]medium50bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
moclobemide[no description available]medium120benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
nabumetone[no description available]medium40methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nevirapine[no description available]medium80cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nicardipine[no description available]medium90benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine[no description available]medium100C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nilvadipine[no description available]medium10dihydropyridine;
isopropyl ester;
methyl ester;
nitrile
nimodipine[no description available]medium902-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine[no description available]medium80C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam[no description available]medium701,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine[no description available]medium50C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nizatidine[no description available]medium801,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nortriptyline[no description available]medium200organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
nortriptyline[no description available]medium202organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
omeprazole[no description available]medium100aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron[no description available]medium140carbazoles
ondansetron[no description available]medium141carbazoles
oxaprozin[no description available]medium501,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxazepam[no description available]high1021,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxazepam[no description available]high1001,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxprenolol[no description available]medium30aromatic ether
pentoxifylline[no description available]medium70oxopurine
perphenazine[no description available]medium90N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenobarbital[no description available]medium70barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenolphthalein[no description available]medium20phenols
phenylbutazone[no description available]medium20pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
pindolol[no description available]high130indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pirenzepine[no description available]medium60pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
prazosin[no description available]high150aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine[no description available]medium70aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone[no description available]medium50pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
probenecid[no description available]medium90benzoic acids;
sulfonamide		uricosuric drug
probucol[no description available]medium20dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procainamide[no description available]medium100benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
prochlorperazine[no description available]medium60N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine[no description available]medium60pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promethazine[no description available]high130phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone[no description available]medium90aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propranolol[no description available]high171naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
propranolol[no description available]high170naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
protriptyline[no description available]medium40carbotricyclic compoundantidepressant
raloxifene[no description available]medium201-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
ranitidine[no description available]medium110aralkylamine
riluzole[no description available]medium60benzothiazoles
risperidone[no description available]high4431,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
risperidone[no description available]high4401,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
sulfadiazine[no description available]medium90pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfamethoxazole[no description available]medium60isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfinpyrazone[no description available]medium50pyrazolidines;
sulfoxide		uricosuric drug
sulfisoxazole[no description available]medium50isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulpiride[no description available]medium90benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sumatriptan[no description available]medium120sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
temazepam[no description available]medium40benzodiazepine
terazosin[no description available]medium70furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline[no description available]medium90phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
thioridazine[no description available]medium60phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
tizanidine[no description available]medium90benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
tolbutamide[no description available]medium80N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolmetin[no description available]medium30aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
ultram[no description available]medium100aromatic ether;
tertiary alcohol;
tertiary amino compound
trazodone[no description available]high363monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
trazodone[no description available]high360monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene[no description available]medium50pteridinesdiuretic;
sodium channel blocker
triazolam[no description available]medium90triazolobenzodiazepinesedative
trimethoprim[no description available]medium90aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
urapidil[no description available]medium40piperazines
venlafaxine[no description available]medium140cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
prednisolone[no description available]medium10011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
spironolactone[no description available]medium403-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
prednisone[no description available]medium9011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
chloramphenicol[no description available]medium90C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
ethinyl estradiol[no description available]medium4017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
phenylephrine[no description available]medium30phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
oxacillin[no description available]medium40penicillinantibacterial agent;
antibacterial drug
norethindrone[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
methylprednisolone[no description available]medium1006-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
nafcillin[no description available]medium50penicillin allergen;
penicillin		antibacterial drug
betamethasone[no description available]medium7011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
dextropropoxyphene[no description available]medium601-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
chlormethiazole[no description available]medium40thiazoles
ethambutol[no description available]medium50ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
dronabinol[no description available]medium100benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride[no description available]medium30aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
pimozide[no description available]medium60benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
dicloxacillin[no description available]medium60dichlorobenzene;
penicillin		antibacterial drug
zalcitabine[no description available]medium60pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
selegiline[no description available]medium100selegiline;
terminal acetylenic compound		geroprotector
clemastine[no description available]medium20monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
du-21220[no description available]medium30benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
timolol[no description available]medium110timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin[no description available]medium30tryptamines
moricizine[no description available]medium30carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
zidovudine[no description available]medium80azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
medifoxamine[no description available]medium10aromatic ether
dobutamine[no description available]medium40catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
penbutolol[no description available]medium30ethanolamines
tocainide[no description available]medium50monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
sq-11725[no description available]medium80
diltiazem[no description available]medium1105-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
meptazinol[no description available]medium40azepanes
prenalterol[no description available]medium10aromatic ether
lorcainide[no description available]medium50acetamides
paroxetine[no description available]high8324aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
paroxetine[no description available]high830aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
captopril[no description available]medium80alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
encainide[no description available]medium60benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
lovastatin[no description available]medium80delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
enoximone[no description available]medium50aromatic ketone
simvastatin[no description available]medium60delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
mibefradil[no description available]medium30tetralinsT-type calcium channel blocker
bromfenac[no description available]medium70aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
rilmenidine[no description available]medium10isourea
diprafenone[no description available]medium30aromatic compound
uk 68798[no description available]medium60aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
bufuralol[no description available]medium40benzofurans
epanolol[no description available]medium10acetamides
methotrimeprazine[no description available]high60phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
atovaquone[no description available]medium60hydroxy-1,2-naphthoquinone
nicotine[no description available]high1303-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
methotrexate[no description available]medium100dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
xamoterol[no description available]medium50morpholines
naproxen[no description available]medium80methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
atropine[no description available]medium120
rimiterol[no description available]medium10catechols
quinidine[no description available]high130cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
dironyl[no description available]medium10organic molecular entity
tretinoin[no description available]medium50retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
mercaptopurine[no description available]medium70aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
terbinafine[no description available]medium50acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
raclopride[no description available]medium10salicylamides
quinine[no description available]medium80cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
zofenoprilate[no description available]medium10aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thiol		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
codeine[no description available]medium80morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
naloxone[no description available]medium110morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
morphine[no description available]medium150morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
morphine[no description available]medium153morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
nalbuphine[no description available]medium50organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
zuclopenthixol[no description available]medium10clopenthixolalpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
fluvoxamine[no description available]high232(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
fluvoxamine[no description available]high230(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium90dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
naltrexone[no description available]medium80cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
famotidine[no description available]medium801,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
nitrofurantoin[no description available]medium70imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
nifurtimox[no description available]medium20nitrofuran antibiotic
scopolamine hydrobromide[no description available]medium50
mobiflex[no description available]medium60heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
warfarin[no description available]medium100benzenes;
hydroxycoumarin;
methyl ketone
ajmaline[no description available]medium20
clozapine[no description available]high323benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
clozapine[no description available]high320benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
olanzapine[no description available]high445benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
olanzapine[no description available]high440benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
allopurinol[no description available]medium90nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
8-hydroxy-2-(di-n-propylamino)tetralin[no description available]high50phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
mazindol[no description available]medium20organic molecular entity
nisoxetine[no description available]medium20aromatic ether;
secondary amino compound		adrenergic uptake inhibitor;
antidepressant
(R)-fluoxetine[no description available]medium10N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amineantidepressant;
serotonin uptake inhibitor
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine[no description available]medium50aromatic ether
quinacrine[no description available]medium40acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
antipyrine[no description available]medium60pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
azelastine[no description available]medium50monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
bromazepam[no description available]medium60organic molecular entity
fentanyl[no description available]medium80anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
itraconazole[no description available]medium80piperazines
nefazodone[no description available]medium380aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
promazine[no description available]medium40phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
propofol[no description available]medium50phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
sotalol[no description available]medium90ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
trimipramine[no description available]medium90dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
trimipramine[no description available]medium91dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
colchicine[no description available]medium50alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
ergotamine[no description available]medium40peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
galantamine[no description available]medium60benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
lormetazepam[no description available]medium401,4-benzodiazepinone;
organochlorine compound		sedative
chlordesmethyldiazepam[no description available]medium20benzodiazepine
amitriptyline n-oxide[no description available]medium10organic tricyclic compound
paclitaxel[no description available]medium70taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
tolamolol[no description available]medium30
sufentanil[no description available]medium70anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
alfentanil[no description available]medium60monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
remoxipride[no description available]medium80dimethoxybenzene
atomoxetine[no description available]medium70aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
tebufelone[no description available]medium10
diltiazem hydrochloride[no description available]medium10hydrochlorideantihypertensive agent;
calcium channel blocker;
vasodilator agent
nebivolol[no description available]medium40chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
voriconazole[no description available]medium50conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
rivastigmine[no description available]medium50carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
tolterodine[no description available]medium70tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
cocaine[no description available]medium190benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
cocaine[no description available]medium191benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
zithromax[no description available]medium90macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
oxycodone[no description available]medium80organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
butorphanol[no description available]medium80morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
4-oxoretinoic acid[no description available]medium10enone;
retinoid		human xenobiotic metabolite
bupropion[no description available]medium570aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
bupropion[no description available]medium5712aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
aminocaproic acid[no description available]medium40amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
acetohydroxamic acid[no description available]medium30acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
alendronate[no description available]medium201,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
altretamine[no description available]medium20triamino-1,3,5-triazine
amifostine anhydrous[no description available]medium20diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
aminoglutethimide[no description available]medium30dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
amlexanox[no description available]medium20monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amoxapine[no description available]medium90dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
anastrozole[no description available]medium40nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
apraclonidine[no description available]medium10dichlorobenzene;
guanidines;
imidazolines		alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug
astemizole[no description available]medium30benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
azathioprine[no description available]medium40aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azelaic acid[no description available]medium10alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite
baclofen[no description available]medium60amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
baclofen[no description available]medium61amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
bicalutamide[no description available]medium40(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
brimonidine[no description available]medium10imidazoles;
quinoxaline derivative;
secondary amine		adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent
buspirone[no description available]high120azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan[no description available]medium70methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
butenafine[no description available]medium10naphthalenes;
tertiary amine		antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor
carmustine[no description available]medium40N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
cetirizine[no description available]medium30ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlormezanone[no description available]medium301,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
ciclopirox[no description available]medium20cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
cinoxacin[no description available]medium40cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
ciprofloxacin[no description available]medium90aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
clofazimine[no description available]medium30monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
chlorazepate[no description available]medium401,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
cyclobenzaprine[no description available]medium50carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
dipivefrin[no description available]medium10ethanolamines;
pivalate ester		adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent
disulfiram[no description available]medium50organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
droperidol[no description available]medium40aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
econazole[no description available]medium20dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
enflurane[no description available]medium20ether;
organochlorine compound;
organofluorine compound		anaesthetic
enoxacin[no description available]medium501,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
estazolam[no description available]medium30triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
etidronate[no description available]medium201,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
brl 42810[no description available]medium402-aminopurines;
acetate ester		antiviral drug;
prodrug
felbamate[no description available]medium40carbamate esteranticonvulsant;
neuroprotective agent
fexofenadine[no description available]medium20piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
fluphenazine[no description available]medium20N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
fluphenazine depot[no description available]medium10decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug
fluphenazine enanthate[no description available]medium10phenothiazines
flutamide[no description available]medium40(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
foscarnet[no description available]medium50carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
gabapentin[no description available]medium130gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gabapentin[no description available]medium131gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
glimepiride[no description available]medium60sulfonamide
granisetron[no description available]medium60aromatic amide;
indazoles
guanfacine[no description available]medium60acetamides
halothane[no description available]medium20haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
hydroxyurea[no description available]medium80one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine[no description available]high50hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
phenelzine[no description available]medium40primary amine
ifosfamide[no description available]medium70ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
indapamide[no description available]medium40indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
iodixanol[no description available]medium10organoiodine compoundradioopaque medium
iohexol[no description available]medium40benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide[no description available]medium30dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
ioversol[no description available]medium20amidobenzoic acid
isoflurane[no description available]medium30organofluorine compoundinhalation anaesthetic
ketoconazole[no description available]medium40dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
lomefloxacin[no description available]medium40fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
loratadine[no description available]medium40benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
losartan[no description available]medium60biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine[no description available]medium40dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
meclofenamic acid[no description available]medium20aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
mefenamic acid[no description available]medium50aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mefloquine hydrochloride[no description available]medium10organofluorine compound;
piperidines;
quinolines;
secondary alcohol
mesalamine[no description available]medium50amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
metformin[no description available]medium90guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
midodrine[no description available]medium20amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
minoxidil[no description available]medium50dialkylarylamine;
tertiary amino compound
mitoxantrone[no description available]medium50dihydroxyanthraquinoneanalgesic;
antineoplastic agent
nilutamide[no description available]medium30(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
masoprocol[no description available]medium20catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
norfloxacin[no description available]medium60fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ofloxacin[no description available]medium803-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
pamidronate[no description available]medium30phosphonoacetic acid
pemoline[no description available]medium401,3-oxazolescentral nervous system stimulant
pentamidine[no description available]medium40aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pirbuterol[no description available]medium10pyridines
prazepam[no description available]medium10benzodiazepine
praziquantel[no description available]medium40isoquinolines
procarbazine[no description available]medium30benzamides;
hydrazines		antineoplastic agent
sch 16134[no description available]medium30benzodiazepine
rimantadine[no description available]medium20alkylamine
salmeterol xinafoate[no description available]medium10ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound
sevoflurane[no description available]medium20ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
sulconazole[no description available]medium10dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide
sulfasalazine[no description available]medium60
suprofen[no description available]medium60aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
tazarotene[no description available]medium20acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
terfenadine[no description available]medium50diarylmethane
thiotepa[no description available]medium50aziridines
ticlopidine[no description available]medium30monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tioconazole[no description available]medium10dichlorobenzene;
ether;
imidazoles;
thiophenes
tiopronin[no description available]medium30N-acyl-amino acid
trientine[no description available]medium10polyazaalkane;
tetramine		copper chelator
trifluoperazine[no description available]medium40N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trimethadione[no description available]medium30oxazolidinoneanticonvulsant;
geroprotector
trimetrexate[no description available]medium40
ici 204,219[no description available]medium40carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zolpidem[no description available]medium180imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zomepirac[no description available]medium10aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
floxuridine[no description available]medium20nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
penicillamine[no description available]medium50non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
pilocarpine[no description available]medium30pilocarpineantiglaucoma drug
vincristine[no description available]medium40acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
testosterone propionate[no description available]medium20steroid ester
bretylium tosylate[no description available]medium10organosulfonate salt;
quaternary ammonium salt		adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
cytarabine[no description available]medium70beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine[no description available]medium10nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
medroxyprogesterone acetate[no description available]medium3020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
mestranol[no description available]medium2017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
estradiol dipropionate[no description available]medium10steroid ester
methohexital[no description available]medium30acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
estradiol 17 beta-cypionate[no description available]medium10steroid ester
testosterone enanthate[no description available]medium20heptanoate ester;
sterol ester		androgen
chenodeoxycholic acid[no description available]medium30bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
podophyllotoxin[no description available]medium20furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
levocarnitine[no description available]medium20carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
megestrol acetate[no description available]medium6020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
acetylcysteine[no description available]medium50acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
erythromycin[no description available]medium90cyclic ketone;
erythromycin
levonorgestrel[no description available]medium4017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
estradiol valerate[no description available]medium20steroid ester
betamethasone valerate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
primary alpha-hydroxy ketone;
steroid ester		anti-inflammatory drug
methylprednisolone hemisuccinate[no description available]medium10corticosteroid hormone;
hemisuccinate
stavudine[no description available]medium60dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
cyclacillin[no description available]medium20penicillinantibacterial drug
tranylcypromine[no description available]medium702-phenylcyclopropan-1-amine
tranylcypromine[no description available]medium732-phenylcyclopropan-1-amine
cladribine[no description available]medium60organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
beclomethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
estradiol enanthate[no description available]medium10steroid ester
betamethasone-17,21-dipropionate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
propanoate ester;
steroid ester		antipsoriatic
olsalazine[no description available]medium40azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
levamisole[no description available]medium206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
cephalexin[no description available]medium60beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
isosorbide-5-mononitrate[no description available]medium60glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
danazol[no description available]medium4017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
daunorubicin[no description available]medium30aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
cephapirin[no description available]medium20cephalosporinantibacterial drug
bromocriptine[no description available]medium30indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
ursodeoxycholic acid[no description available]medium40bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
metipranolol[no description available]medium20acetate ester;
aromatic ether;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
halazepam[no description available]medium10organic molecular entity
cefazolin[no description available]medium70beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin[no description available]medium90penicillin allergen;
penicillin		antibacterial drug
bitolterol[no description available]medium10carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug
tobramycin[no description available]medium50amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
etoposide[no description available]medium60beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
ribavirin[no description available]medium701-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
guanadrel[no description available]medium10guanidines;
spiroketal		adrenergic antagonist;
antihypertensive agent
methyldopa[no description available]medium70L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
levobunolol[no description available]medium10aromatic ether;
cyclic ketone;
propanolamine		antiglaucoma drug;
beta-adrenergic antagonist
vecuronium bromide[no description available]medium30organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
permethrin[no description available]medium20cyclopropanecarboxylate ester;
cyclopropanes		agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide
torsemide[no description available]medium50aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
cefmetazole[no description available]medium20cephalosporinantibacterial drug
desflurane[no description available]medium20organofluorine compoundinhalation anaesthetic
idarubicin[no description available]medium40anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
cefonicid[no description available]medium10cephalosporinantibacterial drug
piperacillin[no description available]medium60penicillin allergen;
penicillin		antibacterial drug
cefoperazone[no description available]medium50cephalosporinantibacterial drug
lodoxamide[no description available]medium10organonitrogen compound;
organooxygen compound
atracurium[no description available]medium30diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
butoconazole[no description available]medium10aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes
naftifine[no description available]medium10allylamine antifungal drug;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor
pergolide[no description available]medium50diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
cefadroxil anhydrous[no description available]medium70cephalosporinantibacterial drug
nedocromil[no description available]medium10dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
cefaclor anhydrous[no description available]medium40cephalosporinantibacterial drug;
drug allergen
cefotetan[no description available]medium50
levocabastine[no description available]medium10piperidines
pravastatin[no description available]medium703-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cabergoline[no description available]medium40N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
quinapril[no description available]medium40dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
fosphenytoin[no description available]medium20imidazolidine-2,4-dione
finasteride[no description available]medium603-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
esmolol[no description available]medium40aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
adapalene[no description available]medium20adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
sparfloxacin[no description available]medium60fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton[no description available]medium401-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
cidofovir anhydrous[no description available]medium120phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
topotecan[no description available]medium40pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine[no description available]medium50organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide[no description available]medium40benzenes;
organic amino compound
remifentanil[no description available]medium40alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin[no description available]medium50aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine[no description available]medium80monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan[no description available]medium60carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan[no description available]medium70biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
adenosine[no description available]medium30adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
cefprozil[no description available]medium40cephalosporin;
semisynthetic derivative		antibacterial drug
methylprednisolone aceponate[no description available]medium10corticosteroid hormone
dexamethasone 17-valerate[no description available]medium1021-hydroxy steroid
dexamethasone dipropionate[no description available]medium10corticosteroid hormone
iopamidol[no description available]medium20benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
dexfenfluramine[no description available]medium40fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
sertraline[no description available]medium680dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
sertraline[no description available]medium6813dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
erythromycin propionate[no description available]medium10erythromycin derivative
dexrazoxane[no description available]medium50razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
antebate[no description available]medium10corticosteroid hormone
flunisolide[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
clarithromycin[no description available]medium70macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
moexipril[no description available]medium20peptide
docetaxel[no description available]medium40hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
levofloxacin[no description available]medium1009-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ropivacaine[no description available]medium30piperidinecarboxamide;
ropivacaine		local anaesthetic
estradiol 3-benzoate[no description available]medium2017beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen
estramustine[no description available]medium3017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
ritonavir[no description available]medium501,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
pentostatin[no description available]medium30coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
meropenem[no description available]medium70alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin[no description available]medium401-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
cefoxitin[no description available]medium30beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
saquinavir[no description available]medium60L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
netilmicin[no description available]medium40
metyrosine[no description available]medium20L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide[no description available]medium20organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
terconazole[no description available]medium101-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
bacampicillin[no description available]medium10penicillanic acid esterprodrug
erythromycin ethylsuccinate[no description available]medium20cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester
amcinonide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal		anti-inflammatory drug
betamethasone acetate[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
steroid ester;
tertiary alpha-hydroxy ketone
acarbose[no description available]medium40amino cyclitol;
glycoside
mycophenolic acid[no description available]medium302-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
mupirocin[no description available]medium20alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
fosfomycin[no description available]medium60epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
teniposide[no description available]medium60aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefamandole[no description available]medium40cephalosporin;
semisynthetic derivative		antibacterial drug
dactinomycin[no description available]medium30actinomycinmutagen
melphalan[no description available]medium60L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sch 22219[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
glucocorticoid;
propanoate ester;
steroid ester		anti-inflammatory drug
mezlocillin[no description available]medium30penicillin allergen;
penicillin		antibacterial drug
cholinophyllin[no description available]medium10
fludarabine[no description available]medium20purine nucleoside
propylthiouracil[no description available]medium70pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
ipratropium bromide anhydrous[no description available]medium10
etomidate[no description available]medium50ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
thiothixene[no description available]medium20N-methylpiperazineanticoronaviral agent
benztropine[no description available]medium30diarylmethane
sulindac[no description available]medium50monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
enclomiphene[no description available]medium10
thioguanine anhydrous[no description available]medium302-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
succimer[no description available]medium20dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
streptozocin[no description available]medium30
tamoxifen[no description available]medium70stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ethionamide[no description available]medium30pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
dezocine[no description available]medium10phenols;
primary amino compound		opioid analgesic
dapiprazole[no description available]medium10N-alkylpiperazine;
N-arylpiperazine;
pyridines		alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
flosequinan[no description available]medium20quinolines
calcitriol[no description available]medium40D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
alprostadil[no description available]medium40prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
amphotericin b[no description available]medium40antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
pulmicort[no description available]medium7011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
olopatadine[no description available]medium10
bw b1090u[no description available]medium10isoquinolines
7432 s[no description available]medium20cephalosporin;
dicarboxylic acid		antibacterial drug
etretinate[no description available]medium30enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin[no description available]medium50retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
misoprostol[no description available]medium20
epoprostenol[no description available]medium20prostaglandins Imouse metabolite
betamethasone benzoate[no description available]medium1021-hydroxy steroid
dorzolamide[no description available]medium10sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
hydromorphone[no description available]medium40morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
ly 163892[no description available]medium20carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nalmefene[no description available]medium40morphinane alkaloid
topiramate[no description available]medium100cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
calcipotriene[no description available]medium10cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol		antipsoriatic;
drug allergen
clobetasol[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
fluticasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
halobetasol[no description available]medium10corticosteroid hormone
latanoprost[no description available]medium20isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
rimexolone[no description available]medium1020-oxo steroid
vinorelbine[no description available]medium50acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
oxiconazole[no description available]medium10conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether		antiinfective agent
cefixime[no description available]medium80cephalosporinantibacterial drug;
drug allergen
lisinopril[no description available]medium80dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril[no description available]medium30benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril[no description available]medium40azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
indinavir sulfate[no description available]medium60dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
enalapril[no description available]medium60dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
cefuroxime[no description available]medium503-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone[no description available]medium701,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime[no description available]medium50cephalosporin;
oxime O-ether		antibacterial drug
ceftazidime[no description available]medium40cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril[no description available]medium40dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
guanabenz[no description available]medium10dichlorobenzene
cefotaxime[no description available]medium601,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam[no description available]medium70beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cci 15641[no description available]medium20cephalosporin
cefpodoxime[no description available]medium20carboxylic acid;
cephalosporin		antibacterial drug
dirithromycin[no description available]medium10macrolide antibioticprodrug
cefpodoxime proxetil[no description available]medium20carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
ceftizoxime[no description available]medium40cephalosporinantibacterial drug
dantrolene[no description available]medium30
fosinopril[no description available]medium30
nystatin a1[no description available]medium20nystatins
mesna[no description available]medium40organosulfonic acid
cefamandole nafate[no description available]medium10organic sodium saltantibacterial drug;
prodrug
tetracycline[no description available]medium80
minocycline[no description available]medium60
piroxicam[no description available]medium60benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
meclocycline[no description available]medium10
acyclovir[no description available]medium802-aminopurines;
oxopurine		antimetabolite;
antiviral drug
rifampin[no description available]medium70cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
didanosine[no description available]medium70purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir[no description available]medium702-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valacyclovir[no description available]medium20L-valyl esterantiviral drug
penciclovir[no description available]medium502-aminopurines;
propane-1,3-diols		antiviral drug
rifabutin[no description available]medium70
antazoline[no description available]medium10aromatic amine;
imidazolines;
tertiary amino compound		cholinergic antagonist;
H1-receptor antagonist;
xenobiotic
benfluorex[no description available]medium10benzoate ester
bromhexine[no description available]medium10organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bromopride[no description available]medium40benzamides
bromperidol[no description available]medium10aromatic ketone
carbetapentane[no description available]medium10benzenes
clebopride[no description available]medium10piperidines
clomiphene[no description available]medium40tertiary amineestrogen antagonist;
estrogen receptor modulator
cloperastine[no description available]medium10diarylmethane
cyproheptadine[no description available]high60piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
dibucaine[no description available]medium10aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
dicyclomine[no description available]medium20carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
dilazep[no description available]medium10benzoate ester;
diazepane;
diester;
methoxybenzenes		cardioprotective agent;
platelet aggregation inhibitor;
vasodilator agent
diphenylpyraline[no description available]medium10piperidines;
tertiary amine		cholinergic antagonist;
H1-receptor antagonist
donepezil[no description available]medium60aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
cycloadiphenine[no description available]medium10benzenes
fendiline[no description available]medium20diarylmethane
fipexide[no description available]medium20benzodioxoles
flavoxate[no description available]medium20carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
fluspirilene[no description available]medium20diarylmethane
alverine[no description available]medium20tertiary amineantispasmodic drug
ketotifen[no description available]medium10cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
mebeverine[no description available]medium10methoxybenzoic acid
mecamylamine[no description available]medium20primary aliphatic amine
memantine[no description available]medium50adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
norfluoxetine[no description available]medium30(trifluoromethyl)benzenes
orphenadrine[no description available]medium30ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxidopamine[no description available]medium40benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
oxybutynin[no description available]medium40acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
oxymetazoline[no description available]medium10carboxamidine;
imidazolines;
phenols		alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
oxyphencyclimine[no description available]medium10monocarboxylic acid
papaverine[no description available]medium70benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
perhexiline[no description available]medium20piperidinescardiovascular drug
periciazine[no description available]medium30hydroxypiperidine;
nitrile;
phenothiazines		adrenergic antagonist;
first generation antipsychotic;
sedative
periciazine[no description available]medium31hydroxypiperidine;
nitrile;
phenothiazines		adrenergic antagonist;
first generation antipsychotic;
sedative
pimethixene[no description available]medium10thioxanthenes
pipamperone[no description available]medium10aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
pridinol[no description available]medium10piperidines;
tertiary alcohol		antiparkinson drug;
muscle relaxant
pyrilamine[no description available]medium30aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
ritanserin[no description available]high40organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
sibutramine[no description available]medium40organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]medium30alkylbenzene
tetracaine[no description available]medium40benzoate ester;
tertiary amino compound		local anaesthetic
tofisopam[no description available]medium10organic molecular entity
triflupromazine[no description available]medium20organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trihexyphenidyl[no description available]medium20amine
trimeprazine[no description available]medium20phenothiazines
xylometazoline[no description available]medium10alkylbenzene
reserpine[no description available]medium50alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
camylofine[no description available]medium10alpha-amino acid ester
cycloheximide[no description available]medium10antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
azacitidine[no description available]medium40N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
penfluridol[no description available]medium10diarylmethane
flupirtine[no description available]medium60aminopyridine
mifepristone[no description available]medium403-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
esreboxetine[no description available]medium10aromatic ether
lercanidipine[no description available]medium10diarylmethane
cloricromen[no description available]medium10coumarins
demecolcine[no description available]medium10alkaloid;
secondary amino compound		antineoplastic agent;
microtubule-destabilising agent
noscapine[no description available]medium20aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
vinpocetine[no description available]medium20alkaloidgeroprotector
chlorprothixene[no description available]medium30chlorprothixene
chlorprothixene[no description available]medium31chlorprothixene
flunarizine[no description available]medium20diarylmethane
cinnarizine[no description available]medium20diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
harmine[no description available]medium10harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
triprolidine[no description available]medium30N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
dextromethorphan[no description available]high416-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
dextromethorphan[no description available]high406-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
1-(3-chlorophenyl)piperazine[no description available]medium70monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
1-(3-chlorophenyl)piperazine[no description available]medium71monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
methiothepin[no description available]medium10aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
nan 190[no description available]medium10N-alkylpiperazine;
N-arylpiperazine;
phthalimides		serotonergic antagonist
octopamine[no description available]medium10phenylethanolamines;
tyramines		neurotransmitter
tyramine[no description available]medium20monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
phenylalanine[no description available]medium20amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
gramine[no description available]medium10aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
ipsapirone[no description available]medium20N-arylpiperazine
eltoprazine[no description available]medium10
mm 77[no description available]medium10piperazines
enprofylline[no description available]medium20oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
acetazolamide[no description available]medium50monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
alfuzosin[no description available]medium30monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron[no description available]medium20imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
diatrizoic acid[no description available]medium30acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
amsacrine[no description available]medium30acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
biperiden[no description available]medium30piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
buflomedil[no description available]medium30aromatic ketone
bunazosin[no description available]medium10quinazolines
bupivacaine[no description available]medium60aromatic amide;
piperidinecarboxamide;
tertiary amino compound
metrizoate[no description available]medium20monocarboxylic acidradioopaque medium
dapsone[no description available]medium70substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
amphetamine[no description available]medium70primary amine
doxapram[no description available]medium30morpholines;
pyrrolidin-2-ones		central nervous system stimulant
dyphylline[no description available]medium40oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
ethacrynic acid[no description available]medium50aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
fenspiride[no description available]medium20azaspiro compound
fleroxacin[no description available]medium50difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
fluorescite[no description available]medium30benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
hydroflumethiazide[no description available]medium40benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine[no description available]medium20aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hypericin[no description available]medium10
iothalamic acid[no description available]medium10organic molecular entity
avapro[no description available]medium40azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ketanserin[no description available]high110aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
letrozole[no description available]medium50nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
mepivacaine[no description available]medium30piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate[no description available]medium30organic molecular entity
methapyrilene[no description available]medium10ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methylphenidate[no description available]medium110beta-amino acid ester;
methyl ester;
piperidines
methylphenidate[no description available]medium112beta-amino acid ester;
methyl ester;
piperidines
metolazone[no description available]medium50organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
acecainide[no description available]medium30acetamides;
benzamides		anti-arrhythmia drug
naratriptan[no description available]medium50heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nefopam[no description available]medium50benzoxazocine;
tertiary amino compound
nomifensine[no description available]medium50isoquinolinesdopamine uptake inhibitor
oxiracetam[no description available]medium20organonitrogen compound;
organooxygen compound
pantoprazole[no description available]medium60aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
pentobarbital[no description available]medium40barbituratesGABAA receptor agonist
phenacetin[no description available]medium30acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
moxonidine[no description available]medium40organohalogen compound;
pyrimidines
pimobendan[no description available]medium10benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
piretanide[no description available]medium20aromatic ether
prilocaine[no description available]medium20amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
pyridostigmine[no description available]medium40pyridinium ion
pyrimethamine[no description available]medium30aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole[no description available]medium40benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
rizatriptan[no description available]medium40tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
risedronic acid[no description available]medium40pyridines
imatinib[no description available]medium40aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat[no description available]medium40dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
suramin[no description available]medium40naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
gatifloxacin[no description available]medium70N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
temozolomide[no description available]medium40imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
thalidomide[no description available]medium60phthalimides;
piperidones
tinidazole[no description available]medium60imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tranexamic acid[no description available]medium30amino acid
viloxazine[no description available]medium20aromatic ether
zaleplon[no description available]medium60nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zopiclone[no description available]medium70monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
zopiclone[no description available]medium71monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
cephaloridine[no description available]medium20beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
penicillin g[no description available]medium60penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
apomorphine[no description available]medium60aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
cephalothin[no description available]medium20azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
kanamycin a[no description available]medium40kanamycinsbacterial metabolite
levodopa[no description available]medium110amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
levodopa[no description available]medium111amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
methicillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
ampicillin[no description available]medium60beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
triamcinolone acetonide[no description available]medium3011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
phencyclidine[no description available]medium40benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
dichloroacetic acid[no description available]medium10monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite
penicillin v[no description available]medium50penicillin allergen;
penicillin
isosorbide dinitrate[no description available]medium40glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
neostigmine bromide[no description available]medium30bromide salt
pirinitramide[no description available]medium20nitrile
edrophonium bromide[no description available]medium10
ketobemidone[no description available]medium10piperidines
methamphetamine[no description available]medium180amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
methamphetamine[no description available]medium184amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
lithium carbonate[no description available]medium60carbonate salt;
lithium salt		antimanic drug
lithium carbonate[no description available]medium62carbonate salt;
lithium salt		antimanic drug
vinblastine[no description available]medium40
vancomycin[no description available]medium70glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
metylperon[no description available]medium20aromatic ketone
spectinomycin[no description available]medium20cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
benperidol[no description available]medium10aromatic ketone
doxifluridine[no description available]medium40organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
streptomycin[no description available]medium30antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
carbenicillin[no description available]medium30penicillin allergen;
penicillin		antibacterial drug
floxacillin[no description available]medium30penicillin allergen;
penicillin		antibacterial drug
beclomethasone dipropionate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester		anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug
terodiline[no description available]medium30diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene[no description available]medium10
metocurine iodide[no description available]medium20aromatic ether
apazone[no description available]medium10benzotriazinesnon-steroidal anti-inflammatory drug;
uricosuric drug
pregnanolone[no description available]medium303-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
pregnanolone[no description available]medium313-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
ribostamycin[no description available]medium10amino cyclitol glycoside;
aminoglycoside antibiotic		antibacterial drug;
antimicrobial agent;
metabolite
toloxatone[no description available]medium20oxazolidinone;
primary alcohol;
toluenes
sisomicin[no description available]medium20amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
amdinocillin[no description available]medium10penicillinantibacterial drug;
antiinfective agent
ticarcillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
trimazosin[no description available]medium10N-arylpiperazine
adinazolam[no description available]medium30triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
amikacin[no description available]medium40alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
cephradine[no description available]medium40beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
sulbenicillin[no description available]medium20penicillin
medroxalol[no description available]medium10salicylamides
epirubicin[no description available]medium50aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
epirubicin[no description available]medium51aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
ceforanide[no description available]medium10cephalosporinantibacterial drug
moxalactam[no description available]medium30cephalosporin;
oxacephem		antibacterial drug
endralazine[no description available]medium10benzamides
pefloxacin[no description available]medium40fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
recainam[no description available]medium30
bambuterol[no description available]medium10carbamate ester;
phenylethanolamines		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent
trospectomycin[no description available]medium10dioxanes
sematilide[no description available]medium30
clinafloxacin[no description available]medium30quinolines
adefovir[no description available]medium506-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
loxiglumide[no description available]medium20organic molecular entity
tiagabine[no description available]medium50beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
aripiprazole[no description available]high192aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
aripiprazole[no description available]high190aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
ibandronic acid[no description available]medium20
ziprasidone[no description available]medium901,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir[no description available]medium30guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan[no description available]medium60oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
tirofiban[no description available]medium30L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
cisatracurium[no description available]medium10diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
fosinoprilat[no description available]medium10L-proline derivative;
phosphinic acids		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin[no description available]medium50
imipramine n-oxide[no description available]medium10dibenzooxazepine
dexloxiglumide[no description available]medium30glutamic acid derivative
intoplicine[no description available]medium20pyridoindole
repaglinide[no description available]medium50piperidines
telmisartan[no description available]medium60benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
ethinyl estradiol-17-sulfate[no description available]medium10
ethinylestradiol-3-sulfate[no description available]medium1017beta-hydroxy steroid;
steroid sulfate		antineoplastic agent;
estrogen
cefcanel[no description available]medium20
zoledronic acid[no description available]medium401,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
epristeride[no description available]medium30steroid acid
talinolol[no description available]medium30ureas
denaverine[no description available]medium10diarylmethane
ljc 10627[no description available]medium20carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
betamipron[no description available]medium20organonitrogen compound;
organooxygen compound
panipenem[no description available]medium10organic molecular entity
perindoprilat[no description available]medium10dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
7-hydroxystaurosporine[no description available]medium10
9-aminocamptothecin[no description available]medium10pyranoindolizinoquinoline
sch 34343[no description available]medium20
squalamine[no description available]medium10bile acid
frovatriptan[no description available]medium40carbazoles
eletriptan[no description available]medium30indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rosiglitazone[no description available]medium60aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
mci 9038[no description available]medium20peptide
imipenem, anhydrous[no description available]medium20beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
bosentan anhydrous[no description available]medium40primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
asulacrine[no description available]medium10acridines
hydroxycotinine[no description available]medium10N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
quinaprilat[no description available]medium30dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
2-hydroxyimipramine[no description available]medium20dibenzoazepine
ecteinascidin 743[no description available]medium20acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
almotriptan[no description available]medium30indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mk 0663[no description available]medium20bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
gefitinib[no description available]medium40aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
tamsulosin[no description available]medium405-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
sulbactam[no description available]medium40penicillanic acids
dilevalol[no description available]medium102-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
irofulven[no description available]medium10cyclohexenones
ym 872[no description available]medium10
ertapenem[no description available]medium20carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
dx 8951[no description available]medium10pyranoindolizinoquinoline
cilomilast[no description available]medium30methoxybenzenes
conivaptan[no description available]medium30benzazepineaquaretic;
vasopressin receptor antagonist
tezosentan[no description available]medium20
sabarubicin[no description available]medium10
moxifloxacin[no description available]medium60aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
clevidipine[no description available]medium20dihydropyridine
solifenacin[no description available]medium40isoquinolines
abanoquil[no description available]medium10
anidulafungin[no description available]medium20antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
melagatran[no description available]medium30azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
tesaglitazar[no description available]medium30
bms204352[no description available]medium20
fosfluconazole[no description available]medium10conazole antifungal drug;
triazole antifungal drug;
triazoles		prodrug
cp 101,606[no description available]medium20
nsc-89199[no description available]medium20carbamate ester;
organochlorine compound;
steroid phosphate
phenethicillin[no description available]medium20penicillin allergen;
penicillin
acivicin[no description available]medium10isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
bortezomib[no description available]medium50amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
digitoxin[no description available]medium30cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
pancuronium[no description available]medium20acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
rocuronium[no description available]medium103alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent
abacavir[no description available]medium302,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
miglitol[no description available]medium50piperidines
linezolid[no description available]medium90acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
darifenacin[no description available]medium201-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
fluticasone propionate[no description available]medium2011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
tacrolimus[no description available]medium70macrolide lactambacterial metabolite;
immunosuppressive agent
cerivastatin[no description available]medium50dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin[no description available]medium50dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
clindamycin[no description available]medium50
bms 214662[no description available]medium10benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
eptifibatide[no description available]medium20homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
gs 4071[no description available]medium30acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite
decitabine[no description available]medium502'-deoxyribonucleoside
sm 8668[no description available]medium20
troxacitabine[no description available]medium10carbohydrate derivative;
nucleobase-containing molecular entity
tiazofurin[no description available]medium201,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
sitafloxacin[no description available]medium30fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
tenofovir[no description available]medium40nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
dibekacin[no description available]medium10kanamycinsantibacterial agent;
protein synthesis inhibitor
micafungin[no description available]medium30antibiotic antifungal drug;
echinocandin		antiinfective agent
tropisetron[no description available]medium20indolyl carboxylic acid
leuprolide[no description available]medium10oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
cotinine[no description available]medium30N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
methimazole[no description available]medium401,3-dihydroimidazole-2-thionesantithyroid drug
drotaverin[no description available]medium40isoquinolines
digoxin[no description available]medium60cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
cancidas[no description available]medium20
lincomycin[no description available]medium30carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
thiopental[no description available]medium20barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
hmr 3647[no description available]medium50
nelarabine[no description available]medium30beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
dolasetron[no description available]medium30indolyl carboxylic acid
or 1259[no description available]medium20hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
gestodene[no description available]medium30steroidestrogen
isepamicin[no description available]medium10
ifetroban[no description available]medium10benzenes;
monocarboxylic acid
lamifiban[no description available]medium10N-acylglycine
telavancin[no description available]medium10glycopeptideantibacterial drug;
antimicrobial agent
sitagliptin[no description available]medium50triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
tolcapone[no description available]medium602-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin[no description available]medium207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
clavulanic acid[no description available]medium40oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
eprosartan[no description available]medium50dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast[no description available]medium50aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium[no description available]medium20isoquinolines
entacapone[no description available]medium602-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol[no description available]medium40hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
sdz psc 833[no description available]medium20homodetic cyclic peptide
indocyanine green[no description available]medium201,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
cyclosporine[no description available]medium60homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
alvocidib[no description available]medium20dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cicaprost[no description available]medium10monoterpenoid
dexmedetomidine[no description available]medium20medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
iloprost[no description available]medium20carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
nateglinide[no description available]medium50phenylalanine derivative
romidepsin[no description available]medium10cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
morphine-6-glucuronide[no description available]medium20morphinane alkaloid
cefodizime[no description available]medium101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone[no description available]medium10phenanthrenes
enalaprilat anhydrous[no description available]medium70dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
hr 810[no description available]medium10cephalosporin;
cyclopentapyridine
cefetamet[no description available]medium30cephalosporin
ginkgolide b[no description available]medium20
palonosetron[no description available]medium20azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
cefatrizine[no description available]medium30amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
eniporide[no description available]medium10
cilastatin[no description available]medium20carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
ixabepilone[no description available]medium301,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
azlocillin[no description available]medium30penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
verlukast[no description available]medium10
carumonam[no description available]medium10monobactamantibacterial drug
eritoran[no description available]medium10lipid As
artesunate[no description available]medium20artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
dexniguldipine[no description available]medium10diarylmethane
napsagatran[no description available]medium10
temsirolimus[no description available]medium30macrolide lactam
bms188797[no description available]medium10
azimilide[no description available]medium10imidazolidine-2,4-dione
tomopenem[no description available]medium20
bb-83698[no description available]medium10
zotarolimus[no description available]medium10lactam;
macrolide
gentamicin sulfate[no description available]medium40
bn 52020[no description available]medium20
vindesine[no description available]medium10
bisaramil[no description available]medium10
teicoplanin[no description available]medium20
ly-146032[no description available]medium40heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
dalbavancin[no description available]medium10carbohydrate acid derivative;
glycopeptide;
monosaccharide derivative;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
cetrorelix[no description available]medium20oligopeptideantineoplastic agent;
GnRH antagonist
chlortetracycline[no description available]medium30
oxytetracycline, anhydrous[no description available]medium40
roquinimex[no description available]medium30aromatic amide
mobic[no description available]medium701,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
isoxicam[no description available]medium40benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
demeclocycline[no description available]medium20
rolitetracycline[no description available]medium20
tigecycline[no description available]medium40
dacarbazine[no description available]medium40dacarbazine
sildenafil[no description available]medium50piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
vardenafil[no description available]medium40imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
leucovorin[no description available]medium50formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
tegaserod[no description available]medium40carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
tirapazamine[no description available]medium20aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
aprepitant[no description available]medium50(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
aprepitant[no description available]medium51(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
ceftobiprole[no description available]medium10cephalosporin;
thiadiazoles		antimicrobial agent
acetone[no description available]medium10ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
indole[no description available]medium10indole;
polycyclic heteroarene		Escherichia coli metabolite
pyridine[no description available]medium10azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
ether[no description available]medium10ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
acetonitrile[no description available]medium40aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
nitromethane[no description available]medium10primary nitroalkane;
volatile organic compound		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
explosive;
NMR chemical shift reference compound;
polar aprotic solvent
quinoxalines[no description available]medium10mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
quinoline[no description available]medium10azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines
benzothiazole[no description available]medium10benzothiazolesenvironmental contaminant;
plant metabolite;
xenobiotic
acetophenone[no description available]medium10acetophenonesanimal metabolite;
photosensitizing agent;
xenobiotic
nitrobenzene[no description available]medium10nitroarene;
nitrobenzenes
benzonitrile[no description available]medium10benzenes;
nitrile
4-cyanopyridine[no description available]medium10
anisole[no description available]medium10monomethoxybenzeneplant metabolite
2-chloropyridine[no description available]medium10monochloropyridine
tetrahydrofuran[no description available]medium10cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
isoquinoline[no description available]medium10azaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene
ethyl acetate[no description available]medium10acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite
cinnoline[no description available]medium10azaarene;
cinnolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene
benzoxazoles[no description available]medium101,3-benzoxazoles;
mancude organic heterobicyclic parent
flavone[no description available]medium10flavonesmetabolite;
nematicide
ferrocin c[no description available]medium10
n,n-dimethylbenzamide[no description available]medium10
triphenylphosphine oxide[no description available]medium10phosphine oxideNMR chemical shift reference compound
diphenyl sulfoxide[no description available]medium10sulfoxide
4-acetylpyridine[no description available]medium10
methyl phenyl sulfoxide[no description available]medium10benzenes;
sulfoxide
1,4-dioxane[no description available]medium10dioxane;
volatile organic compound		carcinogenic agent;
metabolite;
NMR chemical shift reference compound;
non-polar solvent
anthranil[no description available]medium102,1-benzoxazoles;
mancude organic heterobicyclic parent
4-methoxybenzonitrile[no description available]medium10
2,6-difluoropyridine[no description available]medium10
1-benzylimidazole[no description available]medium10
6-chloroindole[no description available]medium10indoles
paliperidone[no description available]medium201,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
l 663581[no description available]medium10
asenapine[no description available]medium105-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
org 4428[no description available]medium10
benzocaine[no description available]medium20benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
bay h 4502[no description available]medium30biphenyls;
imidazoles
carisoprodol[no description available]medium30carbamate estermuscle relaxant
mesoridazine[no description available]medium30phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
procaine[no description available]medium20benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
quetiapine[no description available]medium40dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
corticosterone[no description available]medium6011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
dan 2163[no description available]medium60aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
practolol[no description available]medium20acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
pyrazinamide[no description available]medium40monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
cromolyn[no description available]medium10chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
gliclazide[no description available]medium40N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
propiverine[no description available]medium10diarylmethane
pseudoephedrine[no description available]medium20phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
medroxyprogesterone[no description available]medium3017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
medroxyprogesterone[no description available]medium3117alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
triamcinolone[no description available]medium2011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
gliquidone[no description available]medium20isoquinolines
4-iodo-2,5-dimethoxyphenylisopropylamine[no description available]medium50amphetamines;
dimethoxybenzene;
organoiodine compound
5-carboxamidotryptamine[no description available]medium10tryptamines
pirenperone[no description available]medium10aromatic ketone
quipazine[no description available]medium10piperazines;
pyridines
spiperone[no description available]high20aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
spiroxatrine[no description available]medium10imidazolidines
bufotenin[no description available]medium10tertiary amine;
tryptamine alkaloid		coral metabolite;
hallucinogen
lisuride[no description available]medium10monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
gepirone[no description available]medium40N-arylpiperazine
mesulergine[no description available]medium10ergot alkaloid;
sulfamides		antiparkinson drug;
dopamine agonist;
serotonergic antagonist
6-chloro-2-(1-piperazinyl)pyrazine[no description available]medium20N-arylpiperazine
uh 301[no description available]medium10
rauwolscine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylate
acetic acid[no description available]medium30monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
acetamide[no description available]medium10acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
adenine[no description available]medium206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
allantoin[no description available]medium10imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
betaine[no description available]medium20amino-acid betaine;
glycine derivative		fundamental metabolite
carnitine[no description available]medium10amino-acid betainehuman metabolite;
mouse metabolite
citric acid, anhydrous[no description available]medium10tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
creatine[no description available]medium10glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
lactic acid[no description available]medium302-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
formaldehyde[no description available]medium10aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycine[no description available]medium30alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
hydroquinone[no description available]medium10benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
inositol[no description available]medium10cyclitol;
hexol
niacinamide[no description available]medium10pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin[no description available]medium30pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
orotic acid[no description available]medium10pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
4-aminobenzoic acid[no description available]medium20aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
phenol[no description available]medium10phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phenylacetic acid[no description available]medium10benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin
pyridoxal phosphate[no description available]medium10methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine[no description available]medium20hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thiamine[no description available]medium20primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
uracil[no description available]medium10pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
urea[no description available]medium20isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
urea[no description available]medium21isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
catechin[no description available]medium10hydroxyflavan
menthol[no description available]medium10p-menthane monoterpenoid;
secondary alcohol		volatile oil component
acetohexamide[no description available]medium10acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
albendazole[no description available]medium30aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
ambroxol[no description available]medium10aromatic amine
pimagedine[no description available]medium10guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
anethole trithione[no description available]medium10methoxybenzenes
anthralin[no description available]medium20anthracenesantipsoriatic
barbital[no description available]medium10barbituratesdrug allergen
bendazac[no description available]medium20indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
benzbromarone[no description available]medium301-benzofurans;
aromatic ketone		uricosuric drug
bromisovalum[no description available]medium10N-acylurea;
organobromine compound
butalbital[no description available]medium10barbituratesanalgesic;
sedative
candesartan cilexetil[no description available]medium10biphenyls
carprofen[no description available]medium20carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
celecoxib[no description available]medium40organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chloral hydrate[no description available]medium10aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
chloroxylenol[no description available]medium10monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorzoxazone[no description available]medium301,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
ciprofibrate[no description available]medium20cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clioquinol[no description available]medium20monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clofibrate[no description available]medium30aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clotiazepam[no description available]medium10organic molecular entity
clotrimazole[no description available]medium30conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cyclandelate[no description available]medium10carboxylic ester;
secondary alcohol		vasodilator agent
danthron[no description available]medium10dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
deferoxamine[no description available]medium20acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
eflornithine[no description available]medium10alpha-amino acid;
fluoroamino acid		trypanocidal drug
ddt[no description available]medium10benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant
dipyridamole[no description available]medium30piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
ethoxzolamide[no description available]medium10aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
fenofibrate[no description available]medium30aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
flufenamic acid[no description available]medium20aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fomepizole[no description available]medium20pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
glafenine[no description available]medium20aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
glutethimide[no description available]medium10piperidines
gossypol[no description available]medium10
guaiazulene[no description available]medium10sesquiterpene
fasudil[no description available]medium20isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
hexachlorophene[no description available]medium10bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
miltefosine[no description available]medium10phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexestrol[no description available]medium10stilbenoid
hexetidine[no description available]medium10organic heteromonocyclic compound;
organonitrogen heterocyclic compound
idebenone[no description available]medium201,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
iodipamide[no description available]medium10benzoic acids;
organoiodine compound;
secondary carboxamide		radioopaque medium
iproniazid[no description available]medium40carbohydrazide;
pyridines
2-propanol[no description available]medium10secondary alcohol;
secondary fatty alcohol		protic solvent
isoxsuprine[no description available]medium20alkylbenzene
khellin[no description available]medium10furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
beta-lapachone[no description available]medium10benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
leflunomide[no description available]medium30(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
lomustine[no description available]medium30N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
loperamide[no description available]medium20monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
malathion[no description available]medium10diester;
ethyl ester;
organic thiophosphate
diisopropyl 1,3-dithiol-2-ylidenemalonate[no description available]medium10isopropyl ester
meclizine[no description available]medium20diarylmethane
meclofenoxate[no description available]medium10monocarboxylic acid
vitamin k 3[no description available]medium101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
mephenytoin[no description available]medium20imidazolidine-2,4-dioneanticonvulsant
methoxsalen[no description available]medium20aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methoxyflurane[no description available]medium10ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
methyl salicylate[no description available]medium10benzoate ester;
methyl ester;
salicylates		flavouring agent;
insect attractant;
metabolite
methyprylon[no description available]medium10organic molecular entity
metyrapone[no description available]medium20aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
miconazole[no description available]medium10dichlorobenzene;
ether;
imidazoles
mitotane[no description available]medium20diarylmethane
modafinil[no description available]medium60monocarboxylic acid amide;
sulfoxide
modafinil[no description available]medium61monocarboxylic acid amide;
sulfoxide
moxisylyte[no description available]medium20monoterpenoid
deet[no description available]medium10benzamides;
monocarboxylic acid amide		environmental contaminant;
insect repellent;
xenobiotic
nalidixic acid[no description available]medium401,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
nialamide[no description available]medium20organonitrogen compound;
organooxygen compound
niceritrol[no description available]medium10organic molecular entity
niflumic acid[no description available]medium10aromatic carboxylic acid;
pyridines
nimesulide[no description available]medium30aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nitroglycerin[no description available]medium20nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
oxamniquine[no description available]medium10aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
oxethazaine[no description available]medium10amino acid amide
oxybenzone[no description available]medium10hydroxybenzophenone;
monomethoxybenzene		dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic
oxyphenbutazone[no description available]medium10phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
aminosalicylic acid[no description available]medium30aminobenzoic acid;
phenols		antitubercular agent
perazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug
phenoxybenzamine[no description available]medium20aromatic amine
pinacidil[no description available]medium10pyridines
pipemidic acid[no description available]medium10amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
piperazine[no description available]medium10azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
pyridinolcarbamate[no description available]medium10pyridines
opc 12759[no description available]medium10secondary carboxamide
rofecoxib[no description available]medium20butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
salicylamide[no description available]medium10phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
4-phenylbutyric acid, sodium salt[no description available]medium10organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug
sulfadimethoxine[no description available]medium10aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfameter[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
leprostatic drug;
renal agent
sulfamethazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole[no description available]medium20sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfanilamide[no description available]medium10substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfaphenazole[no description available]medium10primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
sulfapyridine[no description available]medium10pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
tegafur[no description available]medium20organohalogen compound;
pyrimidines
thiabendazole[no description available]medium201,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
tiaprofenic acid[no description available]medium10aromatic ketone;
monocarboxylic acid;
thiophenes		drug allergen;
non-steroidal anti-inflammatory drug
tolazamide[no description available]medium20N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolperisone[no description available]medium10aromatic ketone
triclosan[no description available]medium10aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
troglitazone[no description available]medium30chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
vesnarinone[no description available]medium10organic molecular entity
vigabatrin[no description available]medium40gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
guanidine hydrochloride[no description available]medium10one-carbon compound;
organic chloride salt		protein denaturant
hydrocortisone acetate[no description available]medium10cortisol ester;
tertiary alpha-hydroxy ketone
cortisone acetate[no description available]medium20corticosteroid hormone
mitomycin[no description available]medium30mitomycinalkylating agent;
antineoplastic agent
estriol[no description available]medium1016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
phentolamine[no description available]medium20imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol[no description available]medium30glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
piperonyl butoxide[no description available]medium10benzodioxolespesticide synergist
bromouracil[no description available]medium10nucleobase analogue;
pyrimidines		mutagen
3,3',5-triiodothyroacetic acid[no description available]medium10
histamine dihydrochloride[no description available]medium10
thyroxine[no description available]medium402-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine[no description available]medium601-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
dextroamphetamine[no description available]medium611-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
carbachol[no description available]medium10ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
norethindrone acetate[no description available]medium103-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
cyclobarbital[no description available]medium10barbiturates
allobarbital[no description available]medium10barbiturates
trichlorfon[no description available]medium10organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
estrone[no description available]medium2017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone[no description available]medium2017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
dehydroepiandrosterone[no description available]medium1017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
nad[no description available]medium10NADgeroprotector
triiodothyronine[no description available]medium502-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
triiodothyronine[no description available]medium512-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
glutamine[no description available]medium20amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
cetrimonium bromide[no description available]medium10organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
physostigmine[no description available]medium40carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
aminopyrine[no description available]medium10pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
methyltestosterone[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
tetrabenazine[no description available]medium20benzoquinolizine;
cyclic ketone;
tertiary amino compound
uridine[no description available]medium10uridinesdrug metabolite;
fundamental metabolite;
human metabolite
niridazole[no description available]medium101,3-thiazoles;
C-nitro compound
carbaryl[no description available]medium10carbamate ester;
naphthalenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant
lactose[no description available]medium10lactose
methionine[no description available]medium40aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
Mebutamate[no description available]medium10organic molecular entity
norethynodrel[no description available]medium10oxo steroid
benziodarone[no description available]medium20aromatic ketone
mannitol[no description available]medium20mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
methaqualone[no description available]medium10quinazolinesGABA agonist;
sedative
trypan blue[no description available]medium10
cordycepin[no description available]medium103'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
tryptophan[no description available]medium40erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
tryptophan[no description available]medium41erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine[no description available]medium40arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
trichloroacetic acid[no description available]medium10monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
allylpropymal[no description available]medium10barbiturates
butobarbital[no description available]medium10barbiturates
trichloroethylene[no description available]medium10chloroethenesinhalation anaesthetic;
mouse metabolite
dehydrocholic acid[no description available]medium1012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
synephrine[no description available]medium20ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
benzoyl peroxide[no description available]medium10carbonyl compound
furan[no description available]medium10furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
phenformin[no description available]medium20biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
mephobarbital[no description available]medium10barbituratesanticonvulsant
hexachlorobenzene[no description available]medium10aromatic fungicide;
chlorobenzenes		antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant
trinitrotoluene[no description available]medium10trinitrotolueneexplosive
framycetin[no description available]medium10aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
pyrazolanthrone[no description available]medium10anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
meglumine[no description available]medium20hexosamine;
secondary amino compound
cinchophen[no description available]medium20quinolines
yohimbine[no description available]high60methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
mequinol[no description available]medium10methoxybenzenes;
phenols		metabolite
quinestrol[no description available]medium1017-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
dydrogesterone[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid		progestin
ephedrine[no description available]medium30phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
chlormadinone acetate[no description available]medium10corticosteroid hormone
2,3-dimercaptosuccinic acid[no description available]medium10
evans blue[no description available]medium10organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
aminophylline[no description available]medium30mixturebronchodilator agent;
cardiotonic drug
phenyramidol[no description available]medium10aminopyridine
carbutamide[no description available]medium10benzenes;
sulfonamide
nandrolone decanoate[no description available]medium20steroid ester
bucladesine[no description available]medium103',5'-cyclic purine nucleotide;
butanamides;
butyrate ester		agonist;
cardiotonic drug;
vasodilator agent
perflubron[no description available]medium10haloalkane;
organobromine compound;
perfluorinated compound		blood substitute;
radioopaque medium
cyproterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
glycyrrhetinic acid[no description available]medium10cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
dihydralazine[no description available]medium10phthalazines
phenylpropanolamine[no description available]medium10amphetamines;
phenethylamine alkaloid		plant metabolite
dihydroergotamine[no description available]medium30ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
hesperidin[no description available]medium203'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen
gentian violet[no description available]medium10organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
hematoporphyrin[no description available]medium10
lactulose[no description available]medium20glycosylfructosegastrointestinal drug;
laxative
erythromycin stearate[no description available]medium10aminoglycoside
d-alpha tocopherol[no description available]medium40alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
sulfadoxine[no description available]medium10pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
acadesine[no description available]medium101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
iproclozide[no description available]medium10aromatic ether
carbenicillin disodium[no description available]medium10organic sodium salt
dehydroemetine[no description available]medium10aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug
benorilate[no description available]medium10carbonyl compound
trimetazidine[no description available]medium10aromatic amine
vidarabine[no description available]medium10beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
tiadenol[no description available]medium10aliphatic sulfide
camptothecin[no description available]medium20delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
stanozolol[no description available]medium1017beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
clodronic acid[no description available]medium101,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
xipamide[no description available]medium10benzamides
thiamphenicol[no description available]medium20monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pizotyline[no description available]high20benzocycloheptathiophenehistamine antagonist;
muscarinic antagonist;
serotonergic antagonist
carbimazole[no description available]medium101,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
oxyphenisatin[no description available]medium20indoles
tetrachloroethylene[no description available]medium10chlorocarbon;
chloroethenes		nephrotoxic agent
butachlor[no description available]medium10aromatic amide;
organochlorine compound;
tertiary carboxamide		environmental contaminant;
herbicide;
xenobiotic
rose bengal b disodium salt[no description available]medium10
glutamic acid[no description available]medium20glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
nicergoline[no description available]medium10organic heterotetracyclic compound;
organonitrogen heterocyclic compound
oxcarbazepine[no description available]medium40cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
amineptin[no description available]medium20amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
pirprofen[no description available]medium20pyrroline
ticrynafen[no description available]medium20aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
bezafibrate[no description available]medium10aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
benoxaprofen[no description available]medium201,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
pirfenidone[no description available]medium10pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
desogestrel[no description available]medium2017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
muzolimine[no description available]medium10dichlorobenzene
foscarnet sodium[no description available]medium20one-carbon compound;
organic sodium salt		antiviral drug
nicorandil[no description available]medium20nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
miglustat[no description available]medium20piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
piritrexim[no description available]medium10
atomoxetine hydrochloride[no description available]medium20hydrochlorideadrenergic uptake inhibitor;
antidepressant
clopidogrel[no description available]medium20methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
duloxetine[no description available]medium30duloxetine
adefovir dipivoxil[no description available]medium206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
capecitabine[no description available]medium20carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
halofuginone[no description available]medium10quinazolines
ortho-cept[no description available]medium10
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol[no description available]medium10stilbenoid
efavirenz[no description available]medium30acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir[no description available]medium30aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
doxapram hydrochloride[no description available]medium10hydrochloridecentral nervous system stimulant
1,5-anhydroglucitol[no description available]medium10anhydro sugarhuman metabolite
betulinic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
amprenavir[no description available]medium30carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
glutathione disulfide[no description available]medium10glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
bendamustine[no description available]medium20benzimidazoles
erdosteine[no description available]medium10N-acyl-amino acid
mizolastine[no description available]medium10benzimidazoles
2-methoxyestradiol[no description available]medium1017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
medetomidine[no description available]medium10imidazoles
picosulfate sodium[no description available]medium10aryl sulfate;
pyridines
dienogest[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone		progesterone receptor agonist;
progestin;
synthetic oral contraceptive
morphazinamide[no description available]medium10morpholines;
pyrazines;
secondary carboxamide
cyclobutyrol[no description available]medium10hydroxy monocarboxylic acidbile therapy drug
terlipressin[no description available]medium10polypeptide
isoflavone[no description available]medium10isoflavones
clevudine[no description available]medium10
tetrandrine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
lopinavir[no description available]medium20amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
sr141716[no description available]medium30amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
selenomethionine[no description available]medium10amino acid zwitterion;
selenomethionine		plant metabolite
perindopril[no description available]medium20alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
fingolimod[no description available]medium10aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
nitisinone[no description available]medium20(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
marimastat[no description available]medium10hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
clofarabine[no description available]medium30adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
mitiglinide[no description available]medium10benzenes;
monocarboxylic acid
imatinib mesylate[no description available]medium10methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine[no description available]medium10adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
antiprimod[no description available]medium10
olmesartan medoxomil[no description available]medium30biphenyls
ilomastat[no description available]medium10hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
atazanavir[no description available]medium20carbohydrazideantiviral drug;
HIV protease inhibitor
ezetimibe[no description available]medium30azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
cariporide[no description available]medium10
jtt 501[no description available]medium10
cyc 202[no description available]medium102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
paromomycin[no description available]medium20amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
avasimibe[no description available]medium10monoterpenoid
biotin[no description available]medium10biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
troleandomycin[no description available]medium10acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
deferasirox[no description available]medium40benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
tbc-11251[no description available]medium30benzodioxoles
sitosterol, (3beta)-isomer[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol		anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor
benzarone[no description available]medium201-benzofurans
homoharringtonine[no description available]medium10alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
o-(chloroacetylcarbamoyl)fumagillol[no description available]medium10carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide		angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
nexavar[no description available]medium10organosulfonate salt
glucosamine[no description available]medium10D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
trimethaphan camsylate[no description available]medium10
erythromycin estolate[no description available]medium10aminoglycoside sulfate salt;
erythromycin derivative		enzyme inhibitor
cyclopamine[no description available]medium10piperidinesglioma-associated oncogene inhibitor
devazepide[no description available]medium101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
doxorubicin hydrochloride[no description available]medium10anthracycline
ao 128[no description available]medium20organic molecular entity
retinol[no description available]medium20retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
alpha-D-fructofuranose 1,6-bisphosphate[no description available]medium10D-fructofuranose 1,6-bisphosphate
docosahexaenoate[no description available]medium10docosahexaenoic acid;
omega-3 fatty acid		algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
oleic acid[no description available]medium10octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
eicosapentaenoic acid[no description available]medium20icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
drf 2725[no description available]medium10
diethylstilbestrol[no description available]medium10olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
alitretinoin[no description available]medium10retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
rubitecan[no description available]medium20C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
riboflavin[no description available]medium20flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
sodium bicarbonate[no description available]medium20one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
sodium acetate, anhydrous[no description available]medium10organic sodium saltNMR chemical shift reference compound
sodium benzoate[no description available]medium10organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
dipyrone[no description available]medium10organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
ditiocarb sodium[no description available]medium10organic molecular entity
carbenoxolone[no description available]medium10
discodermolide[no description available]medium10diterpenoid
cannabidiol[no description available]medium20olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
prothionamide[no description available]medium10pyridines
capsaicin[no description available]medium30capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
tacrine hydrochloride[no description available]medium10
sodium propionate[no description available]medium10organic sodium saltantifungal drug;
food preservative
fusidic acid[no description available]medium2011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
estrone sulfate[no description available]medium1017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
toremifene[no description available]medium20aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
telaprevir[no description available]medium10cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
droloxifene[no description available]medium10stilbenoid
orlistat[no description available]medium30beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
idoxifene[no description available]medium10stilbenoid
zd 6474[no description available]medium10aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
silybin[no description available]medium10
chloramine-t[no description available]medium10organic sodium saltallergen;
antifouling biocide;
disinfectant
dinoprostone[no description available]medium20prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost[no description available]medium10monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
beta carotene[no description available]medium10carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
cholecalciferol[no description available]medium10D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
oxymetholone[no description available]medium30
mycophenolate mofetil[no description available]medium30carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
astaxanthine[no description available]medium10carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
diosmin[no description available]medium10dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
cynarine[no description available]medium10alkyl caffeate ester;
quinic acid		plant metabolite
coenzyme q10[no description available]medium20ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite
tranilast[no description available]medium20amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
ozagrel[no description available]medium10cinnamic acids
pitavastatin[no description available]medium20cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
alatrofloxacin mesylate[no description available]medium20
natamycin[no description available]medium20antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin[no description available]medium30acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
dothiepin[no description available]medium10dothiepin
levetiracetam[no description available]medium50pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
nalorphine[no description available]medium10morphinane alkaloid
oxymorphone[no description available]medium20morphinane alkaloid
sirolimus[no description available]medium20antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
seocalcitol[no description available]medium10
fenretinide[no description available]medium10monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
geldanamycin[no description available]medium101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
demycarosylturimycin h[no description available]medium20
furazolidone[no description available]medium10
semaxinib[no description available]medium10olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
orantinib[no description available]medium10
molsidomine[no description available]medium20ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
nitrofurazone[no description available]medium10
bleomycin[no description available]medium20bleomycinantineoplastic agent;
metabolite
imidapril[no description available]medium10dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
sulindac sulfone[no description available]medium10monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran[no description available]medium20amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
guanabenz acetate[no description available]medium10dichlorobenzenegeroprotector
proguanil[no description available]medium10biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rifamycin sv[no description available]medium10acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
epoprostenol sodium[no description available]medium10prostanoid
dantrolene sodium[no description available]medium10
roxithromycin[no description available]medium30roxithromycinenvironmental contaminant;
xenobiotic
beraprost[no description available]medium10enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent
lanreotide[no description available]medium10
lu 208075[no description available]medium20diarylmethane
acetylcarnitine[no description available]medium10O-acetylcarnitine;
saturated fatty acyl-L-carnitine		human metabolite;
Saccharomyces cerevisiae metabolite
nifurtoinol[no description available]medium10hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
eflucimibe[no description available]medium10
etomoxir[no description available]medium10aromatic ether
pentagastrin[no description available]medium20organic molecular entity
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
vinflunine[no description available]medium10acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent
baci-im[no description available]medium20homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
pf 03491390[no description available]medium10
amodiaquine hydrochloride[no description available]medium10
tannins[no description available]medium10tannin
cerivastatin sodium[no description available]medium10organic sodium salt;
statin (synthetic)
monensin[no description available]medium10
oxacillin sodium[no description available]medium20organic sodium salt
sodium diatrizoate[no description available]medium10organic sodium salt;
organoiodine compound		radioopaque medium
ascorbic acid[no description available]medium30ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
novobiocin[no description available]medium10carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
dicumarol[no description available]medium10hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
acenocoumarol[no description available]medium10C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
phenprocoumon[no description available]medium10hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
lornoxicam[no description available]medium20heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
entecavir[no description available]medium302-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
inosine[no description available]medium10inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
folic acid[no description available]medium30folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
oxypurinol[no description available]medium10pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor
raltitrexed[no description available]medium20N-acyl-amino acid
alanosine[no description available]medium10
cloxacillin[no description available]medium20penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
aniracetam[no description available]medium10N-acylpyrrolidine;
pyrrolidin-2-ones
etizolam[no description available]medium10organic molecular entity
ropinirole[no description available]medium30indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
talipexole[no description available]medium10azepine
zonisamide[no description available]medium301,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
carbidopa[no description available]medium10catechols;
hydrate;
hydrazines;
monocarboxylic acid		antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
progabide[no description available]medium10diarylmethane
alpidem[no description available]medium20imidazoles
sertindole[no description available]medium30heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
tianeptine[no description available]medium40dibenzothiazepine;
monocarboxylic acid;
organochlorine compound
metaclazepam[no description available]medium10benzodiazepine
pramipexole[no description available]medium60benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
escitalopram[no description available]medium701-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
escitalopram[no description available]medium721-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
milnacipran[no description available]medium30acetamides
brl 42359[no description available]medium10
(S)-warfarin[no description available]medium104-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one
melatonin[no description available]medium60acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
melatonin[no description available]medium61acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
bisacodyl[no description available]medium20diarylmethane
bronopol[no description available]medium10nitro compound
ciglitazone[no description available]medium10aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cilostazol[no description available]medium20lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide[no description available]medium10sulfonamide
ebastine[no description available]medium10organic molecular entity
4-biphenylylacetic acid[no description available]medium10biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
nadolol[no description available]medium20tetralins
neostigmine[no description available]medium10quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
pioglitazone[no description available]medium20aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
piracetam[no description available]medium20organonitrogen compound;
organooxygen compound
piribedil[no description available]medium10N-arylpiperazine
ono 1078[no description available]medium10chromones
pyranoprofen[no description available]medium10pyridochromene
sulfanitran[no description available]medium10sulfonamide
tiapride[no description available]medium10benzamides
tilorone[no description available]medium10aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
nikethamide[no description available]medium10pyridinecarboxamide
tolnaftate[no description available]medium10monothiocarbamic esterantifungal drug
thenoyltrifluoroacetone[no description available]medium10
undecylenic acid[no description available]medium10undecenoic acidantifungal drug;
plant metabolite
pirinixic acid[no description available]medium10aryl sulfide;
organochlorine compound;
pyrimidines
carbon tetrachloride[no description available]medium10chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
tubocurarine[no description available]medium10bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
triamcinolone diacetate[no description available]medium10corticosteroid hormone
rotenone[no description available]medium10organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
procarbazine hydrochloride[no description available]medium10hydrochlorideantineoplastic agent
emetine[no description available]medium10isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
dimenhydrinate[no description available]medium20diarylmethane
1-naphthylisothiocyanate[no description available]medium10isothiocyanateinsecticide
hydroxychloroquine sulfate[no description available]medium10
ethambutol hydrochloride[no description available]medium10hydrochlorideantitubercular agent
antimycin a[no description available]medium10benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
pregnenolone carbonitrile[no description available]medium10aliphatic nitrile
metocurine[no description available]medium10isoquinolines
etidronate disodium[no description available]medium10organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
mafenide acetate[no description available]medium10carboxylic acid
diacerein[no description available]medium10anthraquinone
selegiline hydrochloride, (r)-isomer[no description available]medium10hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
pancuronium bromide[no description available]medium10bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
ornidazole[no description available]medium10C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
fludarabine phosphate[no description available]medium20nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
benzonidazole[no description available]medium10C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
carbidopa[no description available]medium20catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
feprazone[no description available]medium10organic molecular entity
nitazoxanide[no description available]medium20benzamides;
carboxylic ester
acarbose[no description available]medium20tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
staurosporine[no description available]medium10indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
atracurium besylate[no description available]medium10organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
pergolide mesylate[no description available]medium10methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
talniflumate[no description available]medium10benzofurans
fenoldopam mesylate[no description available]medium10benzazepine
stepronin[no description available]medium10N-acyl-amino acid
salmeterol xinafoate[no description available]medium10naphthoic acid
imiquimod[no description available]medium10imidazoquinolineantineoplastic agent;
interferon inducer
aromasil[no description available]medium2017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
gemcitabine hydrochloride[no description available]medium10hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
atorvastatin calcium anhydrous[no description available]medium10organic calcium salt
duloxetine hydrochloride[no description available]medium330duloxetine hydrochlorideantidepressant
emtricitabine[no description available]medium20monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
paroxetine hydrochloride[no description available]medium10hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
bupropion hydrochloride[no description available]medium10aromatic ketone
trazodone hydrochloride[no description available]medium10hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
doxazosin mesylate[no description available]medium10methanesulfonate saltgeroprotector
mevastatin[no description available]medium102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
bupivacaine hydrochloride[no description available]medium10hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
plerixafor[no description available]medium30azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
ticlopidine hydrochloride[no description available]medium10hydrochloride
epirubicin hydrochloride[no description available]medium10
pazufloxacin[no description available]medium10quinolines
miconazole nitrate[no description available]medium10
artemisinin[no description available]medium10organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide[no description available]medium10sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone[no description available]medium103-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
artemether[no description available]medium10artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
hp 873[no description available]medium201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
loxapine succinate[no description available]medium10succinate saltgeroprotector
uroxatral[no description available]medium10hydrochloride
aceclofenac[no description available]medium20amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
thiocolchicoside[no description available]medium10glycoside
doripenem[no description available]medium20carbapenems
tamiflu[no description available]medium10phosphate salt
bexarotene[no description available]medium20benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098[no description available]medium40acetamides
ketorolac tromethamine[no description available]medium10organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
moxifloxacin hydrochloride[no description available]medium10hydrochlorideantibacterial drug
fulvestrant[no description available]medium2017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
mizoribine[no description available]medium10imidazolesanticoronaviral agent
racecadotril[no description available]medium10N-acyl-amino acid
tadalafil[no description available]medium20benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
plavix[no description available]medium10azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
valdecoxib[no description available]medium20isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
desloratadine[no description available]medium20benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
abiraterone[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
febuxostat[no description available]medium301,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
lexapro[no description available]medium10
docetaxel anhydrous[no description available]medium20secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
cox 189[no description available]medium20amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
telbivudine[no description available]medium20pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
ramelteon[no description available]medium30indanes
tolvaptan[no description available]medium20benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
lenalidomide[no description available]medium20aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lacosamide[no description available]medium20N-acyl-amino acid
vincaleukoblastine[no description available]medium20acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
vincristine sulfate[no description available]medium10organic sulfate saltantineoplastic agent;
geroprotector
wortmannin[no description available]medium10acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
perindopril erbumine[no description available]medium10addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
pemirolast potassium salt[no description available]medium10
eplerenone[no description available]medium203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
loteprednol etabonate[no description available]medium1011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
valrubicin[no description available]medium10anthracycline;
trifluoroacetamide
posaconazole[no description available]medium20aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
arginine vasopressin[no description available]medium30vasopressincardiovascular drug;
hematologic agent;
mitogen
trilostane[no description available]medium1017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
leuprolide acetate[no description available]medium10acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
levosulpiride[no description available]medium10sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
eszopiclone[no description available]medium20zopiclonecentral nervous system depressant;
sedative
epalrestat[no description available]medium10monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
valinomycin[no description available]medium10cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
latoconazole[no description available]medium10conazole antifungal drug;
imidazole antifungal drug
maraviroc[no description available]medium30tropane alkaloid
toremifene citrate[no description available]medium10stilbenoidanticoronaviral agent
azilect[no description available]medium10
dasatinib[no description available]medium201,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
vitamin d 2[no description available]medium20hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
brompheniramine maleate[no description available]medium10maleate saltanti-allergic agent
dexchlorpheniramine maleate[no description available]medium10organic molecular entity
l 660,711[no description available]medium10quinolines
travoprost[no description available]medium10(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
imipenem[no description available]medium10carbapenems
ketotifen fumarate[no description available]medium10organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
dinoprost tromethamine[no description available]medium10organic molecular entity
rosuvastatin calcium[no description available]medium10N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride[no description available]medium10allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
acipimox[no description available]medium10pyrazinecarboxylic acid
atosiban[no description available]medium10oligopeptide
bimatoprost[no description available]medium10monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
enalapril maleate[no description available]medium10maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin[no description available]medium40gamma-amino acidanticonvulsant;
calcium channel blocker
alvimopan anhydrous[no description available]medium20peptide
tenofovir disoproxil fumarate[no description available]medium10fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
dexbrompheniramine maleate[no description available]medium10brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
rifaximin[no description available]medium20acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
everolimus[no description available]medium20cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
fluphenazine[no description available]medium10
cefdinir[no description available]medium30cephalosporin;
ketoxime		antibacterial drug
bisoprolol, fumarate (1:1) salt[no description available]medium10
etoposide phosphate[no description available]medium10furonaphthodioxole
ciclesonide[no description available]medium10organic molecular entity
dutasteride[no description available]medium20(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna[no description available]medium10fumarate saltantihypertensive agent
vildagliptin[no description available]medium10amino acid amide
sgd 301-76[no description available]medium10conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
fluvoxamine maleate[no description available]medium10(trifluoromethyl)benzenes
thioacetazone[no description available]medium10
dexlansoprazole[no description available]medium20benzimidazoles;
sulfoxide
gemifloxacin mesylate[no description available]medium10methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
rivaroxaban[no description available]medium10aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
hki 272[no description available]medium10nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib[no description available]medium10N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
pazopanib[no description available]medium20aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
amg 009[no description available]medium10
cefotaxime sodium[no description available]medium10organic sodium salt
losartan potassium[no description available]medium10
dactolisib[no description available]medium10imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
rabeprazole sodium[no description available]medium10organic sodium salt
bivalirudin[no description available]medium20polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin[no description available]medium10heterodetic cyclic peptide;
peptide hormone
warfarin sodium[no description available]medium10
pravastatin sodium[no description available]medium10organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium[no description available]medium10
sl 80.0750[no description available]medium10
clavulanate potassium[no description available]medium10potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
piperacillin sodium[no description available]medium10organic sodium salt
cefazolin sodium[no description available]medium10organic sodium salt
azlocillin sodium[no description available]medium10organic sodium salt
minocycline hydrochloride[no description available]medium10
valtrex[no description available]medium10organic molecular entity
citrovorum factor[no description available]medium20tetrahydrofolic acid
rifapentine[no description available]medium20N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
sildenafil citrate[no description available]medium10citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
tegaserod maleate[no description available]medium10maleate saltserotonergic agonist
m-chlorophenylguanidine[no description available]medium10
gamma-aminobutyric acid[no description available]medium70amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
beta-alanine[no description available]medium10amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
benzoic acid[no description available]medium10benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
formic acid[no description available]medium10monocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent
gallic acid[no description available]medium10trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
histamine[no description available]medium30aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
dihydroxyphenylalanine[no description available]medium20hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative		human metabolite
picolinic acid[no description available]medium10pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
propionic acid[no description available]medium10saturated fatty acid;
short-chain fatty acid		antifungal drug
pyridoxamine[no description available]medium10aminoalkylpyridine;
hydroxymethylpyridine;
monohydroxypyridine;
vitamin B6		Escherichia coli metabolite;
human metabolite;
iron chelator;
mouse metabolite;
nephroprotective agent;
plant metabolite;
Saccharomyces cerevisiae metabolite
trimethylamine[no description available]medium10methylamines;
tertiary amine		Escherichia coli metabolite;
human xenobiotic metabolite
tryptophan[no description available]medium10alpha-amino acid;
amino acid zwitterion;
aminoalkylindole;
aromatic amino acid;
polar amino acid		Daphnia magna metabolite
2,4-dichlorophenoxyacetic acid[no description available]medium10chlorophenoxyacetic acid;
dichlorobenzene		agrochemical;
defoliant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
environmental contaminant;
phenoxy herbicide;
synthetic auxin
arecoline[no description available]medium10enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
carbidopa[no description available]medium10benzenes;
monocarboxylic acid
celiprolol[no description available]medium10aromatic ketone
dyclonine[no description available]medium10aromatic ketone;
piperidines		topical anaesthetic
flumequine[no description available]medium103-oxo monocarboxylic acid;
organofluorine compound;
pyridoquinoline;
quinolone antibiotic
mephentermine[no description available]medium10amphetamines
methoxyphenamine[no description available]medium10amphetaminesbeta-adrenergic agonist;
bronchodilator agent
3-Hydroxy-alpha-methyl-DL-tyrosine[no description available]medium10benzenes;
monocarboxylic acid
oxotremorine[no description available]medium10N-alkylpyrrolidine
isonicotinic acid[no description available]medium10pyridinemonocarboxylic acidalgal metabolite;
human metabolite
aspartic acid[no description available]medium10aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
tyrosine[no description available]medium20amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
leucine[no description available]medium10amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
ethylamine[no description available]medium10primary aliphatic aminehuman metabolite
tromethamine[no description available]medium20primary amino compound;
triol		buffer
brompheniramine[no description available]medium20organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
phenylpiperazine[no description available]medium10
2-naphthoic acid[no description available]medium10naphthoic acidmouse metabolite;
xenobiotic metabolite
mecoprop[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes
deanol[no description available]medium10ethanolamines;
tertiary amine		curing agent;
radical scavenger
4-methylmorpholine[no description available]medium10
n-butylamine[no description available]medium10primary aliphatic amine
piperidine[no description available]medium10azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine		base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent
morpholine[no description available]medium10morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound
hexahydroazepine[no description available]medium10azacycloalkane;
azepanes;
saturated organic heteromonocyclic parent
n-methylpyrrolidine[no description available]medium10
triethylamine[no description available]medium20tertiary amine
chloroprocaine[no description available]medium10benzoate ester;
monochlorobenzenes		central nervous system depressant;
local anaesthetic;
peripheral nervous system drug
aziridine[no description available]medium10azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent		alkylating agent
dibenzepin[no description available]medium10dibenzodiazepine
trifluoroethylamine[no description available]medium10
2-fluoroethylamine[no description available]medium10
arecaidine[no description available]medium10citraconoyl group
azetidine[no description available]medium10azacycloalkane;
azetidines;
saturated organic heteromonocyclic parent
gluconic acid[no description available]medium10gluconic acidchelator;
Penicillium metabolite
aminopenicillanic acid[no description available]medium10amino acid zwitterion;
penicillanic acids		allergen
glycyl-glycyl-glycine[no description available]medium10tripeptide zwitterion;
tripeptide
n,n-dimethylethylamine[no description available]medium10
diethylmethylamine[no description available]medium10
glycine ethyl ester[no description available]medium10
n-methylpiperidine[no description available]medium10
benzydamine[no description available]medium10aromatic ether;
indazoles;
tertiary amino compound		analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug
tempidon[no description available]medium10piperidones
clopyralid[no description available]medium10organochlorine pesticide;
pyridines		herbicide
dimethylaminopropionitrile[no description available]medium10
5-phenylvaleric acid[no description available]medium10benzenes;
monocarboxylic acid
pyrrolidine[no description available]medium10azacycloalkane;
pyrrolidines;
saturated organic heteromonocyclic parent
propamocarb[no description available]medium10carbamate ester;
carbamate fungicide;
tertiary amino compound		antifungal agrochemical;
environmental contaminant;
xenobiotic
phenyl-2-aminoethyl sulfide[no description available]medium10
Flamprop[no description available]medium10benzamides
d-lactic acid[no description available]medium102-hydroxypropanoic acidEscherichia coli metabolite;
human metabolite
thiamorpholine[no description available]medium10saturated organic heteromonocyclic parent;
thiomorpholines
glycyl-glycyl-glycyl-glycine[no description available]medium10
carazolol[no description available]medium10carbazoles
oleandomycin[no description available]medium10oleandomycins
phenylalanyl-phenylalanyl-phenylalanine[no description available]medium10oligopeptide
3-(4-methoxybenzoyl)propionic acid[no description available]medium10
dimethylaminopropanol[no description available]medium10
4-phenylbutylamine[no description available]medium10benzenes;
phenylalkylamine;
primary amino compound
glycinexylidide[no description available]medium10amino acid amidedrug metabolite
Trp-Trp[no description available]medium10dipeptideMycoplasma genitalium metabolite
kampirone[no description available]medium10N-arylpiperazine
isopelletierine[no description available]medium10citraconoyl group
fenpropimorph[no description available]medium10alkylbenzene
1-(2-pyridinyl)piperazine[no description available]medium10
l-lactic acid[no description available]medium10(2S)-2-hydroxy monocarboxylic acid;
2-hydroxypropanoic acid		Escherichia coli metabolite;
human metabolite
ibuprofen, (r)-isomer[no description available]medium10ibuprofen
deramciclane[no description available]medium10
aspartame[no description available]medium10carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
norpseudoephedrine[no description available]medium10amphetamines;
phenethylamine alkaloid		central nervous system stimulant;
plant metabolite;
psychotropic drug
e-z cinnamic acid[no description available]medium10cinnamic acidplant metabolite
sorbic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
sorbic acid
doxepin hydrochloride[no description available]medium10
4-methylumbelliferyl glucoside[no description available]medium10beta-D-glucoside;
coumarins;
monosaccharide derivative		chromogenic compound
tylosin[no description available]medium10aldehyde;
disaccharide derivative;
enone;
leucomycin;
macrolide antibiotic;
monosaccharide derivative		allergen;
bacterial metabolite;
environmental contaminant;
xenobiotic
dihydrocodeine[no description available]medium10morphinane alkaloid
codeine phosphate[no description available]medium10
dihydromorphine[no description available]medium10morphinane alkaloid
heroin[no description available]medium10morphinane alkaloidmu-opioid receptor agonist;
opioid analgesic;
prodrug
normorphine[no description available]medium10morphinane alkaloid
morphine-3-glucuronide[no description available]medium10morphinane alkaloid
1,2-dielaidoylphosphatidylethanolamine[no description available]medium10
rosaramicin[no description available]medium10aldehyde;
enone;
epoxide;
macrolide antibiotic;
monosaccharide derivative		bacterial metabolite
phenylalanylphenylalanine[no description available]medium10dipeptide;
L-aminoacyl-L-amino acid zwitterion		human blood serum metabolite;
Mycoplasma genitalium metabolite
norcodeine[no description available]medium10morphinane alkaloid
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride[no description available]medium10
decanoylcarnitine[no description available]medium10decanoate ester;
O-acylcarnitine		human urinary metabolite
norclozapine[no description available]medium20dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
alaproclate[no description available]medium20alpha-amino acid ester
ambenonium[no description available]medium10quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
p-aminohippuric acid[no description available]medium10N-acylglycineDaphnia magna metabolite
bendroflumethiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
bethanechol[no description available]medium10carbamate ester;
quaternary ammonium ion		muscarinic agonist
secbutabarbital[no description available]medium10barbiturates
candesartan[no description available]medium10benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbinoxamine[no description available]medium10monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
chlorcyclizine[no description available]medium10diarylmethane
cyclofenil[no description available]medium10organic molecular entity
dichlorphenamide[no description available]medium10dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
pentetic acid[no description available]medium10pentacarboxylic acidcopper chelator
dimercaprol[no description available]medium10dithiol;
primary alcohol		chelator
doxylamine[no description available]medium10pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
edrophonium[no description available]medium10phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
ethotoin[no description available]medium10imidazolidine-2,4-dioneanticonvulsant
fenoldopam[no description available]medium10benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoprofen[no description available]medium10monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flurazepam[no description available]high211,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
flurazepam[no description available]high201,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester[no description available]medium10benzenes
guaifenesin[no description available]medium10methoxybenzenes
guanethidine[no description available]medium10azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanidine[no description available]medium10carboxamidine;
guanidines;
one-carbon compound
isocarboxazid[no description available]medium20benzenes
mechlorethamine[no description available]medium10nitrogen mustard;
organochlorine compound		alkylating agent
mepenzolate[no description available]medium10diarylmethane
methazolamide[no description available]medium10sulfonamide;
thiadiazoles
methocarbamol[no description available]medium10aromatic ether;
carbamate ester;
secondary alcohol
methyclothiazide[no description available]medium10benzothiadiazine
phentermine[no description available]medium10primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid[no description available]medium10monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
polythiazide[no description available]medium10benzothiadiazine
duodote[no description available]medium10pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
propantheline[no description available]medium10xanthenes
salicylsalicylic acid[no description available]medium10benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
secobarbital[no description available]medium10barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
succinylcholine[no description available]medium10quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
sulfathiazole[no description available]medium101,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
trimethobenzamide[no description available]medium10benzamides;
tertiary amino compound		antiemetic
delavirdine[no description available]medium10aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
cysteine[no description available]medium10cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
edetic acid[no description available]medium10ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride[no description available]medium10quaternary ammonium salt
mepazine[no description available]medium10phenothiazines
calcium acetate[no description available]medium10calcium saltchelator
mebanazine[no description available]medium10benzenes
cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
perflutren[no description available]medium10fluoroalkane;
fluorocarbon
fluoxymesterone[no description available]medium1011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
methsuximide[no description available]medium10organic molecular entity
diethylpropion[no description available]medium10aromatic ketone;
tertiary amine		appetite depressant
benzonatate[no description available]medium10benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
methylergonovine[no description available]medium10ergoline alkaloid
4-hydroxybutyric acid[no description available]medium104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
sulfanilylurea[no description available]medium10benzenes;
sulfonamide
pamabrom[no description available]medium10
diphenoxylate[no description available]medium10ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
ibufenac[no description available]medium10monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metaxalone[no description available]medium10aromatic ether
dexbrompheniramine[no description available]medium10brompheniramineanti-allergic agent;
H1-receptor antagonist
megestrol[no description available]medium2017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
clomacran[no description available]medium10acridines
methenamine hippurate[no description available]medium10N-acylglycine
sodium thiosulfate[no description available]medium10inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
fenclozic acid[no description available]medium10
laxagetten 4,4'-diacetoxydiphenylpyridylemethane[no description available]medium10
alclofenac[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fludrocortisone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
dexchlorpheniramine[no description available]medium10chlorphenamine
clometacin[no description available]medium10N-acylindole
vecuronium[no description available]medium10acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
exifone[no description available]medium10benzophenones
mefloquine[no description available]medium10[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
fialuridine[no description available]medium10
haloperidol decanoate[no description available]medium10organic molecular entity
tolrestat[no description available]medium10naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
balsalazide[no description available]medium10
ranolazine[no description available]medium10aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
tasosartan[no description available]medium10biphenyls
tiludronic acid[no description available]medium10organochlorine compound
fenofibric acid[no description available]medium10aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
oseltamivir[no description available]medium10acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
histamine phosphate[no description available]medium10phosphate salthistamine agonist
tilbroquinol[no description available]medium10organohalogen compound;
quinolines
droxicam[no description available]medium10organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
ebrotidine[no description available]medium10sulfonamide
acamprosate[no description available]medium20acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine[no description available]medium10aminopyrimidine
fenoxypropazine[no description available]medium10aromatic ether
nitrefazole[no description available]medium10imidazoles
desvenlafaxine[no description available]medium10cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
rufinamide[no description available]medium10aromatic amide;
heteroarene
dexpanthenol[no description available]medium10amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
fosamprenavir[no description available]medium10sulfonamideprodrug
10-propargyl-10-deazaaminopterin[no description available]medium10N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
pralnacasan[no description available]medium10
dexmethylphenidate[no description available]medium10methyl phenyl(piperidin-2-yl)acetateadrenergic agent
cinacalcet[no description available]medium10(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
lubiprostone[no description available]medium10
17 alpha-hydroxyprogesterone caproate[no description available]medium10corticosteroid hormone
varenicline[no description available]medium10
fiduxosin[no description available]medium10
erlotinib[no description available]medium10aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
etravirine[no description available]medium10aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
dronedarone[no description available]medium101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
lapatinib[no description available]medium10furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
darunavir[no description available]medium10carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
sorafenib[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
regadenoson[no description available]medium10purine nucleoside
oxytocin[no description available]medium10heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
clindamycin phosphate[no description available]medium10
octreotide[no description available]medium10
arsenic trioxide[no description available]medium10arsenic oxideantineoplastic agent;
insecticide
sr 90107[no description available]medium10
meglumine iodipamide[no description available]medium10organoammonium saltradioopaque medium
thyrotropin-releasing hormone[no description available]medium10peptide hormone;
tripeptide		human metabolite
s 1033[no description available]medium10(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
pyrantel[no description available]medium101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
ranitidine[no description available]medium10C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc[no description available]medium10
dermatan sulfate[no description available]medium10amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
fospropofol[no description available]medium10alkylbenzene
rasagiline[no description available]medium20indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
hemabate[no description available]medium10
ethamolin[no description available]medium10long-chain fatty acid
estropipate[no description available]medium10piperazinium salt;
steroid sulfate
nabilone[no description available]medium10
vitamin k 1[no description available]medium10phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
trospium chloride[no description available]medium10
benzphetamine[no description available]medium10amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
deamino arginine vasopressin[no description available]medium10heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
goserelin[no description available]medium10organic molecular entity
silodosin[no description available]medium10indolecarboxamide
su 11248[no description available]medium10monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
levorphanol[no description available]medium10morphinane alkaloid
verteporfin[no description available]medium10
zimeldine[no description available]medium20styrenes
trientine hydrochloride[no description available]medium10
n-methylscopolamine bromide[no description available]medium10
pafuramidine[no description available]medium10
aliskiren[no description available]medium10monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
1-methyl-d-lysergic acid butanolamide[no description available]medium10ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
etonogestrel[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
bibx 1382bs[no description available]medium10substituted aniline
fesoterodine[no description available]medium10diarylmethane
gemifloxacin[no description available]medium101,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
armodafinil[no description available]medium102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
sincalide[no description available]medium10oligopeptide
tapentadol[no description available]medium10alkylbenzene
cefditoren[no description available]medium10carboxylic acid;
cephalosporin		antibacterial drug
prasugrel hydrochloride[no description available]medium10
bms 477118[no description available]medium10adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
enfuvirtide[no description available]medium10
ganirelix[no description available]medium10polypeptide
teriparatide[no description available]medium10polypeptide
salmon calcitonin[no description available]medium10heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide[no description available]medium10polypeptide
exenatide[no description available]medium10
sodium lactate[no description available]medium10lactate salt;
organic sodium salt		food acidity regulator;
food preservative
sodium iothalamate[no description available]medium10
raltegravir[no description available]medium101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
tipranavir[no description available]medium10sulfonamideantiviral drug;
HIV protease inhibitor
fertinex[no description available]medium10
bl 4162a[no description available]medium10imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
pemetrexed[no description available]medium10N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
valganciclovir[no description available]medium10L-valyl ester;
purines		antiviral drug;
prodrug
fosaprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
levomefolate calcium[no description available]medium10organic calcium saltantidepressant
sodium azide[no description available]medium10inorganic sodium saltantibacterial agent;
explosive;
mitochondrial respiratory-chain inhibitor;
mutagen
1,2-diamino-4-nitrobenzene[no description available]medium10C-nitro compound;
primary amino compound
venlafaxine hydrochloride[no description available]medium15732hydrochloride
reboxetine[no description available]medium246aromatic ether
thioctic acid[no description available]medium20dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
lithium[no description available]medium103alkali metal atom
triazoles[no description available]medium2801,2,3-triazole
suvorexant[no description available]medium101,3-benzoxazoles;
aromatic amide;
diazepine;
organochlorine compound;
triazoles		central nervous system depressant;
orexin receptor antagonist
milnacipran[no description available]medium130acetamides
cytidine triphosphate[no description available]medium10cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
quetiapine fumarate[no description available]medium272fumarate salt
paliperidone palmitate[no description available]medium411,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine
dothiepin hydrochloride[no description available]medium20dothiepin
nad[no description available]medium10organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
desvenlafaxine succinate[no description available]medium70
vortioxetine[no description available]medium41aryl sulfide;
N-arylpiperazine		antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist
mefloquine[no description available]medium280
carboplatin[no description available]medium10
platinum[no description available]medium10elemental platinum;
nickel group element atom;
platinum group metal atom
n-vinyl-2-pyrrolidinone[no description available]medium10pyrrolidin-2-ones
brexpiprazole[no description available]medium10N-arylpiperazine
carbostyril[no description available]medium72monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
cadmium[no description available]medium10cadmium molecular entity;
zinc group element atom
sb 258585[no description available]medium10piperazines
flupenthixol[no description available]medium20thioxanthenes
tramadol[no description available]medium502-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
imidacloprid[no description available]medium10imidacloprid;
imidazolidines;
monochloropyridine		environmental contaminant;
genotoxin;
neonicotinoid insectide;
nicotinic acetylcholine receptor agonist;
xenobiotic
moxidectin[no description available]medium10
metallothionein[no description available]medium10
sarpogrelate[no description available]medium10hemisuccinate;
stilbenoid
mdl 100907[no description available]medium121
demethylmirtazapine[no description available]high240benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
human xenobiotic metabolite;
serotonergic antagonist
demethylmirtazapine[no description available]high243benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
human xenobiotic metabolite;
serotonergic antagonist
hydrazine[no description available]medium10azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
anamorelin[no description available]medium10
vilazodone hydrochloride[no description available]medium10hydrochlorideantidepressant;
serotonergic agonist;
serotonin uptake inhibitor
gentamicin[no description available]medium10
nitrites[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
thioacetamide[no description available]medium10thiocarboxamidehepatotoxic agent
n-methyl-3,4-methylenedioxyamphetamine[no description available]medium30amphetamines;
benzodioxoles		neurotoxin
chrysin[no description available]medium107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
malondialdehyde[no description available]medium50dialdehydebiomarker
acid phosphatase[no description available]medium10
cyclohexanol[no description available]medium11829cyclohexanols;
secondary alcohol		solvent
dizocilpine maleate[no description available]medium60maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
desmethyldoxepin[no description available]medium10desmethyldoxepin
concanavalin a[no description available]medium10
boric acid[no description available]medium10boric acidsastringent
8-hydroxymirtazapine[no description available]medium121
thiophenes[no description available]medium210mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
D-fructopyranose[no description available]medium30cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
cortisone[no description available]medium2011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
betadex[no description available]medium10cyclodextrin
carboxymethyl-beta-cyclodextrin[no description available]medium10
pinaverium[no description available]medium10monoterpenoid
ly 341495[no description available]medium10
xanthenes[no description available]medium10xanthene
ubiquinone[no description available]medium10
leptin[no description available]medium64
methylene chloride[no description available]medium10chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
mocetinostat[no description available]medium30aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
oxalates[no description available]medium10
osteoprotegerin[no description available]medium10long-chain fatty acid
lysophosphatidic acid[no description available]medium101-acyl-sn-glycerol 3-phosphate
uridine monophosphate[no description available]medium10pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
sofosbuvir[no description available]medium10isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
cytosine[no description available]medium51aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
organophosphonates[no description available]medium40divalent inorganic anion;
phosphite ion
prothipendyl[no description available]medium10aromatic amine;
tertiary amino compound
ent-dextilidine[no description available]medium10ethyl 2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate
thiazoles[no description available]medium601,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
cardiovascular agents[no description available]medium10
rx 821002[no description available]medium10benzodioxine;
cyclic ketal;
imidazolines		alpha-adrenergic antagonist
clorgyline[no description available]medium20aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
ro 41-1049[no description available]medium10
piperidines[no description available]medium60
pci 32765[no description available]medium10acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
apremilast[no description available]medium10aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
pyrethrins[no description available]medium10
cypermethrin[no description available]medium10aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound		agrochemical;
molluscicide;
pyrethroid ester acaricide;
pyrethroid ester insecticide
decamethrin[no description available]medium10aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound		agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide
dehydroepiandrosterone sulfate[no description available]medium2117-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
atipamezole[no description available]medium10
famotidine[no description available]medium101,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
neopterin[no description available]medium10
ethylene glycol[no description available]medium10ethanediol;
glycol		metabolite;
mouse metabolite;
solvent;
toxin
glyoxylic acid[no description available]medium102-oxo monocarboxylic acid;
aldehydic acid		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
oxalic acid[no description available]medium10alpha,omega-dicarboxylic acidalgal metabolite;
human metabolite;
plant metabolite
glycolic acid[no description available]medium102-hydroxy monocarboxylic acid;
primary alcohol		keratolytic drug;
metabolite
allotetrahydrocortisol[no description available]medium10corticosteroid hormone
tetrahydrocortisol[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3alpha-hydroxy steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
tetrahydrocortisone[no description available]medium1021-hydroxy steroid
fluorobenzenes[no description available]medium20monofluorobenzenesNMR chemical shift reference compound
desoxycorticosterone[no description available]medium2120-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
tetrahydrodeoxycorticosterone[no description available]medium2121-hydroxy steroid
zinc sulfate[no description available]medium10metal sulfate;
zinc molecular entity		fertilizer
methanol[no description available]medium20alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
pargyline[no description available]medium10aromatic amine
vitamin b 6[no description available]medium10
perospirone[no description available]medium10N-arylpiperazine
cellulose[no description available]medium20glycoside
lysergic acid diethylamide[no description available]medium10ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound		dopamine agonist;
hallucinogen;
serotonergic agonist
ng-nitroarginine methyl ester[no description available]medium10alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
glutaral[no description available]medium10dialdehydecross-linking reagent;
disinfectant;
fixative
chitosan[no description available]medium10
pregnenolone[no description available]medium2020-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite
oxonic acid[no description available]medium101,3,5-triazines;
monocarboxylic acid
s 1 (combination)[no description available]medium10
phenyl acetate[no description available]medium20benzenes;
phenyl acetates
ammonium acetate[no description available]medium10acetate salt;
ammonium salt		buffer;
food acidity regulator
penicillanic acid[no description available]medium10penicillanic acids
piperacillin, tazobactam drug combination[no description available]medium10
clopenthixol[no description available]medium20N-alkylpiperazine;
primary alcohol;
thioxanthenes		alpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
deoxycytidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
4-hydroxyphenethylene glycol[no description available]medium10phenols
valine[no description available]medium20L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
homovanillic acid[no description available]medium21guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
methoxyhydroxyphenylglycol[no description available]medium31methoxybenzenes;
phenols
methylnitronitrosoguanidine[no description available]medium10nitroso compoundalkylating agent
hydrochloric acid[no description available]medium10chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
guanine[no description available]medium102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
8-hydroxyguanine[no description available]medium10oxopurine
hydroxyindoleacetic acid[no description available]medium20indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
3,4-dihydroxyphenylacetic acid[no description available]medium20catechols;
dihydroxyphenylacetic acid		human metabolite
substance p[no description available]medium11peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
oxazolidin-2-one[no description available]medium20carbamate ester;
oxazolidinone		metabolite
taurine[no description available]medium20amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
thymine[no description available]medium11pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
pirlindole[no description available]medium10carbazoles
potassium chloride[no description available]medium10inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
urethane[no description available]medium10carbamate esterfungal metabolite;
mutagen
sr 142801[no description available]medium10
neurotensin[no description available]medium10peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
sr 48692[no description available]medium10N-acyl-amino acid
alpha-methyltyrosine methyl ester[no description available]medium10
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane[no description available]medium10
desmethylmianserin[no description available]medium10dibenzooxazepine
didesmethylcitalopram[no description available]medium10benzenes;
organic amino compound
desmethylsertraline[no description available]medium10
monodesmethylcitalopram[no description available]medium10benzenes;
organic amino compound
carbamide peroxide[no description available]medium11mixturedisinfectant;
oxidising agent;
reagent
oxazoles[no description available]medium201,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pramoxine[no description available]medium10aromatic ether;
morpholines		local anaesthetic
salicylates[no description available]medium10monohydroxybenzoateplant metabolite
fura-2[no description available]medium10
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
octanoic acid[no description available]medium11medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
caprylates[no description available]medium11fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
1-anilino-8-naphthalenesulfonate[no description available]medium10aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
gr 65630[no description available]medium10
org gc 94[no description available]medium10
tibolone[no description available]medium1017beta-hydroxy steroid;
terminal acetylenic compound		bone density conservation agent;
hormone agonist
tetrodotoxin[no description available]medium10azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
eedq[no description available]medium10
brl 44408[no description available]medium10
ar-c239[no description available]medium10piperazines
1-naphthylamine[no description available]medium20naphthylaminehuman xenobiotic metabolite
pyrazines[no description available]medium10diazine;
pyrazines		Daphnia magna metabolite
quisqualic acid[no description available]medium10non-proteinogenic alpha-amino acid
befloxatone[no description available]medium10
methysergide[no description available]medium10ergoline alkaloid
isoxazoles[no description available]medium11isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
alpha-naphthoflavone[no description available]medium10extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
fg 7142[no description available]medium30beta-carbolines
dipropylacetamide[no description available]medium10fatty amidegeroprotector;
metabolite;
teratogenic agent
methoxamine[no description available]medium10amphetaminesalpha-adrenergic agonist;
antihypotensive agent
technetium tc 99m exametazime[no description available]medium11
cpp 199[no description available]medium10
alanine[no description available]medium10alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
indeloxazine[no description available]medium10indene
s,n,n'-tripropylthiocarbamate[no description available]medium20tertiary amine
propiconazole[no description available]medium10conazole fungicide;
cyclic ketal;
dichlorobenzene;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic
exudates[no description available]medium11
hypericum[no description available]medium10penicillanic acids
isomethyleugenol[no description available]medium20isomethyleugenol
4-methoxyamphetamine[no description available]medium10
kava[no description available]medium10
fomesafen[no description available]medium11aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
setiptiline[no description available]medium00tertiary amino compound;
tetracyclic antidepressant		alpha-adrenergic antagonist;
serotonergic antagonist
tolazoline[no description available]low00imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
wb 4101[no description available]low00aromatic ether;
benzodioxine;
secondary amino compound		alpha-adrenergic antagonist
cleistanthin b[no description available]low00beta-D-glucoside;
cleistanthins;
monosaccharide derivative		alpha-adrenergic antagonist;
antihypertensive agent;
diuretic
roxindole[no description available]low00indolesalpha-adrenergic antagonist;
serotonergic drug
raubasine[no description available]low00methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound		alpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
dihydroergocristine monomesylate[no description available]low00methanesulfonate saltalpha-adrenergic antagonist;
geroprotector;
vasodilator agent
tamsulosin hydrochloride[no description available]low00hydrochloridealpha-adrenergic antagonist;
antineoplastic agent
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzodioxan hydrochloride[no description available]low00hydrochloridealpha-adrenergic antagonist
cleistanthin[no description available]low00cleistanthins;
xylose derivative		alpha-adrenergic antagonist;
antihypertensive agent;
diuretic
oxatomide[no description available]low00benzimidazoles;
diarylmethane;
N-alkylpiperazine		anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
propiomazine[no description available]low00aromatic ketone;
phenothiazines;
tertiary amino compound		dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
sedative;
serotonergic antagonist
thiethylperazine[no description available]low00N-methylpiperazine;
phenothiazines		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
metergoline[no description available]low00carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
dotarizine[no description available]low00cyclic ketal;
dioxolane;
N-alkylpiperazine		calcium channel blocker;
serotonergic antagonist;
vasodilator agent
alosetron hydrochloride[no description available]low00hydrochlorideantiemetic;
serotonergic antagonist
tramadol hydrochloride[no description available]low00hydrochlorideadrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
spiramide[no description available]low00aromatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
serotonergic antagonist
clomipramine hydrochloride[no description available]low00hydrochlorideanticoronaviral agent;
antidepressant;
serotonergic antagonist;
serotonergic drug
amperozide[no description available]low00diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
amperozide hydrochloride[no description available]low00hydrochlorideanxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine[no description available]low00hydrobromideserotonergic antagonist
gr 113808[no description available]low00indolyl carboxylate ester;
piperidines;
sulfonamide		serotonergic antagonist
fk 1052[no description available]low00imidazoles;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
lurasidone[no description available]low001,2-benzisothiazole;
bridged compound;
dicarboximide;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
picrotoxinin[no description available]low00epoxide;
gamma-lactone;
organic heteropentacyclic compound;
picrotoxane sesquiterpenoid;
tertiary alcohol		GABA antagonist;
plant metabolite;
serotonergic antagonist
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea[no description available]low001,2-thiazoles;
indoles;
ureas		receptor modulator;
serotonergic antagonist
sb-224289[no description available]low001,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound		serotonergic antagonist
brl 15572[no description available]low00monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol		geroprotector;
serotonergic antagonist
LY-310762[no description available]low00aromatic ketone;
monofluorobenzenes;
oxindoles;
piperidines;
tertiary amino compound		receptor modulator;
serotonergic antagonist
ly 367265[no description available]low00dihydropyridine;
fluoroindole;
tertiary amino compound;
thiadiazoloquinoline		antidepressant;
geroprotector;
serotonergic antagonist;
serotonin uptake inhibitor
flibanserin[no description available]low00benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound		antidepressant;
serotonergic agonist;
serotonergic antagonist
rs 25259-197[no description available]low00hydrochlorideantiemetic;
serotonergic antagonist
pimavanserin[no description available]low00aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas		5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist
lurasidone hydrochloride[no description available]low00hydrochlorideadrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
GR 127935 hydrochloride[no description available]low00hydrochlorideserotonergic antagonist
pipamperone dihydrochloride[no description available]low00hydrochloridedopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
brl 15572[no description available]low00hydrochlorideprodrug;
serotonergic antagonist
1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one[no description available]low00hydrochloridereceptor modulator;
serotonergic antagonist
rs 39604[no description available]low00hydrochlorideserotonergic antagonist
3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid[no description available]low0011-oxo steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
steroid acid		antineoplastic agent;
cholinergic antagonist;
metabolite;
serotonergic antagonist
clemizole[no description available]low00benzimidazoles;
monochlorobenzenes;
pyrrolidines		histamine antagonist
epinastine[no description available]medium00benzazepine;
guanidines		anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug
profenamine[no description available]low00phenothiazines;
tertiary amino compound		adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist
methixene[no description available]low00piperidines;
thioxanthenes		antiparkinson drug;
histamine antagonist;
muscarinic antagonist
buclizine[no description available]low00monochlorobenzenes;
N-alkylpiperazine		antiemetic;
central nervous system depressant;
cholinergic antagonist;
histamine antagonist;
local anaesthetic
methdilazine[no description available]low00N-alkylpyrrolidine;
phenothiazines		antipruritic drug;
cholinergic antagonist;
histamine antagonist
cubebin[no description available]low00benzodioxoles;
cyclic acetal;
lactol;
lignan;
secondary alcohol		analgesic;
anti-inflammatory agent;
antimicrobial agent;
histamine antagonist;
plant metabolite;
trypanocidal drug
profenamine hydrochloride[no description available]low00hydrochlorideadrenergic antagonist;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist
quercetin 3-o-glucopyranoside[no description available]low00beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
etazolate[no description available]low00ethyl ester;
hydrazone;
pyrazolopyridine		alpha-secretase activator;
antidepressant;
antipsychotic agent;
anxiolytic drug;
GABA agent;
neuroprotective agent;
phosphodiesterase IV inhibitor
fludiazepam[no description available]low001,4-benzodiazepinone;
organochlorine compound;
organofluorine compound		anxiolytic drug
didesethylflurazepam[no description available]low001,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
primary amino compound		anticonvulsant;
anxiolytic drug;
drug metabolite;
GABAA receptor agonist;
sedative
buspirone hydrochloride[no description available]low00hydrochlorideanxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
midazolam hydrochloride[no description available]low00hydrochloride;
imidazobenzodiazepine		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
glutaurine[no description available]low00dipeptide zwitterion;
dipeptide;
L-glutamine derivative;
sulfonic acid		anticonvulsant;
anxiolytic drug;
hormone;
human metabolite;
mammalian metabolite;
mouse metabolite
tandospirone[no description available]low00bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines		antidepressant;
anxiolytic drug
1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride[no description available]low00hydrochlorideanxiolytic drug;
serotonergic agonist
spinosin[no description available]low00dihydroxyflavone;
flavone C-glycoside;
monomethoxyflavone		anxiolytic drug;
plant metabolite
clorazepate dipotassium[no description available]low00potassium saltanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
ANA-12[no description available]low001-benzothiophenes;
caprolactams;
secondary carboxamide		antidepressant;
anxiolytic drug;
tropomyosin-related kinase B receptor antagonist
6-methyl-2-(phenylethynyl)pyridine[no description available]low00acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
paroxetine maleate[no description available]low00maleate saltantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
2-methyl-6-(phenylethynyl)pyridine hydrochloride[no description available]low00hydrochlorideanxiolytic drug;
metabotropic glutamate receptor antagonist
ly 404039[no description available]low00bridged compound;
dicarboxylic acid;
non-proteinogenic amino acid derivative;
organic heterobicyclic compound;
sulfone		antipsychotic agent;
anxiolytic drug;
dopamine agonist;
metabotropic glutamate receptor agonist
ly 379268[no description available]low00amino dicarboxylic acid;
bridged compound;
organic heterobicyclic compound		antipsychotic agent;
anxiolytic drug;
metabotropic glutamate receptor agonist;
neuroprotective agent
benzquinamide[no description available]low00monocarboxylic acid amideantiemetic;
antipsychotic agent;
H1-receptor antagonist;
muscarinic antagonist;
sedative
bromodiphenhydramine[no description available]low00organobromine compound;
tertiary amino compound		antimicrobial agent;
H1-receptor antagonist;
muscarinic antagonist
emedastine[no description available]low00benzimidazolesanti-allergic agent;
antipruritic drug;
H1-receptor antagonist
promethazine hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
cyclizine[no description available]low00N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
methapyrilene hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
diphenhydramine hydrochloride[no description available]low00hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
orphenadrine hydrochloride[no description available]low00hydrochlorideantiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
azatadine[no description available]low00benzocycloheptapyridine;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
azelastine hydrochloride[no description available]low00hydrochlorideanti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
diphenylpyraline hydrochloride[no description available]low00hydrochloridecholinergic antagonist;
H1-receptor antagonist
orphenadrine citrate[no description available]low00citrate saltH1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
clemizolpenicillin[no description available]low00clemizole(1+) saltH1-receptor antagonist
tau 284[no description available]low00organosulfonate saltanti-allergic agent;
H1-receptor antagonist
clemastine fumarate[no description available]low00fumarate saltanti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
carbinoxamine maleate[no description available]low00maleate saltanti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
acrivastine[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
triprolidine hydrochloride anhydrous[no description available]low00hydrochlorideH1-receptor antagonist
cyclizine hydrochloride[no description available]low00hydrochlorideantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist
alcaftadine[no description available]low00aldehyde;
imidazobenzazepine;
piperidines;
tertiary amino compound		anti-allergic agent;
H1-receptor antagonist
(S)-carbinoxamine maleate[no description available]low00carbinoxamine maleateanti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
aripiprazole lauroxil[no description available]low00aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist
harmaline[no description available]low00harmala alkaloidoneirogen
muscimol[no description available]low00alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
salvinorin a[no description available]low00organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
sk&f 81297[no description available]low00benzazepine
sk&f 82958[no description available]low00benzazepine
sk&f 77434[no description available]low00benzazepine;
catechols;
tertiary amino compound		dopamine agonist
sk&f-38393[no description available]low00benzazepine;
catechols;
secondary amino compound
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-[no description available]low00benzazepine
7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol[no description available]low00benzazepine;
organochlorine compound;
tertiary amino compound		dopaminergic antagonist
azapetine[no description available]low00benzazepine
fluperlapine[no description available]low00benzazepine
zatebradine[no description available]low00benzazepine
ecopipam[no description available]low00benzazepine
sk&f 104078[no description available]low00benzazepine
sk&f 86466[no description available]low00benzazepine
nnc 112[no description available]low00benzazepine
ivabradine[no description available]low00aromatic ether;
benzazepine;
carbobicyclic compound;
tertiary amino compound		cardiotonic drug
sk&f 83959[no description available]low00benzazepine;
catechols;
organochlorine compound;
tertiary amino compound		dopamine agonist
sanguinine[no description available]low00benzazepine
lycoramine[no description available]low00benzazepine
7,8-dimethoxy-1,3-dihydro-3-benzazepin-2-one[no description available]low00benzazepine
5-Methyl-8-nitro-3-spirocyclohexyl-2,3,4,5-tetrahydro-1H-2-benzazepine[no description available]low00benzazepine
capsazepine[no description available]low00benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
sch 23390[no description available]low00benzazepine
ru 42173[no description available]low00benzazepine
benazeprilat[no description available]low00benzazepine;
dicarboxylic acid;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
(5R)-9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol[no description available]low00benzazepine
lorcaserin[no description available]low00benzazepine;
organochlorine compound		anti-obesity agent;
appetite depressant
mln8054[no description available]low00benzazepine
mln 8237[no description available]low00benzazepine
evacetrapib[no description available]low00benzazepine
dizocilpine[no description available]low00secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0low40
2019 Novel Coronavirus Infection0low40
2019-nCoV Disease0low40
2019-nCoV Infection0low40
Abdominal Epilepsy0low10
Abdominal Migraine0medium11
Abdominal Pain0low40
Abnormal Movements0low10
Abnormal Proliferation Cortical Malformations0low10
Abnormalities, Drug-Induced0low60
Abortion, Spontaneous0low40
Abortion, Tubal0low40
Abscess, Hepatic0low10
Absence Seizure0low60
Absence Seizures0low60
Absence Status0low20
ACA Infarct0low10
ACA Infarction0low10
Acantholysis0low10
Acanthosis Nigricans0low10
Acathisia, Drug-Induced0medium132
Ache0medium111
Acid Aspiration Syndrome0low10
Acidosis, Diabetic0low10
Acquired Immune Deficiency Syndrome0low10
Acquired Immuno-Deficiency Syndrome0low10
Acquired Immunodeficiency Syndrome0low10
Acquired Neuromyotonia0low10
Acquired-Immune Deficiency Syndrome Dementia Complex0low10
Action Tremor0low20
Acute Autoimmune Neuropathy0low10
Acute Confusional Migraine0medium11
Acute Confusional Senile Dementia0medium113
Acute Disease0low120
Acute Edematous Pancreatitis0low70
Acute Hypercapnic Respiratory Failure0low20
Acute Hypoxemic Respiratory Failure0low20
Acute Infectious Polyneuritis0low10
Acute Inflammatory Demyelinating Polyneuropathy0low10
Acute Inflammatory Demyelinating Polyradiculoneuropathy0low10
Acute Inflammatory Polyneuropathy0low10
Acute Inflammatory Polyradiculoneuropathy0low10
Acute Kidney Failure0low10
Acute Kidney Injury0low10
Acute Kidney Insufficiency0low10
Acute Liver Injury, Drug-Induced0low70
Acute Myelogenous Leukemia0low10
Acute Myeloid Leukemia0low10
Acute Myeloid Leukemia with Maturation0low10
Acute Myeloid Leukemia without Maturation0low10
Acute Necrotizing Pancreatitis0low10
Acute Pancreatitis0low70
Acute Post-operative Pain0medium32
Acute Post-Traumatic Stress Disorder0medium217
Acute Postoperative Pain0medium32
Acute Relapsing Multiple Sclerosis0low10
Acute Renal Failure0low10
Acute Renal Injury0low10
Acute Renal Insufficiency0low10
ADDH0low10
Adenocarcinoma0low10
Adenocarcinoma, Basal Cell0low10
Adenocarcinoma, Granular Cell0low10
Adenocarcinoma, Oxyphilic0low10
Adenocarcinoma, Tubular0low10
Adenoma, Malignant0low10
Adenoma, Prolactin-Secreting, Pituitary0low10
Adiadochokinesis0low10
Adipocere0low10
Adjustment Disorder0medium32
Adjustment Disorders0medium32
Adolescent Gynecomastia0low30
Advanced Sleep Phase Syndrome0medium11
Adverse Drug Event0medium82
Adverse Drug Reaction0medium82
Affective Disorders0low30
Affective Psychosis, Bipolar0medium252
Age-Related Memory Disorders0medium31
Aggression0medium51
Aggressive Systemic Mastocytosis0low10
Aging0low50
Agitation, Psychomotor0medium61
Agoraphobia0medium11
Agranulocytosis0low50
AIDS0low10
AIDS Dementia Complex0low10
AIDS Encephalopathy0low10
AIDS Seroconversion0medium21
AIDS Seropositivity0medium21
AIDS-Related Dementia Complex0low10
AIDS-Related Opportunistic Infections0low10
Airflow Obstruction, Chronic0medium11
Airway Obstruction0low10
Akathisia0medium61
Akathisia, Drug-Induced0medium132
Akathisia, Tardive0medium132
Akinetic-Rigid Variant of Huntington Disease0low10
Alcohol Abuse0medium144
Alcohol Addiction0medium144
Alcohol Dependence0medium144
Alcohol Drinking0medium32
Alcohol Problem0medium32
Alcohol Use Disorder0medium144
Alcohol-Related Disorders0medium32
Alcoholic Intoxication, Chronic0medium144
Algor Mortis0low10
Alice in Wonderland Syndrome0low10
Allergy, Drug0medium21
Allodynia0low60
Allodynia, Mechanical0low60
Allodynia, Tactile0low60
Allodynia, Thermal0low60
Alloxan Diabetes0low20
Alopecia0low10
Alopecia Cicatrisata0low10
Alopecia, Androgenetic0low10
Alopecia, Male Pattern0low10
Altidudinal Hemianopia0low10
Altitudinal Hemianopsia0low10
Alzheimer Dementia0medium113
Alzheimer Disease0medium113
Alzheimer Disease, Early Onset0medium113
Alzheimer Disease, Late Onset0medium113
Alzheimer Sclerosis0medium113
Alzheimer Syndrome0medium113
Alzheimer Type Senile Dementia0medium113
Alzheimer-Type Dementia (ATD)0medium113
Alzheimer's Disease0medium113
Alzheimer's Disease, Focal Onset0medium113
Alzheimer's Diseases0medium113
Ambulation Disorders, Neurologic0low30
Amentia0medium117
Amphetamine Abuse0medium76
Amphetamine Addiction0medium76
Amphetamine Dependence0medium76
Amygdalo-Hippocampal Epilepsy0low10
Anankastic Personality0medium104
Anasarca0low60
Androgenetic Alopecia0low10
Androgenic Alopecia0low10
Anemia, Cooley's0low10
Anemia, Erythroblastic0low10
Anemia, Fanconi0low10
Anemia, Mediterranean0low10
Anesthesia0low10
Angelman Syndrome0low10
ANLL0low10
Anniversary Reaction0medium32
Anochlesia0low20
Anomalous Ventricular Excitation Syndrome0low10
Anterior Cerebral Artery Infarction0low10
Anterior Cerebral Artery Stroke0low10
Anterior Cerebral Artery Syndrome0low10
Anterior Cervical Pain0low10
Anterior Fascicular Block0low10
Anterior Neck Pain0low10
Anti-HIV Positivity0medium21
Antidiuretic Hormone, Inappropriate Secretion0low60
Antopol Disease0low10
Anxiety Disorders0medium3512
Anxiety Neuroses0medium3512
Anxiety States, Neurotic0medium3512
Apnea, Central0low20
Apnea, Central Sleep0low20
Apnea, Obstructive Sleep0medium63
Apnea, Sleep0medium11
Apnea, Sleep, Central0low20
Apoplexy0medium32
Appetite Disorders0medium111
Apraxia0low10
Apraxia of Phonation0low10
Apraxia, Articulatory0low10
Apraxia, Developmental Verbal0low10
Apraxia, Facial-Oral0low10
Apraxia, Gestural0low10
Apraxia, Motor0low10
Apraxia, Oral0low10
Apraxia, Verbal0low10
Apraxias0low10
Arrhythmia0low20
Arrhythmias, Cardiac0low20
Arrythmia0low20
Arthralgia0low30
Arthritis, Rheumatoid0low10
Asialia0medium43
Asphyxia0low10
Aspiration Pneumonia0low10
Asterixis0low10
Astrocytoma, Grade IV0low10
Asystole0low20
Ataxia0low10
Ataxia, Appendicular0low10
Ataxia, Cerebellar0low10
Ataxia, Limb0low10
Ataxia, Motor0low10
Ataxia, Sensory0low10
Ataxia, Truncal0low10
Ataxy0low10
Atonic Absence Seizure0low60
Atonic Absence Seizures0low60
Atonic Seizure0low60
Atonic Seizures0low60
Atrial Fibrillation0low10
Atrioventricular Nodal Re-Entrant Tachycardia0low10
Atrioventricular Reentrant Tachycardia0low10
Atrophy0low10
Attention Deficit Disorder0low10
Attention Deficit Disorder with Hyperactivity0low10
Attention Deficit Disorders with Hyperactivity0low10
Attention Deficit Hyperactivity Disorder0low10
Attention Deficit Hyperactivity Disorders0low10
Attention Deficit-Hyperactivity Disorder0low10
Atypical Cluster Headache0low10
Aura0low30
Auricular Fibrillation0low10
Auriculoventricular Accessory Pathway Syndrome0low10
Autism0medium51
Autism Spectrum Disorder0medium21
Autism Spectrum Disorders0medium21
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome0medium31
Autism, Dementia, Ataxia, and Loss of Purposeful Hand Use0medium31
Autism, Early Infantile0medium51
Autism, Infantile0medium51
Autistic Disorder0medium51
Autistic Spectrum Disorder0medium21
Autoimmune Diabetes0low20
Autokinetic Effect0low20
Autokinetic Illusions0low20
Autosomal Dominant Juvenile Parkinson Disease0low50
Autosomal Dominant Juvenile Parkinsonism0low50
Autosomal Dominant Parkinsonism0low50
Autosomal Recessive Juvenile Parkinson Disease0low50
Autosomal Recessive Juvenile Parkinsonism0low50
Autosomal Recessive Parkinsonism0low50
Awakening Epilepsy0low30
B-Cell Chronic Lymphocytic Leukemia0low20
B-Cell Leukemia, Chronic0low20
B-Cell Malignancy, Low-Grade0low20
B-Lymphocytic Leukemia, Chronic0low20
B16 Melanoma0low10
Back Ache0low40
Back Pain0low40
Back Pain with Radiation0low40
Back Pain without Radiation0low40
Backache0low40
Bacteremia0low10
Baldness0low10
Baldness, Male Pattern0low10
Ballismus0low10
Bannayan-Riley-Ruvalcaba Syndrome0low10
Bannayan-Ruvalcaba-Riley Syndrome0low10
Bannayan-Zonana Syndrome0low10
Basal Ganglia Diseases0low30
Basal Ganglia Disorders0low30
Behavior Disorder, Rapid Eye Movement Sleep0low30
Behavior Disorder, REM0low30
Behavior Disorders0medium172
Benign Essential Tremor0medium11
Benign Focal Epilepsy, Childhood0low10
Benign Infantile Myoclonic Epilepsy0low10
Benign Neonatal Sleep Myoclonus0low10
Benign Neoplasms0medium279
Benign Neoplasms, Brain0low10
Benign Occipital Epilepsy0low10
Benign Occipital Epilepsy, Childhood0low10
Benign Psychomotor Epilepsy, Childhood0medium11
Besnier-Boeck Disease0low60
Besnier-Boeck-Schaumann Syndrome0low60
beta Thalassemia0low10
beta-Thalassemia0low10
Bewilderment0low20
Bilateral Headache0medium73
Bile Duct Obstruction0low20
Biliary Cirrhosis0low10
Biliary Cirrhosis, Primary0low10
Biliary Cirrhosis, Primary, 10low10
Biliary Cirrhosis, Secondary0low10
Biliary Stasis0low20
Binasal Hemianopia0low10
Binge Eating0medium11
Bipolar Disorder0medium252
Bipolar Mood Disorder0medium252
Birth Weight0low30
Bitemporal Hemianopia0low10
Bleb0low10
Bleeding0low30
Blister0low10
Blood Poisoning0low10
Blood Pressure, High0low80
Blood Pressure, Low0low10
Bloodstream Infection0low10
Bodily Distress Disorder0medium11
Body Weight0medium186
Boeck Disease0low60
Boeck's Disease0low60
Boeck's Sarcoid0low60
Bone Cancer0low10
Bone Marrow Diseases0low10
Bone Neoplasms0low10
Borderline Personality Disorder0low10
Bowel Diseases, Inflammatory0low10
Bradyarrhythmia0low10
Bradyarrhythmias0low10
Bradycardia0low10
Brain Cancer0low10
Brain Dysfunction, Minimal0low10
Brain Hemorrhage, Cerebral0low10
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Brain Vascular Disorders0low10
Breast Cancer0medium11
Breast Carcinoma0medium11
Breast Neoplasms0medium11
Breast Tumors0medium11
Breathlessness0medium41
Briquet Syndrome0medium41
Brugada ECG Pattern0low10
Brugada Syndrome0low10
Brugada Syndrome 10low10
Brugada Type ECG Pattern0low10
Bulimia0medium11
Bulla0low10
Bullae0low10
Bullous Lesion0low10
Bundle Branch Block0low10
Bundle-Branch Block0low10
Burns0low10
CACH Syndrome0low10
CACH VWM Syndrome0low10
Cadaver0low20
Calcification, Pathologic0low10
Calcinosis0low10
Calcinosis, Tumoral0low10
Cancer0medium279
Cancer of Bone0low10
Cancer of Brain0low10
Cancer of Breast0medium11
Cancer of Colon0low30
Cancer of Esophagus0low20
Cancer of Liver0low10
Cancer of Lung0low30
Cancer of Pancreas0low50
Cancer of Pituitary0low10
Cancer of Skin0low20
Cancer of Stomach0low20
Cancer of the Bone0low10
Cancer of the Brain0low10
Cancer of the Breast0medium11
Cancer of the Colon0low30
Cancer of the Esophagus0low20
Cancer of the Liver0low10
Cancer of the Lung0low30
Cancer of the Pancreas0low50
Cancer of the Pituitary0low10
Cancer of the Skin0low20
Cancer of the Stomach0low20
Cancer, Hepatocellular0low10
Cannabis Abuse0medium31
Cannabis Dependence0medium31
Cannabis-Related Disorder0medium31
Capgras Syndrome0low20
Carcinoma0low30
Carcinoma, Anaplastic0low30
Carcinoma, Cribriform0low10
Carcinoma, Ductal, Breast0low10
Carcinoma, Epidermoid0low20
Carcinoma, Granular Cell0low10
Carcinoma, Infiltrating Duct0low10
Carcinoma, Invasive Ductal, Breast0low10
Carcinoma, Mammary Ductal0low10
Carcinoma, Planocellular0low20
Carcinoma, Spindle-Cell0low30
Carcinoma, Squamous0low20
Carcinoma, Squamous Cell0low20
Carcinoma, Tubular0low10
Carcinoma, Undifferentiated0low30
Carcinomatosis0low30
Cardiac Arrest0low20
Cardiac Arrest, Sudden0low10
Cardiac Arrhythmia0low20
Cardiac Arrhythmias0low20
Cardiac Death0low10
Cardiac Diseases0medium11
Cardiac Disorders0medium11
Cardiac Dysrhythmia0low20
Cardiac Failure0low20
Cardiac Sudden Death0low10
Cardiac Toxicity0low10
Cardiomyopathy, Hypertrophic0low10
Cardiomyopathy, Hypertrophic Obstructive0low10
Cardiopulmonary Arrest0low20
Cardiotoxicity0low10
Cardiovascular Diseases0medium21
Cardiovascular Stroke0medium55
Carditis0low10
Cat Diseases0medium63
Catalepsy0low20
Catatonia0low10
Catatonia, Malignant0low10
Catatonia, Organic0low10
CD4-Positive T-Lymphocytopenia, Idiopathic0low10
CD4+ T-Lymphocytopenia0low10
CD4+ T-Lymphocytopenia, Idiopathic0low10
Cellulitis, Orbital0low10
Central Alveolar Hypoventilation Syndrome0low20
Central Nervous System Origin Vertigo0medium11
Central Sleep Apnea0low20
Central Sleep Apnea Syndrome0low20
Central Sleep Apnea, Primary0low20
Central Sleep Apnea, Secondary0low20
Central Sleep Disordered Breathing0low20
Cephalalgia0medium73
Cephalgia0medium73
Cephalodynia0medium73
Cerea Flexibilitas0low20
Cerebellar Ataxia0low10
Cerebellar Dysmetria0low10
Cerebellar Hemiataxia0low10
Cerebellar Incoordination0low10
Cerebral Cryptococcosis0low10
Cerebral Hemorrhage0low10
Cerebral Parenchymal Hemorrhage0low10
Cerebral Stroke0medium32
Cerebroatrophic Hyperammonemia0medium31
Cerebrovascular Accident0medium32
Cerebrovascular Accident, Acute0medium32
Cerebrovascular Apoplexy0medium32
Cerebrovascular Diseases0low10
Cerebrovascular Disorders0low10
Cerebrovascular Insufficiency0low10
Cerebrovascular Occlusion0low10
Cerebrovascular Stroke0medium32
Cervical Migraine Syndrome0medium11
Cervical Pain0low10
Cervicalgia0low10
Cervicodynia0low10
Charcot Gait0low30
Charcot's Gait0low30
Chemical and Drug Induced Liver Injury0low70
Chemical Dependence0medium92
Chemically-Induced Liver Toxicity0low70
Childhood Ataxia with Central Nervous System Hypomyelination0low10
Childhood Ataxia with Central Nervous System Hypomyelinization0low10
Childhood Ataxia with Diffuse Central Nervous System Hypomyelination0low10
Childhood Benign Focal Epilepsy0low10
Childhood Benign Occipital Epilepsy0low10
Childhood Benign Psychomotor Epilepsy0medium11
Childhood Tic Disorders0low10
Choking0low10
Cholangitis0low10
Cholangitis, Chronic Nonsuppurative Destructive0low10
Cholestasis0low20
Chorea, Chronic Progressive Hereditary (Huntington)0low10
Chromosome 6-Linked Autosomal Recessive Parkinsonism0low50
Chromosome-Defective Micronuclei0low20
Chronic Airflow Obstruction0medium11
Chronic Cluster Headache0low10
Chronic Disease0medium308
Chronic Fatigue and Immune Dysfunction Syndrome0medium11
Chronic Fatigue Disorder0medium11
Chronic Fatigue Syndrome0medium11
Chronic Fatigue-Fibromyalgia Syndrome0medium11
Chronic Hepatitis C0low10
Chronic Illness0medium308
Chronic Insomnia0medium4816
Chronic Kidney Diseases0medium33
Chronic Kidney Failure0low30
Chronic Kidney Insufficiency0medium33
Chronic Lymphocytic Leukemia0low20
Chronic Motor or Vocal Tic Disorder0low10
Chronic Obstructive Airway Disease0medium11
Chronic Obstructive Lung Disease0medium11
Chronic Obstructive Pulmonary Disease0medium11
Chronic Obstructive Pulmonary Diseases0medium11
Chronic Pain0low30
Chronic Post-operative Pain0medium32
Chronic Post-surgical Pain0medium32
Chronic Post-Traumatic Stress Disorder0medium217
Chronic Postoperative Pain0medium32
Chronic Postsurgical Pain0medium32
Chronic Progressive Hereditary Chorea (Huntington)0low10
Chronic Renal Diseases0medium33
Chronic Renal Insufficiency0medium33
Chronically Ill0medium308
Ciliary Neuralgia0low10
Circadian Rhythm Sleep Disorder0medium11
Circadian Rhythm Sleep Disorders0medium11
Cirrhoses, Experimental Liver0low10
Cirrhosis0low20
Cirrhosis, Experimental Liver0low10
Cirrhosis, Liver0low20
Claustrophobia0medium65
Clerambault Syndrome0low20
Clonic Seizure0low60
Clonic Seizures0low60
Clostridioides difficile Infection0low10
Clostridioides Infections0low10
Clostridioides perfringens Food Poisoning0low10
Clostridioides perfringens Infections0low10
Clostridioides sordellii Infection0low10
Clostridium difficile Infection0low10
Clostridium difficile Infections0low10
Clostridium Infections0low10
Clostridium perfringens Food Poisoning0low10
Clostridium perfringens Infections0low10
Clostridium sordellii Infection0low10
Clostridium sordellii Infections0low10
Cluster Headache0low10
Cluster Headache Syndrome0low10
CNS Origin Vertigo0medium11
Co-infection0low20
COAD0medium11
Coarse Tremor0low20
Cocaine Abuse0medium91
Cocaine Addiction0medium91
Cocaine Dependence0medium91
Cockayne-Touraine Disease0low10
Cockayne-Touraine Type Epidermolysis Bullosa0low10
Cognition Disorders0medium73
Cognitive Decline0low30
Cognitive Dysfunction0low30
Cognitive Impairments0low30
Coinfection0low20
Colicky Pain0low40
Colitis Gravis0low20
Colitis, Mucous0low30
Colitis, Ulcerative0low20
Colon Cancer0low30
Colon Neoplasms0low30
Colon, Irritable0low30
Colonic Cancer0low30
Colonic Diseases, Functional0low20
Colonic Inertia0medium22
Colonic Neoplasms0low30
Coma0low20
Comatose0low20
Combat Disorders0low10
Combat Neuroses0low10
Combat Neurosis0low10
Combat Stress Disorders0low10
Common Variable Hypogammaglobulinemia0low20
Common Variable Immune Deficiency0low20
Common Variable Immunodeficiency0low20
Complex Partial Seizure0low60
Complex Partial Seizures0low60
Complex Partial Status Epilepticus0low20
Complication, Postoperative0low50
Complications of Diabetes Mellitus0low10
Complications, Pregnancy0low100
Confusion0low20
Confusion, Post-Ictal0low20
Confusion, Reactive0low20
Confusional State0low20
Congenital Immunodeficiency Disease0low10
Congenital Immunodeficiency Diseases0low10
Congenital Immunodeficiency Disorder0low10
Congenital Immunodeficiency Disorders0low10
Congenital Immunodeficiency Syndrome0low10
Congenital Immunodeficiency Syndromes0low10
Congenital Myotonic Dystrophy0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Congestive Heart Failure0low20
Consciousness, Loss of0low20
Constipation0medium22
Constricted Pupil0low10
Continuous Muscle Activity Syndrome0low10
Continuous Tremor0low20
Conus Medullaris Syndrome0low10
Convulsion0low60
Convulsion, Non-Epileptic0low60
Convulsions0low60
Convulsions, Grand Mal0low10
Convulsive Seizure0low60
Convulsive Seizures0low60
Coordination Impairment0low10
COPD0medium11
Corneal Dystrophies0low10
Corneal Dystrophies, Hereditary0low10
Coronary Disease0medium11
Coronary Heart Disease0medium11
Coronavirus Disease 20190low40
Coronavirus Disease-190low40
Coronavirus Infections0low10
Corpse0low20
Cortical Malformations, Group I0low10
COVID-190low40
COVID-19 Pandemic0low40
COVID-19 Pandemics0low40
COVID-19 Virus Disease0low40
COVID-19 Virus Infection0low40
COVID190low40
Cowden Disease0low10
Cowden Syndrome0low10
Cowden's Disease0low10
Cowden's Syndrome0low10
Cranial Nerve Injuries0low10
Cranial Neuropathies, Traumatic0low10
Cranial Pain0medium73
Craniofacial Pain0low20
Cree Leukoencephalopathy0low10
Cruor0low10
Cruveilhier-Baumgarten Syndrome0low10
Cryptococcal Meningitis0low10
Cryptogenic Fibrosing Alveolitis0low10
Cryptogenic Myoclonic Epilepsy0low10
Cryptogenic Tonic-Clonic Epilepsy0low10
Cutaneous T-Cell Lymphoma0low10
CVA (Cerebrovascular Accident)0medium32
Cystic Fibrosis0low10
Cystic Fibrosis of Pancreas0low10
Danon Disease0low10
Darkness Tremor0low20
Day Blindness0medium21
Daytime Sleepiness0medium62
Daytime Somnolence0medium62
DDPAC0low10
Deaf Mutism0low10
Deaf-Mutism0low10
Deafness0low10
Deafness Permanent0low10
Deafness, Acquired0low10
Death0low10
Death, Sudden, Cardiac0low10
Degenerative Diseases, Central Nervous System0low10
Degenerative Diseases, Nervous System0low10
Degenerative Diseases, Neurologic0low10
Degenerative Diseases, Spinal Cord0low10
Degenerative Neurologic Diseases0low10
Degenerative Neurologic Disorders0low10
Deglutition Disorders0low10
Dejerine-Roussy Syndrome0low10
Delayed Effects, Prenatal Exposure0low20
Delayed Onset Post-Traumatic Stress Disorder0medium217
Delayed Sleep Phase Syndrome0medium11
Delayed Sleep-Phase Syndrome0medium11
Delirium0low50
Delirium of Mixed Origin0low50
Delirium, Dementia, Amnestic, Cognitive Disorders0low20
Delusional Disorder0low10
Dementia Complex, Acquired Immune Deficiency Syndrome0low10
Dementia Complex, AIDS-Related0low10
Dementia Praecox0medium4014
Dementia, Alzheimer Type0medium113
Dementia, Frontotemporal0low10
Dementia, Frontotemporal, with Parkinsonism0low10
Dementia, Hereditary Dysphasic Disinhibition0low10
Dementia, Presenile0medium113
Dementia, Primary Senile Degenerative0medium113
Dementia, Senile0medium113
Demyelinating Polyradiculoneuropathy, Acute Inflammatory0low10
Depression0medium15831
Depression, Bipolar0medium252
Depression, Endogenous0medium24962
Depression, Involutional0medium23881
Depression, Neurotic0medium24962
Depression, Postpartum0low40
Depression, Reactive0medium32
Depression, Unipolar0medium24962
Depressive Disorder, Treatment-Resistant0medium73
Depressive Syndrome0medium24962
Dermatitis0low10
Dermatitis Exfoliativa0low10
Dermatitis Exfoliative0low10
Dermatitis Exfoliative Generalised0low10
Dermatitis Exfoliative Generalized0low10
Dermatitis, Atopic0low10
Dermatitis, Contact, Phototoxic0low10
Dermatitis, Exfoliative0low10
Dermatitis, Phototoxic0low10
Dermatomyositis0low20
Dermatomyositis, Adult Type0low20
Dermatomyositis, Childhood Type0low20
Dermatopolymyositis0low20
Determination of Death0low10
Developmental Verbal Dyspraxia0low10
Diabetes Complications0low10
Diabetes Mellitus0low40
Diabetes Mellitus, Adult-Onset0medium21
Diabetes Mellitus, Brittle0low20
Diabetes Mellitus, Experimental0low20
Diabetes Mellitus, Insulin-Dependent0low20
Diabetes Mellitus, Insulin-Dependent, 10low20
Diabetes Mellitus, Juvenile-Onset0low20
Diabetes Mellitus, Ketosis-Prone0low20
Diabetes Mellitus, Ketosis-Resistant0medium21
Diabetes Mellitus, Maturity-Onset0medium21
Diabetes Mellitus, Non Insulin Dependent0medium21
Diabetes Mellitus, Non-Insulin-Dependent0medium21
Diabetes Mellitus, Noninsulin Dependent0medium21
Diabetes Mellitus, Noninsulin-Dependent0medium21
Diabetes Mellitus, Slow-Onset0medium21
Diabetes Mellitus, Stable0medium21
Diabetes Mellitus, Sudden-Onset0low20
Diabetes Mellitus, Type 10low20
Diabetes Mellitus, Type 20medium21
Diabetes Mellitus, Type I0low20
Diabetes Mellitus, Type II0medium21
Diabetes-Related Complications0low10
Diabetes, Autoimmune0low20
Diabetic Acidosis0low10
Diabetic Complications0low10
Diabetic Ketoacidosis0low10
Diabetic Ketosis0low10
Diagnosis, Psychiatric0medium172
Diathesis0low10
Diffuse Myofascial Pain Syndrome0medium63
Diffuse Parenchymal Lung Disease0medium11
Diffuse Parenchymal Lung Diseases0medium11
Diffuse Well-Differentiated Lymphocytic Lymphoma0low20
Digestive Epilepsy0low10
DIMS (Disorders of Initiating and Maintaining Sleep)0medium4816
Dirofilariasis0low10
Disease Exacerbation0low70
Disease Models, Animal0medium341
Disease Progression0low70
Disease Susceptibility0low10
Disease, Pulmonary0low10
Diseases in Twins0low10
Diseases, Metabolic0medium11
Diseases, Pulmonary0low10
Disinhibition-Dementia-Parkinsonism-Amyotrophy Complex0low10
Disinhibition-Dementia-Parkinsonism-Amytrophy Complex0low10
Disorder, Borderline Personality0low10
Disorders of Excessive Somnolence0medium62
Disorders of Initiating and Maintaining Sleep0medium4816
Disorientation0low20
Disrupted In B-Cell Malignancy0low20
Disruptive, Impulse Control, and Conduct Disorders0low10
Dissociative Identity Disorder0low20
Disturbed Nyctohemeral Rhythm0medium11
Dizziness0medium32
Dizzyness0medium32
DOES (Disorders of Excessive Somnolence)0medium62
Doose Syndrome0low10
Dravet Syndrome0low10
Dressing Apraxia0low10
Drop Attack0low10
Dropsy0low60
Drowning0low10
Drug Abuse0medium92
Drug Addiction0medium92
Drug Allergy0medium21
Drug Dependence0medium92
Drug Habituation0medium92
Drug Hypersensitivity0medium21
Drug Overdose0low220
Drug Side Effects0medium82
Drug Toxicity0medium82
Drug Use Disorders0medium92
Drug Withdrawal Symptoms0medium175
Drug-Induced Abnormalities0low60
Drug-Induced Acute Liver Injury0low70
Drug-Induced Akathisia0medium132
Drug-Induced Liver Disease0low70
Drug-Induced Liver Injury0low70
Drug-Induced Stevens Johnson Syndrome0low20
Drug-Induced Stevens-Johnson Syndrome0low20
Drug-Related Side Effects and Adverse Reactions0medium82
Dual Personality0low20
Duck Gait0low30
Duncan Disease0low10
Duncan's Syndrome0low10
Dysarthosis0low10
Dysarthria0low10
Dysarthria, Flaccid0low10
Dysarthria, Guttural0low10
Dysarthria, Mixed0low10
Dysarthria, Scanning0low10
Dysarthria, Spastic0low10
Dyschezia0medium22
Dyscoordination0low10
Dysembryoma0low10
Dysesthesia0low10
Dyskinesia, Drug-Induced0medium72
Dyskinesia, Medication-Induced0medium72
Dyskinesias0low10
Dyslipidemia0low30
Dyslipidemias0low30
Dyslipoproteinemias0low30
Dysmetria0low10
Dyspepsia0medium62
Dysphagia0low10
Dysplastic Gangliocytoma of Cerebellum0low10
Dysplastic Gangliocytoma of the Cerebellum0low10
Dyspnea0medium41
Dyspraxia0low10
Dyspraxia, Articulatory0low10
Dyspraxia, Oral0low10
Dyspraxia, Verbal0low10
Dyssynergia0low10
Dysthymia0medium92
Dysthymia and Chronic Depression0medium92
Dysthymic Disorder0medium92
Dystonia0medium41
Dystonia, Diurnal0medium41
Dystonia, Limb0medium41
Dystonia, Paroxysmal0medium41
Dystrophia Myotonica0low10
Dystrophia Myotonica 10low10
Dystrophia Myotonica 20low10
Dystrophic Epidermolysis Bullosa0low10
Dystrophic Epidermolysis Bullosa, Autosomal Recessive0low10
Early Awakening0medium4816
Early Childhood Epilepsy, Myoclonic0low10
Early Childhood, Myoclonic Epilepsy0low10
Early Onset Alzheimer Disease0medium113
Early Pregnancy Loss0low40
Eating and Feeding Disorders0medium111
Eating Disorders0medium111
Ecchymosis0low10
Eczema, Atopic0low10
Eczema, Infantile0low10
Edema0low60
Edema-Proteinuria-Hypertension Gestosis0low10
Edema, Pulmonary0low10
Edemas, Pulmonary0low10
Effect, Autokinetic0low20
Electrocardiogram QT Prolonged0low70
Electrolytes0low10
Elevated Cholesterol0low10
Embolism, Pulmonary0low10
Embolisms, Pulmonary0low10
Emesis0medium142
Emesis, Postoperative0medium52
Encephalitis, JC Polyomavirus0medium511
Encephalomyelitis, Myalgic0medium11
Encephalopathy, AIDS0low10
Encephalopathy, HIV0low10
Encephalopathy, Hypertensive0low10
Encephalopathy, Myoclonic0low10
End Of Life0low10
End-Of-Life0low10
End-Stage Kidney Disease0low30
End-Stage Renal Disease0low30
Endotoxin Shock0low10
Eosinophilia0low10
Eosinophilia, Tropical0low10
EPH Complex0low10
EPH Gestosis0low10
EPH Toxemias0low10
Epidermal Necrolysis, Toxic0low20
Epidermolysis Bullosa Dystrophica0low10
Epidermolysis Bullosa Dystrophica, Autosomal Recessive0low10
Epidermolysis Bullosa Dystrophica, Cockayne-Touraine Type0low10
Epidermolysis Bullosa Dystrophica, Dominant0low10
Epidermolysis Bullosa Dystrophica, Hallopeau-Siemens Type0low10
Epidermolysis Bullosa Dystrophica, Recessive0low10
Epidermolysis Bullosa, Dystrophic0low10
Epidural Neoplasm, Malignant0low10
Epidural Neoplasms0low10
Epidural Tumors0low10
Epilepsies, Myoclonic0low10
Epilepsies, Partial0low10
Epilepsy0low30
Epilepsy, Benign Occipital0low10
Epilepsy, Benign Psychomotor, Childhood0medium11
Epilepsy, Cryptogenic0low30
Epilepsy, Early Childhood, Myoclonic0low10
Epilepsy, Focal0low10
Epilepsy, Grand Mal0low10
Epilepsy, Lateral Temporal0medium11
Epilepsy, Localization-Related0low10
Epilepsy, Major0low10
Epilepsy, Myoclonic, Early Childhood0low10
Epilepsy, Myoclonic, Infantile0low10
Epilepsy, Myoclonic, Infantile, Benign0low10
Epilepsy, Myoclonic, Infantile, Severe0low10
Epilepsy, Myoclonus0low10
Epilepsy, Partial0low10
Epilepsy, Partial, Motor0low10
Epilepsy, Simple Partial0low10
Epilepsy, Temporal Lobe0medium11
Epilepsy, Tonic-Clonic0low10
Epilepsy, Tonic-Clonic, Cryptogenic0low10
Epilepsy, Tonic-Clonic, Familial0low10
Epilepsy, Tonic-Clonic, Symptomatic0low10
Epilepsy, Uncinate0medium11
Epileptic Seizure0low60
Epileptic Seizures0low60
Episodic Cluster Headache0low10
Epistaxis0low20
Epithelial Neoplasms, Malignant0low30
Epithelial Tumors, Malignant0low30
Epithelioma0low30
Epstein-Barr Virus Infection, Familial Fatal0low10
Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males0low10
ER-Negative PR-Negative HER2-Negative Breast Cancer0low10
ER-Negative PR-Negative HER2-Negative Breast Neoplasms0low10
Erectile Dysfunction0low30
Erythremia0low20
Erythroblastic Anemia0low10
Erythroderma0low10
Erythroderma, Sezary0low10
Esophageal Cancer0low20
Esophageal Dysphagia0low10
Esophageal Neoplasms0low20
Esophageal Reflux0low10
Esophagus Cancer0low20
Esophagus Neoplasm0low20
ESRD0low30
Essential Tremor0medium11
Ethanol Abuse0medium144
Excessive Daytime Sleepiness0medium62
Excessive Periodic Sleep-Related Leg Movements0medium21
Excessive Somnolence Disorders0medium62
Excitement, Psychomotor0medium61
Exomphalos0low10
Experimental Diabetes Mellitus0low20
Experimental Liver Cirrhoses0low10
Experimental Liver Cirrhosis0low10
Experimental Lung Inflammation0low10
Experimental Melanoma0low10
Experimental Melanomas0low10
Experimental Parkinson Disease0low50
Experimental Parkinsonism0low50
Experimental Parkinsonism, MPTP-Induced0low50
Extramedullary Spinal Cord Compression0low10
Extrapyramidal Disorders0low30
Face Pain0low20
Facial Pain0low20
Fainting0low10
False Bundle-Branch Block Syndrome0low10
Familial Alzheimer Disease (FAD)0medium113
Familial Atrial Fibrillation0low10
Familial Dementia0medium117
Familial Fatal Epstein-Barr Infection0low10
Familial Idiopathic Pulmonary Fibrosis0low10
Familial Juvenile Parkinsonism0low50
Familial Parkinson Disease, Autosomal Recessive0low50
Familial Pick's Disease0low10
Familial Tonic-Clonic Epilepsy0low10
Familial Tremor0medium11
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Fascicular Block0low10
Fatigue0medium53
Fatigue Syndrome, Chronic0medium11
Fatigue Syndrome, Postviral0medium11
Fatty Liver0low10
Feeding and Eating Disorders0medium111
Feeding Disorders0medium111
Feline Diseases0medium63
Female Pattern Baldness0low10
Fetishism (Psychiatric)0low10
Fetishism, Psychiatric0low10
Fever0low30
Fever, Zika0low10
Fibrocystic Disease of Pancreas0low10
Fibrocystic Pulmonary Dysplasia0low10
Fibroma, Shope0low10
Fibromyalgia-Fibromyositis Syndrome0medium63
Fibromyalgia, Primary0medium63
Fibromyalgia, Secondary0medium63
Fibromyositis-Fibromyalgia Syndrome0medium63
Fibrosing Alveolitis, Cryptogenic0low10
Fibrosis0low20
Fibrosis, Liver0low20
Fibrositis0medium63
Fine Tremor0low20
Flaccid Quadriplegia0low30
Flaccid Tetraplegia0low30
Flexibility, Waxy0low20
Focal Clonic Seizures0low10
Focal Motor Epilepsy0low10
Focal Onset Alzheimer's Disease0medium113
Focal Seizure Disorder0low10
Focal Tonic Seizures0low10
Formication0low10
Frigidity0medium135
Frontotemporal Dementia0low10
Frontotemporal Dementia with Parkinsonism0low10
Frontotemporal Dementia with Parkinsonism-170low10
Frontotemporal Dementia, Ubiquitin-Positive0low10
Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions0low10
Frontotemporal Lobe Dementia0low10
Frontotemporal Lobe Dementia (FLDEM)0low10
FTD-GRN0low10
FTD-PGRN0low10
FTDP-170low10
FTLD with TDP-43 Pathology0low10
FTLD-17 GRN0low10
FTLD-TDP0low10
Functional Colonic Diseases0low20
Gait Disorder, Sensorimotor0low30
Gait Disorders, Neurologic0low30
Gait Dysfunction, Neurologic0low30
Gait, Athetotic0low30
Gait, Broadened0low30
Gait, Drop Foot0low30
Gait, Festinating0low30
Gait, Frontal0low30
Gait, Hemiplegic0low30
Gait, Hysterical0low30
Gait, Reeling0low30
Gait, Rigid0low30
Gait, Scissors0low30
Gait, Shuffling0low30
Gait, Spastic0low30
Gait, Stumbling0low30
Gait, Unsteady0low30
Gait, Widebased0low30
Galactorrhea0low30
Gambling0low10
Gambling, Pathologic0low10
Gambling, Pathological0low10
Gamstorp-Wohlfart Syndrome0low10
Gastric Acid Aspiration Syndrome0low10
Gastric Acid Reflux0low10
Gastric Acid Reflux Disease0low10
Gastric Cancer0low20
Gastric Cancer, Familial Diffuse0low20
Gastric Neoplasms0low20
Gastric Stasis0low40
Gastric Ulcer0low20
Gastro-Esophageal Reflux0low10
Gastro-Esophageal Reflux Disease0low10
Gastro-oesophageal Reflux0low10
Gastroesophageal Reflux0low10
Gastroesophageal Reflux Disease0low10
Gastrointestinal Hemorrhage0low30
Gastroparesis0low40
Gelastic Epilepsy0low10
Generalized Absence Seizure0low60
Generalized Absence Seizures0low60
Generalized Convulsive Status Epilepticus0low20
Generalized Headache0medium73
Generalized Resistance to Thyroid Hormone0low10
Generalized Thyroid Hormone Resistance0low10
Generalized Tonic-Clonic Seizures0low60
Genetic Predisposition0low40
Genetic Predisposition to Disease0low40
Genetic Susceptibility0low40
Genotoxicant-Induced Micronuclei0low20
GERD0low10
Gestosis, EPH0low10
Giant Cell Glioblastoma0low10
Glaucoma, Angle Closure0low10
Glaucoma, Angle-Closure0low10
Glaucoma, Closed-Angle0low10
Glaucoma, Narrow-Angle0low10
Glaucoma, Uncompensated0low10
Glaucoma, Uncompensative0low10
Glioblastoma0low10
Glioblastoma Multiforme0low10
Glucose Intolerance0low10
Glycogen Storage Cardiomyopathy0low10
Glycogen Storage Disease IIb0low10
Glycogen Storage Disease Limited to the Heart0low10
Glycogen Storage Disease Type 2B0low10
Glycogen Storage Disease Type IIb0low10
Graft vs Host Disease0low10
Graft-Versus-Host Disease0low10
Graft-vs-Host Disease0low10
Grand Mal Seizure Disorder0low10
Grand Mal Status Epilepticus0low20
Granular Dystrophy, Corneal0low10
Granulocytopenia0low50
Granulomatous Slack Skin0low10
Granulomous Cerebral Cryptococcosis0low10
GRN-Related Frontotemporal Dementia0low10
Groenouw's Dystrophies0low10
Guillain-Barre Syndrome0low10
Guillain-Barre Syndrome, Familial0low10
Guillain-Barru00E9 Syndrome0low10
Guillaine-Barre Syndrome0low10
Gynecomastia0low30
Hair Loss0low10
Hallopeau-Siemens Disease0low10
Hallucination of Body Sensation0low110
Hallucinations0low110
Hallucinations, Auditory0low110
Hallucinations, Dissociative0low110
Hallucinations, Elementary0low110
Hallucinations, Formed, of People0low110
Hallucinations, Gustatory0low110
Hallucinations, Hypnagogic0low110
Hallucinations, Hypnapompic0low110
Hallucinations, Internal Body Sensation0low110
Hallucinations, Kinesthetic0low110
Hallucinations, Mood Congruent0low110
Hallucinations, Mood Incongruent0low110
Hallucinations, Olfactory0low110
Hallucinations, Organic0low110
Hallucinations, Reflex0low110
Hallucinations, Sensory0low110
Hallucinations, Somatic0low110
Hallucinations, Tactile0low110
Hallucinations, Verbal Auditory0low110
Hallucinations, Visual0low110
Hallucinations, Visual, Formed0low110
Hallucinations, Visual, Unformed0low110
Hamartoma Syndrome, Multiple0low10
Happy Puppet Syndrome0low10
Harding Passey Melanoma0low10
Hashish Abuse0medium31
HDDD10low10
HDDD20low10
Head Pain0medium73
Headache0medium73
Headache, Cluster0low10
Headache, Migraine0medium11
Headache, Tension0medium52
Hearing Loss Permanent0low10
Hearing Loss, Complete0low10
Hearing Loss, Extreme0low10
Heart Arrest0low20
Heart Attack0medium55
Heart Decompensation0low20
Heart Diseases0medium11
Heart Disorders0medium11
Heart Failure0low20
Heart Failure, Congestive0low20
Heart Failure, Left-Sided0low20
Heart Failure, Right-Sided0low20
Heartworm Disease0low10
Hematochezia0low30
Hemeralopia0medium21
Hemianopia0low10
Hemianopsia0low10
Hemianopsia, Binasal0low10
Hemianopsia, Bitemporal0low10
Hemianopsia, Homonymous0low10
Hemiballism0low10
Hemiballismus0low10
Hemicrania0medium73
Hemicrania Migraine0medium11
Hemimotor Epilepsy0low10
Hemimotor Seizure Disorder0low10
Hemisensory Neglect0low10
Hemispatial Neglect0low10
Hemoglobin F Disease0low10
Hemorrhage0low30
Hemorrhage, Cerebral0low10
Hemorrhage, Cerebrum0low10
Hemorrhage, Gastrointestinal0low30
Hemorrhagic Necrotic Pancreatitis0low10
Hepatic Cancer0low10
Hepatic Cirrhosis0low20
Hepatic Cirrhosis, Experimental0low10
Hepatic Neoplasms0low10
Hepatitis0low10
Hepatitis C0low20
Hepatitis C, Chronic0low10
Hepatitis, Drug-Induced0low70
Hepatitis, Toxic0low70
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0low20
Hepatocellular Cancer0low10
Hereditary Dysphasic Disinhibition Dementia0low10
Hereditary Essential Tremor0medium11
Hernia, Umbilical0low10
Heubner Artery Infarction0low10
Heubner's Artery Infarction0low10
High Cholesterol Levels0low10
Histamine Cephalgia0low10
HIV0low10
HIV Antibody Positivity0medium21
HIV Coinfection0medium82
HIV Dementia0low10
HIV Encephalopathy0low10
HIV Infections0medium82
HIV Seroconversion0medium21
HIV Seropositivity0medium21
HIV-1 Cognitive and Motor Complex0low10
HIV-1-Associated Cognitive Motor Complex0low10
HIV-Associated Cognitive Motor Complex0low10
HIV-Related Opportunistic Infections0low10
Hives0low20
Homologous Wasting Disease0low10
Homonymous Hemianopia0low10
Horton Syndrome0low10
Horton's Syndrome0low10
Hot Flashes0medium41
HTLV-III Infections0medium82
HTLV-III Seroconversion0medium21
HTLV-III Seropositivity0medium21
HTLV-III-LAV Infections0medium82
Human Mammary Carcinoma0medium11
Huntington Chorea0low10
Huntington Chronic Progressive Hereditary Chorea0low10
Huntington Disease0low10
Huntington Disease, Akinetic-Rigid Variant0low10
Huntington Disease, Juvenile0low10
Huntington Disease, Juvenile-Onset0low10
Huntington Disease, Late Onset0low10
Huntington's Chorea0low10
Huntington's Disease0low10
Hydrops0low60
Hyperactivity, Motor0low20
Hyperalgesia0low60
Hyperalgesia, Mechanical0low60
Hyperalgesia, Primary0low60
Hyperalgesia, Secondary0low60
Hyperalgesia, Tactile0low60
Hyperalgesia, Thermal0low60
Hyperalgesic Sensations0low60
Hyperalgia0low60
Hyperalgia, Mechanical0low60
Hyperalgia, Primary0low60
Hyperalgia, Secondary0low60
Hypercapnic Acute Respiratory Failure0low20
Hypercapnic Respiratory Failure0low20
Hypercholesteremia0low10
Hypercholesterolemia0low10
Hyperemesis Gravidarum0medium81
Hyperglycemia0low20
Hyperglycemia, Postprandial0low20
Hyperkinesia0low20
Hyperkinesia, Generalized0low20
Hyperkinesis0low20
Hyperkinetic Movements0low20
Hyperkinetic Syndrome0low10
Hyperlipemia0medium11
Hyperlipidemia0medium11
Hyperlipidemias0medium11
Hypermelanosis0low10
Hypermetria0low10
Hypernatremia0low10
Hyperpigmentation0low10
Hyperprolactinaemia0low10
Hyperprolactinemia0low10
Hypersensitivity, Drug0medium21
Hypersomnia0medium62
Hypersomnia with Periodic Respiration0medium11
Hypersomnia, Recurrent0medium62
Hypersomnolence0medium62
Hypersomnolence Disorders0medium62
Hypersomnolence Disorders, Primary0medium62
Hypersomnolence Disorders, Secondary0medium62
Hypertension0low80
Hypertension-Edema-Proteinuria Gestosis0low10
Hypertension, Portal0low10
Hypertensive Encephalopathy0low10
Hypertriglyceridemia0low20
Hypoactive Sexual Desire Disorder0medium135
Hypochondriacal Neuroses0low10
Hypochondriasis0low10
Hypogammaglobulinemia, Acquired0low20
Hyponatremia0low110
Hyposalivation0medium43
Hypotension0low10
Hypotension, Vascular0low10
Hypothermia0low20
Hypothermia, Accidental0low20
Hypoventilation, Central Alveolar0low20
Hypoxemic Acute Respiratory Failure0low20
Hypoxemic Respiratory Failure0low20
Ichthyosis0low10
Icterus0low10
IDDM0low20
Ideational Apraxia0low10
Idiopathic CD4 Positive T-Lymphocytopenia0low10
Idiopathic CD4-Positive T-Lymphocytopenia0low10
Idiopathic CD4+ T-Lymphocytopenia0low10
Idiopathic Fibrosing Alveolitis, Chronic Form0low10
Idiopathic Headache0medium52
Idiopathic Myoclonic Epilepsy0low10
Idiopathic Parkinson Disease0low70
Idiopathic Parkinson's Disease0low70
Idiopathic Proctocolitis0low20
Idiopathic Pulmonary Fibrosis0low10
Idiopathic Pulmonary Fibrosis, Familial0low10
Idiopathic Ventricular Tachycardia0low10
Illusions0low20
Illusions, Auditory0low20
Illusions, Kinesthetic0low20
Illusions, Tactile0low20
Illusions, Visual0low20
Immune Reconstitution Disease0low20
Immune Reconstitution Inflammatory Syndrome0low20
Immune Reconstitution Syndrome0low20
Immune Restoration Disease0low20
Immune Restoration Syndrome0low20
Immunodeficiency 50low10
Immunodeficiency Syndrome, Acquired0low10
Immunodeficiency, Common Variable0low20
Immunodeficiency, X-Linked Progressive Combined Variable0low10
Immunoglobulin Deficiency, Late-Onset0low20
Immunologic Deficiency Syndrome, Acquired0low10
Impaired Glucose Tolerance0low10
Impairment, Light Touch Sensation0medium11
Impotence0low30
Impulse Control Disorders0low10
Impulse-Control Disorders0low10
Inadequate Sleep0low20
Inappropriate ADH Syndrome0low60
Inappropriate Prolactin Secretion0low10
Inappropriate Prolactin Secretion Syndrome0low10
Inappropriate Vasopressin Secretion Syndrome0low60
Incipient Schizophrenia0low10
Incoordination0low10
Indigestion0medium62
Indolent Systemic Mastocytosis0low10
Infant Gynecomastia0low30
Infant, Small for Gestational Age0low10
Infantile Severe Myoclonic Epilepsy0low10
Infarction, Anterior Cerebral Artery0low10
Infarction, Anterior Cerebral Artery Circulation0low10
Infarction, Anterior Cerebral Artery Distribution0low10
Infarction, Heubner Artery0low10
Infections, Clostridium0low10
Infections, Coronavirus0low10
Infections, Klebsiella0low10
Infections, Staphylococcal0low10
Infections, Tumor Virus0low10
Infectious Mononucleosis-Like Syndrome, Chronic0medium11
Infertility, Female0low20
Inflammation0low30
Inflammatory Bowel Disease, Ulcerative Colitis Type0low20
Inflammatory Bowel Diseases0low10
Inflammatory Demyelinating Polyradiculoneuropathy, Acute0low10
Inflammatory Polyneuropathy Acute0low10
Inherited Immunodeficiency Disease0low10
Inherited Immunodeficiency Diseases0low10
Inherited Immunodeficiency Disorder0low10
Inherited Immunodeficiency Disorders0low10
Inherited Immunodeficiency Syndrome0low10
Inherited Immunodeficiency Syndromes0low10
Injuries, Whiplash0low10
Injury, Ischemia-Reperfusion0low10
Injury, Reperfusion0low10
Innate Inflammatory Response0low30
Insomnia0medium4816
Insomnia Disorder0medium4816
Insufficient Sleep0low20
Insufficient Sleep Syndrome0low20
Insulin Resistance0low20
Insulin Sensitivity0low20
Insulin-Dependent Diabetes Mellitus 10low20
Intention Tremor0low20
Intermittent Explosive Disorder0low10
Intermittent Tremor0low20
Interstitial Lung Disease0medium11
Interstitial Lung Diseases0medium11
Interstitial Pneumonitis, Usual0low10
Intracerebral Hemorrhage0low10
Intracranial Neoplasms0low10
Intracranial Vascular Disorders0low10
Intraocular Pressure0low10
Invasive Ductal Carcinoma, Breast0low10
Involuntary Movements0low10
Involuntary Quiver0low20
Irritable Bowel Syndrome0low30
Isaacs Syndrome0low10
Isaacs-Mertens Syndrome0low10
Isaacs' Syndrome0low10
Ischemia-Reperfusion Injury0low10
Itching0medium142
Jacksonian Seizure0low60
Jaundice0low10
Jaundice, Hemolytic0low10
JC Polyomavirus Encephalopathy0medium511
Joint Pain0low30
Juvenile Dermatomyositis0low20
Juvenile Huntington Disease0low10
Juvenile Myositis0low20
Juvenile Parkinson Disease0low50
Juvenile Parkinson Disease, Autosomal Dominant0low50
Juvenile Parkinson Disease, Autosomal Recessive0low50
Juvenile Parkinsonism, Autosomal Dominant0low50
Juvenile Parkinsonism, Autosomal Recessive0low50
Juvenile-Onset Diabetes0low20
Juvenile-Onset Huntington Disease0low10
Kahler Disease0low20
Kandinsky Syndrome0low20
Kanner's Syndrome0medium51
Keratosis Seborrheica0low10
Keratosis, Seborrheic0low10
Ketoacidosis, Diabetic0low10
Ketosis, Diabetic0low10
Kidney Diseases0low30
Kidney Failure0low30
Kidney Failure, Acute0low10
Kidney Failure, Chronic0low30
Kidney Insufficiency0low30
Kidney Insufficiency, Acute0low10
Kidney Insufficiency, Chronic0medium33
Klebsiella Infections0low10
Kleptomania0low10
Lack of Coordination0low10
Lactotroph Adenoma0low10
Landry-Guillain-Barre Syndrome0low10
Lassitude0medium53
Late Effects, Prenatal Exposure0low20
Late Onset Alzheimer Disease0medium113
Late-Onset Huntington Disease0low10
Latent Schizophrenia0low10
Leanness0low20
Left Bundle-Branch Block0low10
Left-Sided Heart Failure0low20
Lenticulostriate Disorders0low30
Lethal Catatonia0low10
Lethargy0low20
Leukemia, Acute Myelogenous0low10
Leukemia, Acute Myeloid0low10
Leukemia, B Cell, Chronic0low20
Leukemia, B-Cell, Chronic0low20
Leukemia, Chronic Lymphatic0low20
Leukemia, Chronic Lymphocytic0low20
Leukemia, Chronic Lymphocytic, B-Cell0low20
Leukemia, Lymphoblastic, Chronic0low20
Leukemia, Lymphocytic, Chronic0low20
Leukemia, Lymphocytic, Chronic, B Cell0low20
Leukemia, Lymphocytic, Chronic, B-Cell0low20
Leukemia, Myeloblastic, Acute0low10
Leukemia, Myelocytic, Acute0low10
Leukemia, Myelogenous, Acute0low10
Leukemia, Myeloid, Acute0low10
Leukemia, Myeloid, Acute, M10low10
Leukemia, Myeloid, Acute, M20low10
Leukemia, Nonlymphoblastic, Acute0low10
Leukemia, Nonlymphocytic, Acute0low10
Leukocytopenia0low20
Leukoencephalopathies0low10
Leukoencephalopathy0low10
Leukoencephalopathy with Vanishing White Matter0low10
Leukoencephalopathy, Progressive Multifocal0medium511
Leukopenia0low20
Lewy Body Parkinson Disease0low70
Lewy Body Parkinson's Disease0low70
Lhermitte-Duclos Disease0low10
Libman-Sacks Disease0low10
Light Touch Sensation Impairment0medium11
Light-Headedness0medium32
Lightheadedness0medium32
Lingual-Facial-Buccal Dyskinesia0low10
Linguofacial Dyskinesia0low10
Lipemia0medium11
Lipidemia0medium11
Liver Abscess0low10
Liver Cancer0low10
Liver Cirrhoses, Experimental0low10
Liver Cirrhosis0low20
Liver Cirrhosis, Biliary0low10
Liver Cirrhosis, Experimental0low10
Liver Cirrhosis, Obstructive0low10
Liver Diseases0low40
Liver Dysfunction0low40
Liver Fibrosis0low20
Liver Injury, Drug-Induced0low70
Liver Injury, Drug-Induced, Acute0low70
Liver Neoplasms0low10
Liver Steatosis0low10
Livor Mortis0low10
Lobar Pneumonia0low10
Locomotion Disorders, Neurologic0low30
Long QT Syndrome0low70
Long Sleeper Syndrome0medium135
Low Back Ache0low10
Low Back Pain0low10
Low Back Pain, Mechanical0low10
Low Back Pain, Posterior Compartment0low10
Low Back Pain, Postural0low10
Low Back Pain, Recurrent0low10
Low Backache0low10
Low Blood Pressure0low10
Lower Back Pain0low10
Lumbago0low10
Lung Cancer0low30
Lung Diseases0low10
Lung Diseases, Interstitial0medium11
Lung Inflammation0low10
Lung Neoplasms0low30
Lupus Erythematosus Disseminatus0low10
Lupus Erythematosus, Systemic0low10
Lyell's Syndrome0low20
Lymphoblastic Leukemia, Chronic0low20
Lymphocytic Leukemia, Chronic0low20
Lymphocytic Leukemia, Chronic, B Cell0low20
Lymphocytic Leukemia, Chronic, B-Cell0low20
Lymphocytic Lymphoma0low20
Lymphocytic Lymphoma, Diffuse, Well Differentiated0low20
Lymphocytic Lymphoma, Diffuse, Well-Differentiated0low20
Lymphocytic Lymphoma, Well Differentiated0low20
Lymphocytic Lymphoma, Well-Differentiated0low20
Lymphocytopenia0low40
Lymphoma, Lymphocytic0low20
Lymphoma, Lymphocytic, Diffuse, Well Differentiated0low20
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated0low20
Lymphoma, Lymphocytic, Well Differentiated0low20
Lymphoma, Lymphocytic, Well-Differentiated0low20
Lymphoma, Lymphoplasmacytoid, CLL0low20
Lymphoma, Small Lymphocytic0low20
Lymphoma, Small Lymphocytic, Plasmacytoid0low20
Lymphoma, Small-Cell0low20
Lymphoma, T Cell, Cutaneous0low10
Lymphoma, T Cell, Peripheral0low20
Lymphoma, T-Cell, Cutaneous0low10
Lymphoma, T-Cell, Peripheral0low20
Lymphopenia0low40
Lymphoplasmacytoid Lymphoma, CLL0low20
Lymphoproliferative Disease, X-Linked0low10
Lymphoproliferative Disorders0low10
Lymphoproliferative Syndrome, X-Linked, 10low10
Lysosomal Glycogen Storage Disease with Normal Acid Maltase0low10
Lysosomal Glycogen Storage Disease without Acid Maltase Deficiency0low10
Macrocephaly, Multiple Lipomas, and Hemangiomata0low10
Macrocephaly, Pseudopapilledema, and Multiple Hemangiomas0low10
Macrocephaly, Pseudopapilledema, and Multiple Hemangiomata0low10
Macroglossia0low10
Macroprolactinoma0low10
Macropsia0medium21
Macular Dystrophy, Corneal0low10
Major Depressive Disorder0medium23881
Major Motor Seizure Disorder0low10
Male Breast Enlargement0low30
Male Impotence0low30
Male Pattern Baldness0low10
Male Sexual Impotence0low30
Malformations Due to Abnormal Neuronal and Glial Proliferation or Apoptosis0low10
Malformations of Cortical Development, Group I0low10
Malformations Secondary to Abnormal Neuronal and Glial Proliferation or Apoptosis0low10
Malignancy0medium279
Malignant Epidural Neoplasm0low10
Malignant Epithelial Neoplasms0low30
Malignant Melanoma0low20
Malignant Neoplasm of Breast0medium11
Malignant Neoplasms0medium279
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Breast0medium11
Malnourishment0low10
Malnutrition0low10
Mammary Cancer0medium11
Mammary Carcinoma, Human0medium11
Mammary Ductal Carcinoma0low10
Mammary Neoplasm, Human0medium11
Mammary Neoplasms, Human0medium11
Manic Depression0medium252
Manic Disorder0medium252
Manic-Depressive Psychosis0medium252
Marche a Petit Pas0low30
Marihuana Abuse0medium31
Marijuana Abuse0medium31
Marijuana Dependence0medium31
Massive Tremor0low20
Mastocytosis, Systemic0low10
Maturity-Onset Diabetes0medium21
Maturity-Onset Diabetes Mellitus0medium21
Mechanical Allodynia0low60
Mechanical Hyperalgesia0low60
Mechanical Low Back Pain0low10
Medically Unexplained Symptoms0low10
Medically Unexplained Syndrome0medium41
Medically Unexplained Syndromes0medium41
Medication-Induced Dyskinesia0medium72
Mediterranean Anemia0low10
Melancholia0medium24962
Melancholia, Involutional0medium23881
Melanoma0low20
Melanoma, B160low10
Melanoma, Cloudman S910low10
Melanoma, Experimental0low10
Melanoma, Harding-Passey0low10
Melanomas, Experimental0low10
Memory Deficits0medium31
Memory Disorder, Semantic0medium31
Memory Disorder, Spatial0medium31
Memory Disorders0medium31
Memory Disorders, Age-Related0medium31
Memory Loss0medium31
Mendelson Syndrome0low10
Mendelson's Syndrome0low10
Meningitis, Cryptococcal0low10
Menopause0medium41
Mental Deterioration0low30
Mental Disorders0medium172
Mental Disorders, Organic0low20
Mental Disorders, Severe0medium172
Mental Illness0medium172
MERS (Middle East Respiratory Syndrome)0low10
Metabolic Diseases0medium11
Metamorphopsia0medium21
Metastase0low10
Metastases, Neoplasm0low10
Metastasis0low10
Metastasis, Neoplasm0low10
Microcalcification0low10
Microcalcinosis0low10
Microcytemia, beta Type0low10
Microglossia0low10
Micronuclei, Chromosome-Defective0low20
Micronuclei, Genotoxicant-Induced0low20
Micronucleus, Chromosome-Defective0low20
Microprolactinoma0low10
Micropsia0medium21
Middle East Respiratory Syndrome0low10
Migraine0medium11
Migraine Disorders0medium11
Migraine Headache0medium11
Migraine Variant0medium11
Mild Cognitive Impairment0low30
Mild Neurocognitive Disorder0low30
Minimal Brain Dysfunction0low10
Miosis0low10
Miosis, Persistent0low10
Miscarriage0low40
Mixed Central and Obstructive Sleep Apnea0medium11
Mixed Infection0low20
MODS0low10
MODY0medium21
Monkey Diseases0low10
Mood Disorders0low30
Moral Injury0medium217
Morbid Obesity0low20
Morphine Abuse0low20
Morphine Addiction0low20
Morphine Dependence0low20
Motor or Vocal Tic Disorder, Chronic0low10
Motor Partial Seizure Disorder0low10
Motor Seizure Disorder0low10
Motor Tic Disorders0low10
Mouth Dryness0medium43
MPTP Neurotoxicity Syndrome0low20
MPTP Poisoning0low20
MPTP-Induced Degeneration of the Striatum0low20
MPTP-Induced Experimental Parkinsonism0low50
MPTP-Induced Parkinsonism0low20
MS (Multiple Sclerosis)0low20
Mucoviscidosis0low10
Multiple Hamartoma Syndrome0low10
Multiple Identity Disorder0low20
Multiple Myeloma0low20
Multiple Organ Dysfunction Syndrome0low10
Multiple Organ Failure0low10
Multiple Personalities0low20
Multiple Personality Disorder0low20
Multiple Sclerosis0low20
Multiple Sclerosis, Acute Fulminating0low20
Multiple Sclerosis, Acute Relapsing0low10
Multiple Sclerosis, Relapsing-Remitting0low10
Multiple System Tauopathy with Presenile Dementia0low10
Muscle Disorders0medium11
Muscle Dystonia0medium41
Muscular Diseases0medium11
Myalgic Encephalomyelitis0medium11
Mycoplasma-Induced Stevens Johnson Syndrome0low20
Mycoplasma-Induced Stevens-Johnson Syndrome0low20
Mycosis Fungoides0low10
Myelinosis Centralis Diffusa0low10
Myeloblastic Leukemia, Acute0low10
Myelocytic Leukemia, Acute0low10
Myelogenous Leukemia, Acute0low10
Myeloid Leukemia, Acute0low10
Myeloid Leukemia, Acute, M10low10
Myeloid Leukemia, Acute, M20low10
Myeloma-Multiple0low20
Myeloma, Multiple0low20
Myeloma, Plasma-Cell0low20
Myelomatosis0low20
Myelopathy, Compressive0low10
Myhre-Riley-Smith Syndrome0low10
Myocardial Failure0low20
Myocardial Infarct0medium55
Myocardial Infarction0medium55
Myocarditis0low10
Myoclonic Absence Epilepsy0low10
Myoclonic Astatic Epilepsy0low10
Myoclonic Encephalopathy0low10
Myoclonic Epilepsy0low10
Myoclonic Epilepsy, Benign Infantile0low10
Myoclonic Epilepsy, Early Childhood0low10
Myoclonic Epilepsy, Infantile0low10
Myoclonic Epilepsy, Infantile, Benign0low10
Myoclonic Epilepsy, Infantile, Severe0low10
Myoclonic Epilepsy, Severe Infantile0low10
Myoclonic Epilepsy, Severe, Of Infancy0low10
Myoclonic Seizure0low60
Myoclonic Seizure Disorder0low10
Myoclonic Seizures0low60
Myoclonus, Benign Neonatal Sleep0low10
Myofacial Pain0low20
Myofascial Pain Syndrome, Diffuse0medium63
Myokymia, Continuous0low10
Myokymia, Myotonia, Muscle Wasting, And Hyperhidrosis0low10
Myopathic Conditions0medium11
Myopathies0medium11
Myotonia Atrophica0low10
Myotonia Dystrophica0low10
Myotonic Dystrophy0low10
Myotonic Dystrophy 10low10
Myotonic Dystrophy 20low10
Myotonic Dystrophy, Congenital0low10
Myotonic Myopathy, Proximal0low10
Narcosis0low10
Nasal Bleeding0low20
Nausea and Vomiting, Postoperative0medium52
Nausea, Postoperative0medium52
Near-Death Experience0low10
Neck Ache0low10
Neck Pain0low10
Neckache0low10
Necrotizing Pancreatitis, Acute0low10
Neonatal Death0low10
Neonatal Sleep Myoclonus, Benign0low10
Neoplasia0medium279
Neoplasm0medium279
Neoplasm Metastases0low10
Neoplasm Metastasis0low10
Neoplasms0medium279
Neoplasms, Benign0medium279
Neoplasms, Bone0low10
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Breast0medium11
Neoplasms, Colonic0low30
Neoplasms, Epidural0low10
Neoplasms, Esophageal0low20
Neoplasms, Gastric0low20
Neoplasms, Hepatic0low10
Neoplasms, Intracranial0low10
Neoplasms, Liver0low10
Neoplasms, Lung0low30
Neoplasms, Malignant Epithelial0low30
Neoplasms, Pancreatic0low50
Neoplasms, Pulmonary0low30
Neoplasms, Skin0low20
Neoplasms, Stomach0low20
Nephrosclerosis0low10
Nerve Pain0medium61
Nervous System Degenerative Diseases0low10
Nervous System Diseases0low10
Nervous System Disorders0low10
Neuralgia0medium61
Neuralgia, Atypical0medium61
Neuralgia, Iliohypogastric Nerve0medium61
Neuralgia, Ilioinguinal0medium61
Neuralgia, Perineal0medium61
Neuralgia, Postherpetic0low10
Neuralgia, Stump0medium61
Neuralgia, Supraorbital0medium61
Neuralgia, Vidian0medium61
Neuralgic Facial Pain0low20
Neuralgic Migraine0low10
Neurasthenia0medium11
Neurasthenic Neuroses0medium11
Neuroblastoma0low10
Neurocognitive Disorders0low20
Neurodegenerative Diseases0low10
Neurodegenerative Disorders0low10
Neurodermatitis, Atopic0low10
Neurodermatitis, Disseminated0low10
Neurodynia0medium61
Neuroleptic Malignant Syndrome0low30
Neuroleptic-Induced Neuroleptic Malignant Syndrome0low30
Neuroleptic-Malignant Syndrome, Neuroleptic Induced0low30
Neurologic Ambulation Disorders0low30
Neurologic Degenerative Conditions0low10
Neurologic Degenerative Diseases0low10
Neurologic Diseases, Degenerative0low10
Neurologic Disorders0low10
Neurologic Locomotion Disorders0low30
Neurological Disorders0low10
Neuromyotonia0low10
Neuropathic Pain0medium61
Neuroses, Anxiety0medium3512
Neuroses, Neurasthenic0medium11
Neuroses, Phobic0medium65
Neuroses, Post-Traumatic0medium217
Neuroses, Posttraumatic0medium217
Neuroses, War0low10
Neurosis, Depressive0medium24962
Neurosis, Hypochondriacal0low10
Neurosis, Obsessive-Compulsive0medium104
Neurotic Depression, Persistent Depressive Disorder0medium92
Neurotoxicity Syndrome, MPTP0low20
Neutropenia0low70
Newborn Gynecomastia0low30
Newborn Primary Sleep Apneas0low20
NIDDM0medium21
Night Terrors0low10
Night Terrors, Adult0low10
Night Terrors, Childhood0low10
Night Terrors, Primary0low10
Night Terrors, Secondary0low10
NMS (Neuroleptic Malignant Syndrome)0low30
Nociceptive Pain0low10
Nocturnal Myoclonus Syndrome0medium21
Non-24 Hour Sleep-Wake Disorder0medium11
Non-Convulsive Status Epilepticus0low20
Non-Epileptic Seizure0low60
Non-Epileptic Seizures0low60
Nonepileptic Seizure0low60
Nonepileptic Seizures0low60
Noninsulin-Dependent Diabetes Mellitus0medium21
Nonlymphoblastic Leukemia, Acute0low10
Nonlymphocytic Leukemia, Acute0low10
Nonorganic Insomnia0medium4816
Nonorganic Sleep Wake Cycle Disorder0medium11
Nonorganic Sleep Wake Cycle Disorders0medium11
Nonpsychotic Organic Brain Syndrome0low20
Nonstaphylococcal Scalded Skin Syndrome0low20
Nonsustained Ventricular Tachycardia0low10
Nose Bleed0low20
Nosebleed0low20
Nosebleeds0low20
Nutritional Deficiency0low10
Obesity0medium41
Obesity, Morbid0low20
Obesity, Severe0low20
Obsessive-Compulsive Disorder0medium104
Obstructive Sleep Apnea0medium63
Obstructive Sleep Apnea Syndrome0medium63
Occipital Lobe Epilepsy0low10
Ocular Headache0medium73
Omphalocele0low10
Ondine Syndrome0low20
Opiate Overdose0low10
Opioid Overdose0low10
Opportunistic Infections0low10
Opportunistic Infections, AIDS-Related0low10
Opportunistic Infections, HIV-Related0low10
Oral Dyskinesia0low10
Oral-Facial Dyskinesia0low10
Orbital Cellulitis0low10
Organ Dysfunction Syndrome, Multiple0low10
Organ Failure, Multiple0low10
Organic Brain Syndrome, Nonpsychotic0low20
Organic Catatonic Disorder0low10
Organic Mental Disorders0low20
Organic Mental Disorders, Psychotic0low20
Organic Mental Disorders, Substance-Induced0medium92
Orgasmic Disorder0medium135
Orofacial Dyskinesia0low10
Orofacial Pain0low20
Oropharyngeal Dysphagia0low10
Orthostasis0medium32
Orthostatic Headache0medium73
OSAHS0medium63
Osler-Vaquez Disease0low20
Osteogenic Sarcoma0low10
Osteomyelitis0low10
Osteosarcoma0low10
Osteosarcoma Tumor0low10
Out-of-Hospital Cardiac Arrest0low10
Out-of-Hospital Heart Arrest0low10
Overinclusion0medium73
Overweight0medium11
Pain0medium111
Pain Disorder0medium41
Pain Sensation Diminished0medium11
Pain, Burning0medium111
Pain, Chronic0low30
Pain, Crushing0medium111
Pain, Facial0low20
Pain, Intractable0low10
Pain, Migratory0medium111
Pain, Post-operative0medium32
Pain, Postoperative0medium32
Pain, Radiating0medium111
Pain, Splitting0medium111
Palmoplantaris Pustulosis0low20
Palsy0low10
Panayiotopoulos Syndrome0low10
Pancreas Cancer0low50
Pancreas Neoplasms0low50
Pancreatic Cancer0low50
Pancreatic Cystic Fibrosis0low10
Pancreatic Necrosis0low10
Pancreatic Neoplasms0low50
Pancreatic Parenchyma with Edema0low70
Pancreatic Parenchymal Edema0low70
Pancreatitis0low70
Pancreatitis Necrotising0low10
Pancreatitis Necrotizing0low10
Pancreatitis, Acute0low70
Pancreatitis, Acute Edematous0low70
Pancreatitis, Acute Necrotizing0low10
Pancytopenia0low10
Panic Attacks0medium136
Panic Disorder0medium136
Papilloma, Shope0low10
Papulosquamous Disorders0low10
Papulosquamous Skin Diseases0low10
Paralysis0low10
Paralysis Agitans0low70
Paralysis, Spinal, Quadriplegic0low30
Paraneoplastic Syndromes0low10
Paranoid Schizophrenia0low10
Paraphrenia, Involutional0medium23881
Parasitic Skin Diseases0low10
Parasomnias0low10
Parenterally-Transmitted Non-A, Non-B Hepatitis0low20
Paresthesia0low10
Paresthesia, Distal0low10
Paresthesia, Painful0low10
Parkinson Disease0low70
Parkinson Disease 20low50
Parkinson Disease 2, Autosomal Recessive Juvenile0low50
Parkinson Disease Autosomal Recessive, Early Onset0low50
Parkinson Disease, Autosomal Dominant. Juvenile0low50
Parkinson Disease, Experimental0low50
Parkinson Disease, Familial, Autosomal Recessive0low50
Parkinson Disease, Idiopathic0low70
Parkinson Disease, Juvenile0low50
Parkinson Disease, Juvenile, Autosomal Dominant0low50
Parkinson Disease, Juvenile, Autosomal Recessive0low50
Parkinson's Disease0low70
Parkinson's Disease, Idiopathic0low70
Parkinson's Disease, Lewy Body0low70
Parkinsonian Diseases0low50
Parkinsonian Disorders0low50
Parkinsonian Syndrome0low50
Parkinsonian Syndromes0low50
Parkinsonism0low50
Parkinsonism, Early Onset, with Diurnal Fluctuation0low50
Parkinsonism, Early-Onset, With Diurnal Fluctuation0low50
Parkinsonism, Experimental0low50
Parkinsonism, Juvenile0low50
Parkinsonism, Juvenile, Autosomal Dominant0low50
Parkinsonism, Juvenile, Autosomal Recessive0low50
Paroxysmal Atrial Fibrillation0low10
Paroxysmal Nerve Pain0medium61
Paroxysmal Supraventricular Tachycardia0low10
Partial Epilepsy0low10
Partial Epilepsy, Motor0low10
Partial Seizure0low60
Partial Seizure Disorder0low10
Partial Seizure Disorder, Motor0low10
Partial Seizures0low60
Partial Seizures, Simple, Consciousness Preserved0low10
Passive Tremor0low20
Pathologic Calcification0low10
Pathological Gambling0low10
Pattern Baldness0low10
Pavor Nocturnus0low10
Pavor Nocturnus, Adult0low10
Pavor Nocturnus, Childhood0low10
Perceptual Disorders0low10
Perinatal Death0low10
Periodic Leg Movements, Excessive, Sleep-Related0medium21
Periodic Limb Movement Disorder0medium21
Periodic Movement Disorder, Sleep0medium21
Periorbital Headache0medium73
Peripancreatic Fat Necrosis0low70
Peripheral Nerve Diseases0medium11
Peripheral Nervous System Disease0medium11
Peripheral Nervous System Diseases0medium11
Peripheral Nervous System Disorders0medium11
Peripheral Neuropathies0medium11
Peripheral T-Cell Lymphoma0low20
Pernicious Vomiting of Pregnancy0medium81
Persistent Atrial Fibrillation0low10
Persistent Depressive Disorder, Dysthymia0medium92
Persistent Postsurgical Pain0medium32
Persistent Tremor0low20
Personality Disorder, Borderline0low10
Personality Disorder, Schizotypal0low10
Pervasive Child Development Disorders0medium11
Pervasive Development Disorders0medium11
Petit Mal Convulsion0low60
Petit Mal Status0low20
Phobia, School0medium65
Phobia, Social0low10
Phobias0medium65
Phobic Disorders0medium65
Phobic Neuroses0medium65
Phototoxic Contact Dermatitis0low10
Phototoxic Dermatitis0low10
Phototoxicity0low10
Pill Rolling Tremor0low20
Pinprick Sensation Diminished0medium11
Pituitary Adenoma0low10
Pituitary Adenoma, Prolactin-Secreting0low10
Pituitary Cancer0low10
Pituitary Carcinoma0low10
Pituitary Neoplasms0low10
Pituitary Tumors0low10
Plasma Cell Myeloma0low20
Plegia0low10
Pneumonia0low10
Pneumonia, Aspiration0low10
Pneumonia, Interstitial0medium11
Pneumonia, Lobar0low10
Pneumonia, Viral0low10
Pneumonitis0low10
Pneumonitis, Interstitial0medium11
PNS (Peripheral Nervous System) Diseases0medium11
PNS Diseases0medium11
Poisoning0low30
Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine0low20
Poisoning, Blood0low10
Polyarthralgia0low30
Polycythemia Ruba Vera0low20
Polycythemia Rubra Vera0low20
Polycythemia Vera0low20
Polydipsia0low10
Polymicrobial Infection0low20
Polymyositis-Dermatomyositis0low20
Polyneuropathies0low10
Polyneuropathy, Acquired0low10
Polyneuropathy, Acute Inflammatory0low10
Polyneuropathy, Critical Illness0low10
Polyneuropathy, Familial0low10
Polyneuropathy, Inflammatory Demyelinating, Acute0low10
Polyneuropathy, Inherited0low10
Polyneuropathy, Motor0low10
Polyomavirus Infections0low30
Polyradiculoneuropathy, Acute Inflammatory0low10
Polyradiculoneuropathy, Acute Inflammatory Demyelinating0low10
PONV0medium52
Position Sense Disorders0medium11
Positional Vertigo0medium11
Post Traumatic Stress Disorder0medium217
Post-Dural Puncture Headache0low10
Post-Lumbar Puncture Headache0low10
Post-Natal Depression0low40
Post-operative Pain0medium32
Post-operative Pain, Acute0medium32
Post-operative Pain, Chronic0medium32
Post-Partum Depression0low40
Post-surgical Pain0medium32
Post-Traumatic Stress Disorders0medium217
Post-Traumatic Tic Disorder0low10
Postdural Puncture Headache0low10
Posterior Cervical Pain0low10
Posterior Fascicular Block0low10
Posterior Neck Pain0low10
Postherpetic Neuralgia0low10
Postmortem Changes0low10
Postnatal Depression0low40
Postoperative Complications0low50
Postoperative Emesis0medium52
Postoperative Nausea0medium52
Postoperative Pain0medium32
Postoperative Pain, Acute0medium32
Postoperative Pain, Chronic0medium32
Postoperative Vomiting0medium52
Postpartum Depression0low40
Postprandial Hyperglycemia0low20
Postsurgical Pain0medium32
Posttraumatic Stress Disorders0medium217
Postural Low Back Pain0low10
Postviral Fatigue Syndrome0medium11
Pre-Eclampsia0low10
Predisposition, Genetic0low40
Preeclampsia0low10
Preeclampsia Eclampsia 10low10
Pregnancy0medium271
Pregnancy Complications0low100
Pregnancy Toxemias0low10
Prelingual Deafness0low10
Premature Birth0low20
Prenatal Exposure Delayed Effects0low20
Prescription Drug Abuse0medium92
Presenile Alzheimer Dementia0medium113
Presyncope0low10
Preterm Birth0low20
Priapism0low10
Primary Antibody Deficiencies0low10
Primary Antibody Deficiency Disorder0low10
Primary Antibody Deficiency Disorders0low10
Primary Antibody Deficiency Syndrome0low10
Primary Antibody Deficiency Syndromes0low10
Primary Biliary Cholangitis0low10
Primary Biliary Cirrhosis0low10
Primary Brain Neoplasms0low10
Primary Central Sleep Apnea0low20
Primary Hypersomnia Disorders0medium62
Primary Hypersomnolence Disorders0medium62
Primary Immune Deficiency0low10
Primary Immune Deficiency Disease0low10
Primary Immune Deficiency Diseases0low10
Primary Immune Deficiency Disorder0low10
Primary Immune Deficiency Disorders0low10
Primary Immune Deficiency Syndrome0low10
Primary Immune Deficiency Syndromes0low10
Primary Immunodeficiency Disease0low10
Primary Immunodeficiency Diseases0low10
Primary Immunodeficiency Disorder0low10
Primary Immunodeficiency Disorders0low10
Primary Immunodeficiency Syndromes0low10
Primary Insomnia0medium4816
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Parkinsonism0low70
Primary Polycythemia0low20
Primary Senile Degenerative Dementia0medium113
Primary Sleep Apneas of Newborn0low20
PRL-Secreting Pituitary Adenoma0low10
Progressive Chorea, Chronic Hereditary (Huntington)0low10
Progressive Chorea, Hereditary, Chronic (Huntington)0low10
Progressive Multifocal Leukoencephalopathy0medium511
Prolactin Hypersecretion Syndrome0low10
Prolactin-Producing Pituitary Adenoma0low10
Prolactin-Secreting Pituitary Adenoma0low10
Prolactin, Inappropriate Secretion0low10
Prolactinoma0low10
Prolactinoma, Familial0low10
PROMM (Proximal Myotonic Myopathy)0low10
Proprioceptive Disorders0medium11
Prostatism0low10
Proteinuria-Edema-Hypertension Gestosis0low10
Proximal Myotonic Myopathy0low10
Pruritis0medium142
Pruritus0medium142
Pseudoakathisia0medium132
Pseudocoma0low20
Pseudoglycogenosis 20low10
Pseudoglycogenosis II0low10
Pseudomyotonia0low10
Pseudomyotonia Syndrome of Isaacs0low10
Pseudoneurotic Schizophrenia0low10
Pseudopelade0low10
Pseudopsychopathic Schizophrenia0low10
Psoriasis0low20
Psychiatric Diagnosis0medium172
Psychiatric Diseases0medium172
Psychiatric Disorders0medium172
Psychiatric Illness0medium172
Psychogenic Headache0medium52
Psychomotor Agitation0medium61
Psychomotor Hyperactivity0medium61
Psychomotor Restlessness0medium61
Psychophysiologic Disorders0low10
Psychophysiological Disorders0low10
Psychophysiological Insomnia0medium4816
Psychoses0medium231
Psychoses, Drug0low30
Psychoses, Manic-Depressive0medium252
Psychoses, Substance-Induced0low30
Psychoses, Toxic0low30
Psychoses, Traumatic0low20
Psychosexual Disorders0medium135
Psychosexual Dysfunctions0medium135
Psychosis0medium231
Psychosis, Brief Reactive0medium231
Psychosis, Involutional0medium23881
Psychosis, Manic-Depressive0medium252
Psychosomatic Disorders0low10
Psychotic Disorders0medium231
PT-NANBH0low20
PTEN Hamartoma Tumor Syndrome0low10
PTSD0medium217
Puerperal Disorders0low10
Pulmonary Cancer0low30
Pulmonary Cystic Fibrosis0low10
Pulmonary Disease0low10
Pulmonary Disease, Chronic Obstructive0medium11
Pulmonary Diseases0low10
Pulmonary Edema0low10
Pulmonary Edemas0low10
Pulmonary Embolism0low10
Pulmonary Embolisms0low10
Pulmonary Fibrosis, Idiopathic0low10
Pulmonary Inflammation0low10
Pulmonary Neoplasms0low30
Pulmonary Thromboembolism0low10
Pulmonary Thromboembolisms0low10
Pulsatile Tinnitus0low10
Pupillary Miosis0low10
Puppet Children0low10
Purtilo Syndrome0low10
Pustular Psoriasis of Palms and Soles0low20
Pustulosis of Palms and Soles0low20
Pustulosis Palmaris et Plantaris0low20
Pyaemia0low10
Pyemia0low10
Pyohemia0low10
Pyrexia0low30
Quadrantanopia0low10
Quadrantanopsia0low10
Quadriparesis0low30
Quadriplegia0low30
Quantal Squander0low10
Ramsay Hunt Paralysis Syndrome0low50
Rapid Eye Movement Sleep Behavior Disorder0low30
Rapid Fatigue of Gait0low30
Reactive Disorders0medium32
Rebound Insomnia0medium4816
Recrudescence0medium258
Recurrence0medium258
Recurrent Low Back Pain0low10
Refetoff Syndrome0low10
Refetoff-DeWind-DeGroot Syndrome0low10
Reflux, Gastroesophageal0low10
Refractory Depression0medium73
Refractory Pain0low10
Relapse0medium258
Relapsing-Remitting Multiple Sclerosis0low10
REM Behavior Disorder0low30
REM Sleep Behavior Disorder0low30
REM Sleep Deprivation0low20
Remission, Spontaneous0low10
Remitting-Relapsing Multiple Sclerosis0low10
Renal Disease, End-Stage0low30
Renal Failure0low30
Renal Failure, Acute0low10
Renal Failure, Chronic0low30
Renal Failure, End-Stage0low30
Renal Insufficiency0low30
Renal Insufficiency, Acute0low10
Renal Insufficiency, Chronic0medium33
Reperfusion Damage0low10
Reperfusion Injury0low10
Respiration Disorders0low10
Respiratory Depression0low20
Respiratory Failure0low20
Respiratory Insufficiency0low20
Rest Tremor0low20
Resting Tremor0low20
Restless Leg Syndrome0medium111
Restless Legs0medium111
Restless Legs Syndrome0medium111
Restlessness0medium61
Retention Disorders, Cognitive0medium31
Retinal Degeneration0low10
Retro-Ocular Headache0medium73
Rett Disorder0medium31
Rett Syndrome0medium31
Rett's Disorder0medium31
Rett's Syndrome0medium31
Rhabdomyolysis0low60
Rheumatism, Muscular0medium63
Rheumatoid Arthritis0low10
Rhinencephalic Epilepsy0low10
Ricker Syndrome0low10
Right Bundle Branch Block, ST Segment Elevation, and Sudden Death Syndrome0low10
Right Bundle-Branch Block0low10
Right-Sided Heart Failure0low20
Riley-Smith Syndrome0low10
Ringing-Buzzing-Tinnitus0low10
Royal Free Disease0medium11
Runt Disease0low10
Ruvalcaba-Myhre Syndrome0low10
Ruvalcaba-Myhre-Smith Syndrome0low10
Sarcoidosis0low60
Sarcoma, Osteogenic0low10
Sarcopenia0low10
SARS Coronavirus 2 Infection0low40
SARS-CoV-2 Infection0low40
Saturnine Tremor0low20
Scalded Skin Syndrome, Nonstaphylococcal0low20
Schaumann Disease0low60
Schaumann Syndrome0low60
Schaumann's Syndrome0low60
Schizoaffective Disorder0medium231
Schizophrenia, Borderline0low10
Schizophrenia, Latent0low10
Schizophrenia, Paranoid0low10
Schizophrenia, Pseudoneurotic0low10
Schizophrenic Disorders0medium4014
Schizophreniform Catatonia0low10
Schizophreniform Disorders0medium231
Schizotypal Personality Disorder0low10
Schwartz-Bartter Syndrome0low60
Sclerosis, Disseminated0low20
Seborrheic Keratosis0low10
Secondary Biliary Cholangitis0low10
Secondary Biliary Cirrhosis0low10
Secondary Central Sleep Apnea0low20
Secondary Hypersomnia Disorders0medium62
Secondary Hypersomnolence Disorders0medium62
Secondary Infection0low20
Secondary Infections0low20
Secondary Insomnia0medium4816
Seizure0low60
Seizure Disorder0low30
Seizure Disorder, Focal0low10
Seizure Disorder, Grand Mal0low10
Seizure Disorder, Hemimotor0low10
Seizure Disorder, Major Motor0low10
Seizure Disorder, Motor0low10
Seizure Disorder, Partial0low10
Seizure Disorder, Partial, Motor0low10
Seizure Disorder, Tonic Clonic0low10
Seizures0low60
Seizures, Auditory0low60
Seizures, Clonic0low60
Seizures, Convulsive0low60
Seizures, Epileptic0low60
Seizures, Focal0low60
Seizures, Generalized0low60
Seizures, Gustatory0low60
Seizures, Motor0low60
Seizures, Olfactory0low60
Seizures, Sensory0low60
Seizures, Somatosensory0low60
Seizures, Tonic0low60
Seizures, Tonic-Clonic0low60
Seizures, Vertiginous0low60
Seizures, Vestibular0low60
Seizures, Visual0low60
Semantic Dementia0low10
Semantic Memory Disorder0medium31
Senile Dementia, Acute Confusional0medium113
Senile Dementia, Alzheimer Type0medium113
Senile Paranoid Dementia0medium117
Senile Tremor0low20
Sensitivity and Specificity0medium152
Sensorimotor Gait Disorder0low30
Sensory Neglect0low10
Sensory Paroxysms, Sleep0low10
Sepsis0low10
Sepsis Associated Delirium0low10
Sepsis Associated Encephalopathy0low10
Sepsis-Associated Delirium0low10
Sepsis-Associated Encephalopathy0low10
Septic Shock0low10
Septicemia0low10
Serotonin Syndrome0low240
Severe Infantile Myoclonic Epilepsy0low10
Severe Myoclonic Epilepsy Of Infancy0low10
Severe Myoclonic Epilepsy, Infantile0low10
Severe Sepsis0low10
Sex Disorders0medium83
Sexual Arousal Disorder0medium135
Sexual Aversion Disorder0medium135
Sexual Disorders, Physiological0medium83
Sexual Dysfunction, Physiological0medium83
Sexual Dysfunctions, Physiological0medium83
Sexual Dysfunctions, Psychological0medium135
Sezary Syndrome0low10
Sezary's Lymphoma0low10
Sharp Headache0medium73
Shell Shock0low10
Shift-Work Sleep Disorder0medium11
Shock, Endotoxic0low10
Shock, Septic0low10
Shock, Toxic0low10
Short Sleep Phenotype0medium135
Short Sleeper Syndrome0medium135
Shortness of Breath0medium41
SIADH0low60
Sick Headache0medium11
Side Effects of Drugs0medium82
Simple Partial Seizures0low10
Simple Partial Status Epilepticus0low20
Single Seizure0low60
Skin Cancer0low20
Skin Diseases, Papulosquamous0low10
Skin Diseases, Parasitic0low10
Skin Neoplasms0low20
Sleep Apnea Hypopnea Syndrome0medium63
Sleep Apnea Syndrome, Obstructive0medium63
Sleep Apnea Syndromes0medium11
Sleep Apnea, Central0low20
Sleep Apnea, Lethal Central0low20
Sleep Apnea, Mixed0medium11
Sleep Apnea, Mixed Central and Obstructive0medium11
Sleep Apnea, Newborn, Primary0low20
Sleep Debt0low20
Sleep Deprivation0low20
Sleep Disorder, Periodic Movements0medium21
Sleep Disorder, Shift-Work0medium11
Sleep Disorders0medium135
Sleep Disorders, Circadian Rhythm0medium11
Sleep Drunkenness0low10
Sleep Fragmentation0low20
Sleep Hypopnea0medium11
Sleep Initiation Dysfunction0medium4816
Sleep Insufficiency0low20
Sleep Myoclonus Syndrome0medium21
Sleep Terror Disorder0low10
Sleep Terrors0low10
Sleep Wake Disorders0medium135
Sleep-Disordered Breathing0medium11
Sleep-Disordered Breathing, Central0low20
Sleep-Related Abnormal Swallowing Syndrome0low10
Sleep-Related Neurogenic Tachypnea0medium135
Sleep-Related Periodic Leg Movements, Excessive0medium21
Sleep-Wake Cycle Disorder0medium11
Sleep-Wake Cycle Disorders0medium11
Sleep-Wake Disorder, Non-24 Hour0medium11
Sleep-Wake Schedule Disorder0medium11
Sleep-Wake Schedule Disorders0medium11
Sleepiness0low10
Sleeplessness0medium4816
Small Pupil0low10
Small-Cell Lymphoma0low20
Social Anxiety Disorder0low10
Somatic Pain0low10
Somatic Sensation Disorders0medium11
Somatic Symptoms0low10
Somatization Disorder0medium41
Somatoform Disorders0medium41
Somatosensory Discrimination Disorder0low10
Somatosensory Disorders0medium11
Somnolence0low10
Spastic Quadriplegia0low30
Spastic Tetraplegia0low30
Spatial Memory Disorder0medium31
Speech And Language Disorder With Orofacial Dyspraxia0low10
Speech-Language Disorder 10low10
Spinal Cord Compression0low10
Spinal Cord Compression, Extramedullary0low10
Spinning Sensation0medium11
Spontaneous Abortion0low40
Spontaneous Oto-Acoustic Emission Tinnitus0low10
Squamous Cell Carcinoma0low20
Staphylococcal Infections0low10
Staphylococcus aureus Infection0low10
Starvation0low10
Static Tremor0low20
Status Epilepticus0low20
Status Epilepticus, Complex Partial0low20
Status Epilepticus, Electrographic0low20
Status Epilepticus, Generalized0low20
Status Epilepticus, Generalized Convulsive0low20
Status Epilepticus, Grand Mal0low20
Status Epilepticus, Non-Convulsive0low20
Status Epilepticus, Simple Partial0low20
Status Epilepticus, Subclinical0low20
Status Migrainosus0medium11
Steatohepatitis0low10
Steatosis of Liver0low10
Steinert Disease0low10
Steinert Myotonic Dystrophy0low10
Steinert's Disease0low10
Sterility, Female0low20
Sterility, Postpartum0low20
Stevens Johnson Syndrome Toxic Epidermal Necrolysis0low20
Stevens Johnson Syndrome Toxic Epidermal Necrolysis Spectrum0low20
Stevens-Johnson Syndrome0low20
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis0low20
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum0low20
Stillbirth0low10
Stomach Cancer0low20
Stomach Neoplasms0low20
Stomach Ulcer0low20
Streptozocin Diabetes0low20
Streptozotocin Diabetes0low20
Stress Disorder, Post Traumatic0medium217
Stress Disorders, Post-Traumatic0medium217
Stress Disorders, Posttraumatic0medium217
Stress Headache0medium52
Stroke0medium32
Stroke, Acute0medium32
Stroke, Anterior Cerebral Artery0low10
Stromal Dystrophies, Corneal0low10
Stupor0low10
Sub-Fertility, Female0low20
Subacute Delirium0low50
Subclinical Seizure0low10
Subfertility, Female0low20
Substance Abuse0medium92
Substance Addiction0medium92
Substance Dependence0medium92
Substance Use0medium92
Substance Use Disorders0medium92
Substance Withdrawal Syndrome0medium175
Substance-Induced Psychoses0low30
Subwakefullness Syndrome0medium135
Sudden Cardiac Arrest0low10
Sudden Cardiac Death0low10
Sudden Unexplained Death Syndrome0low10
Sudden Unexplained Nocturnal Death Syndrome0low10
Sudden Unexplained Nocturnal Death Syndrome (SUNDS)0low10
Suffering, Physical0medium111
Suffocation0low10
Suicidal Ideation0medium124
Superior Vena Cava Obstruction0low10
Superior Vena Cava Syndrome0low10
Superior Vena Cava Thrombosis0low10
Susceptibility, Disease0low10
Susceptibility, Genetic0low40
Swallowing Disorders0low10
Symptom Cluster0low40
Symptomatic Myoclonic Epilepsy0low10
Symptomatic Tonic-Clonic Epilepsy0low10
Syncopal Episode0low10
Syncopal Vertigo0low10
Syncope0low10
Syncope, Cardiogenic0low10
Syncope, Carotid Sinus0low10
Syncope, Convulsive0low10
Syncope, Deglutitional0low10
Syncope, Effort0low10
Syncope, Hyperventilation0low10
Syncope, Micturition0low10
Syncope, Postural0low10
Syncope, Situational0low10
Syncope, Stokes-Adams0low10
Syncope, Tussive0low10
Syndrome0low40
Syndrome of Continuous Muscle Activity0low10
Syndrome of Inappropriate ADH (SIADH) Secretion0low60
Syndrome, Anterior Cerebral Artery0low10
Syndrome, Obstructive Sleep Apnea0medium63
Syndrome, Sleep Apnea, Obstructive0medium63
Syndrome, Upper Airway Resistance, Sleep Apnea0medium63
Systemic Exertion Intolerance Disease0medium11
Systemic Lupus Erythematosus0low10
Systemic Mast-Cell Disease0low10
T-Cell Lymphoma, Cutaneous0low10
T-Cell Lymphoma, Peripheral0low20
T-Lymphocytopenia, Idiopathic CD4-Positive0low10
T-Lymphocytopenia, Idiopathic CD4+0low10
T-Lymphotropic Virus Type III Infections, Human0medium82
Tachyarrhythmia0low50
Tachycardia0low50
Tachycardia, Ventricular0low10
Tactile Allodynia0low60
Tardive Oral Dyskinesia0low10
Tension Headache0medium52
Tension-Type Headache0medium52
Tension-Vascular Headache0medium52
Tensor Palatini Induced Tinnitus0low10
Tensor Tympani Induced Tinnitus0low10
Teratoid Tumor0low10
Teratoma0low10
Teratoma, Benign0low10
Teratoma, Cystic0low10
Teratoma, Immature0low10
Teratoma, Malignant0low10
Teratoma, Mature0low10
Tetraplegia0low30
Thalamic Diseases0low10
Thalamic Syndrome0low10
Thalassemia Intermedia0low10
Thalassemia Major0low10
Thalassemia Major (beta-Thalassemia Major)0low10
Thalassemia Minor0low10
Thalassemia Minor (beta-Thalassemia Minor)0low10
Thalassemia, beta Type0low10
Therapy-Resistant Depression0medium73
Thermal Allodynia0low60
Thermal Sensation Disorders0medium11
Thesaurismosis0medium11
Thinness0low20
Thoracic Neoplasms0low10
Throbbing Headache0medium73
Thrombocytopenia0low10
Thromboembolism, Pulmonary0low10
Thromboembolisms, Pulmonary0low10
Thrombopenia0low10
Thyroid Hormone Resistance0low10
Thyroid Hormone Resistance Syndrome0low10
Tic Disorder, Chronic Motor or Vocal0low10
Tic Disorder, Post-Traumatic0low10
Tic Disorder, Transient0low10
Tic Disorders0low10
Tic Disorders, Childhood0low10
Tic Disorders, Motor0low10
Tic Disorders, Vocal0low10
Tinnitus0low10
Tinnitus of Vascular Origin0low10
Tinnitus, Clicking0low10
Tinnitus, Leudet0low10
Tinnitus, Leudet's0low10
Tinnitus, Noise Induced0low10
Tinnitus, Objective0low10
Tinnitus, Spontaneous Oto-Acoustic Emission0low10
Tinnitus, Subjective0low10
Tinnitus, Tensor Palatini Induced0low10
Tinnitus, Tensor Tympani Induced0low10
Tissue Pain0low10
Todd Paralysis0low10
Todd's Paralysis0low10
Tongue Diseases0low10
Tonic Clonic Convulsions0low10
Tonic Clonic Seizure0low60
Tonic Seizure0low60
Tonic Seizures0low60
Tonic-Clonic Convulsion Disorder0low10
Tonic-Clonic Convulsion Syndrome0low10
Tonic-Clonic Seizure0low60
Tonic-Clonic Seizure Disorder0low10
Tonic-Clonic Seizure Syndrome0low10
Tonic-Clonic Seizures0low60
Torsade de Pointes0low40
Torsades de Pointes0low40
Toruloma0low10
Toxemia Of Pregnancy0low10
Toxemias, Pregnancy0low10
Toxic Epidermal Necrolysis0low20
Toxic Epidermal Necrolysis Stevens Johnson Syndrome0low20
Toxic Epidermal Necrolysis Stevens Johnson Syndrome Spectrum0low20
Toxic Epidermal Necrolysis Stevens-Johnson Syndrome0low20
Toxic Epidermal Necrolysis Stevens-Johnson Syndrome Spectrum0low20
Toxic Hepatitis0low70
Toxic Psychoses0low30
Toxic Shock0low10
Toxic Shock Syndrome0low10
Toxicity, Drug0medium82
Transient Insomnia0medium4816
Transient Situational Disturbance0medium32
Transient Tic Disorder0low10
Treatment Resistant Depression0medium73
Tremor0low20
Tremor, Limb0low20
Tremor, Muscle0low20
Tremor, Neonatal0low20
Tremor, Nerve0low20
Tremor, Perioral0low20
Tremor, Rubral0low10
Tremor, Semirhythmic0low20
Triple Negative Breast Cancer0low10
Triple Negative Breast Neoplasms0low10
Triple-Negative Breast Cancer0low10
Triple-Negative Breast Neoplasm0low10
Tropical Eosinophilia0low10
Tumor Virus Infections0low10
Tumors0medium279
Tumors, Breast0medium11
Type 1 Diabetes0low20
Type 1 Diabetes Mellitus0low20
Type 2 Diabetes0medium21
Type 2 Diabetes Mellitus0medium21
Ulcerative Colitis0low20
Umbilical Hernia0low10
Uncinate Seizures0low10
Unconscious State0low20
Unconsciousness0low20
Undernutrition0low10
Underweight0low20
Unilateral Headache0medium73
Unipolar Depression0medium24962
Upper Airway Resistance Sleep Apnea Syndrome0medium63
Urinary Incontinence0low10
Urinary Incontinence, Stress0low10
Urinary Retention0low50
Urinary Stress Incontinence0low10
Urticaria0low20
Usual Interstitial Pneumonia0low10
Vacuolar Cardiomyopathy and Myopathy, X-linked0low10
Vanishing White Matter Disease0low10
Vanishing White Matter Leukodystrophy0low10
Vascular Accident, Brain0medium32
Vascular Diseases, Intracranial0low10
Vascular Hypotension0low10
Vascular Origin Tinnitus0low10
Ventilatory Depression0low20
Ventricular Fibrillation0low10
Ventricular Pre-Excitation with Arrhythmia0low10
Ventricular Tachyarrhythmias0low10
Ventricular Tachycardia0low10
Versive Seizures0low10
Vertebrogenic Pain Syndrome0low40
Vertex Headache0medium73
Vertigo0medium11
Vertigo, Brain Stem0medium11
Vertigo, Brainstem0medium11
Vertigo, Central Nervous System Origin0medium11
Vertigo, Central Origin0medium11
Vertigo, Constant0medium11
Vertigo, Essential0medium11
Vertigo, Intermittant0medium11
Vertigo, Paroxysmal0medium11
Vertigo, Peripheral0medium11
Vertigo, Subjective0medium11
Vesication0low10
Viral Diseases0low10
Viral Infections0low10
Viremia0low10
Virus Diseases0low10
Virus Infections0low10
Visceral Steatosis0low10
Vision Disability0medium21
Vision Disorders0medium21
Visual Disorders0medium21
Visual Impairment0medium21
Vocal Tic Disorders0low10
Vomiting0medium142
Vomiting, Postoperative0medium52
War Neuroses0low10
War Neurosis0low10
Wasting Disease0low10
Wasting Syndrome0low10
Weight Gain0medium3011
Weight Reduction0medium93
Wet Lung0low10
Whiplash Injuries0low10
White Matter Diseases0low10
Widespread Chronic Pain0low30
Wilhelmsen-Lynch Disease0low10
Willis Ekbom Disease0medium111
Willis Ekbom Syndrome0medium111
Willis-Ekbom Disease0medium111
Willis-Ekbom Syndrome0medium111
Withdrawal Symptoms0medium175
Wittmaack Ekbom Syndrome0medium111
Wittmaack-Ekbom Syndrome0medium111
Wolf-Parkinson-White Syndrome0low10
Wolff-Parkinson-White Syndrome0low10
WPW Syndrome0low10
X-Linked Lymphoproliferative Disease0low10
X-Linked Lymphoproliferative Disorder0low10
X-Linked Lymphoproliferative Syndrome0low10
X-Linked Vacuolar Cardiomyopathy and Myopathy0low10
Xeroderma0low10
Xerostomia0medium43
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (51)

ArticleYear
The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis.
Systematic reviews, 03-30, Volume: 12, Issue: 1		2023
A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation.
Neuropsychopharmacology reports, Volume: 42, Issue: 3		2022
What is the effectiveness and safety of mirtazapine versus escitalopram in alleviating cancer-associated poly-symptomatology (the MIR-P study)? A mixed-method randomized controlled trial protocol.
BMC palliative care, May-23, Volume: 21, Issue: 1		2022
Combined toxicity and toxicity persistence of antidepressants citalopram and mirtazapine to zooplankton Daphnia magna.
Environmental science and pollution research international, Volume: 29, Issue: 44		2022
Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort.
Rheumatology international, Volume: 42, Issue: 9		2022
Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Volume: 30, Issue: 7		2022
Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study.
Acta psychiatrica Scandinavica, Volume: 145, Issue: 6		2022
Ethanol potentiates mirtazapine-induced cardiotoxicity by inducing dysfunctional autophagy via HMGB1-dependent Akt/mTOR signaling pathway.
Toxicology letters, Apr-01, Volume: 358		2022
Toxic effect of antidepressants on male reproductive system cells: evaluation of possible fertility reduction mechanism.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, Volume: 72, Issue: 3		2021
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
International journal of molecular sciences, Nov-01, Volume: 22, Issue: 21		2021
Difference in patterns of prescribing antidepressants known for their weight-modulating and cardiovascular side effects for patients with obesity compared to patients with normal weight.
Journal of affective disorders, 12-01, Volume: 295		2021
Nephroprotective effects of febuxostat and/or mirtazapine against gentamicin-induced nephrotoxicity through modulation of ERK 1/2, NF-κB and MCP1.
Expert review of clinical pharmacology, Volume: 14, Issue: 8		2021
Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 09-15, Volume: 16, Issue: 9		2020
Combining big data search analytics and the FDA Adverse Event Reporting System database to detect a potential safety signal of mirtazapine abuse.
Health informatics journal, Volume: 26, Issue: 3		2020
Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
Canadian journal of physiology and pharmacology, Volume: 97, Issue: 8		2019
Short-Term Safety of Paroxetine Plus Low-Dose Mirtazapine During Lactation.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, Volume: 14, Issue: 2		2019
Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.
The Annals of pharmacotherapy, Volume: 53, Issue: 3		2019
Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011).
Journal of feline medicine and surgery, Volume: 18, Issue: 11		2016
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
Sleep medicine, Volume: 16, Issue: 7		2015
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial.
Sleep medicine, Volume: 16, Issue: 7		2015
The in vitro genotoxic and cytotoxic effects of remeron on human peripheral blood lymphocytes.
Drug and chemical toxicology, Volume: 38, Issue: 3		2015
Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.
South Dakota medicine : the journal of the South Dakota State Medical Association, Volume: 67, Issue: 4		2014
Mirtazapine overdose is unlikely to cause major toxicity.
Clinical toxicology (Philadelphia, Pa.), Volume: 52, Issue: 1		2014
Biochemical and histologic study of lethal cisplatin nephrotoxicity prevention by mirtazapine.
Pharmacological reports : PR, Volume: 64, Issue: 3		2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, Volume: 7, Issue: 12		2011
Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test.
Neuro endocrinology letters, Volume: 31 Suppl 2		2010
Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
CNS drugs, Volume: 24, Issue: 1		2010
Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.
The Journal of clinical psychiatry, Volume: 70, Issue: 3		2009
Restless legs syndrome as side effect of second generation antidepressants.
Journal of psychiatric research, Volume: 43, Issue: 1		2008
[Applications and safety of modern antidepressants in patients with liver diseases].
Wiadomosci lekarskie (Warsaw, Poland : 1960), Volume: 60, Issue: 1-2		2007
The antidepressant mirtazapine-induced cytosolic Ca2+ elevation and cytotoxicity in human osteosarcoma cells.
The Chinese journal of physiology, Dec-31, Volume: 49, Issue: 6		2006
Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit.
Clinical toxicology (Philadelphia, Pa.), Volume: 45, Issue: 1		2007
Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Clinical pharmacology and therapeutics, Volume: 81, Issue: 5		2007
Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients.
Neuropsychobiology, Volume: 53, Issue: 2		2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Current drug discovery technologies, Volume: 1, Issue: 4		2004
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Human psychopharmacology, Volume: 21, Issue: 3		2006
Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice.
Pharmacopsychiatry, Volume: 38, Issue: 3		2005
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Archives of general psychiatry, Volume: 61, Issue: 11		2004
Comparative toxicity of citalopram and the newer antidepressants after overdose.
Journal of toxicology. Clinical toxicology, Volume: 42, Issue: 1		2004
Tolerability and safety aspects of mirtazapine.
Human psychopharmacology, Volume: 17 Suppl 1		2002
Mirtazapine-induced hepatotoxicity.
Journal of clinical gastroenterology, Volume: 35, Issue: 3		2002
Relative safety of mirtazapine overdose.
Veterinary and human toxicology, Volume: 43, Issue: 6		2001
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.
The Journal of clinical psychiatry, Volume: 62, Issue: 6		2001
Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Journal of affective disorders, Volume: 51, Issue: 3		1998
Safety of mirtazapine in overdose.
The Journal of clinical psychiatry, Volume: 59, Issue: 5		1998
Mirtazapine: pharmacology in relation to adverse effects.
Acta psychiatrica Scandinavica. Supplementum, Volume: 391		1997
Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression.
Acta psychiatrica Scandinavica. Supplementum, Volume: 391		1997
Safety and tolerability of the new antidepressants.
The Journal of clinical psychiatry, Volume: 58 Suppl 6		1997
Safety of mirtazapine: a review.
International clinical psychopharmacology, Volume: 10 Suppl 4		1995
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (16)

ArticleYear
The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex.
Pharmacological reports : PR, Volume: 70, Issue: 5		2018
Comparative Evaluation of Partial α2 -Adrenoceptor Agonist and Pure α2 -Adrenoceptor Antagonist on the Behavioural Symptoms of Withdrawal after Chronic Alcohol Administration in Mice.
Basic & clinical pharmacology & toxicology, Volume: 119, Issue: 2		2016
Chronic administration of duloxetine and mirtazapine downregulates proapoptotic proteins and upregulates neurotrophin gene expression in the hippocampus and cerebral cortex of mice.
Journal of psychiatric research, Volume: 47, Issue: 6		2013
Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats.
Behavioural brain research, Nov-20, Volume: 225, Issue: 1		2011
Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions.
Neuropharmacology, Volume: 60, Issue: 4		2011
Influence of mirtazapine on the hypotensive activity of enalapril and propranolol in spontaneously hypertensive rats.
Basic & clinical pharmacology & toxicology, Volume: 103, Issue: 5		2008
Chronic administration of the SSRI fluvoxamine markedly and selectively reduces the sensitivity of cortical serotonergic neurons to footshock stress.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 15, Issue: 3		2005
Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects.
Human psychopharmacology, Volume: 18, Issue: 2		2003
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, Volume: 14, Issue: 3		2002
Prevention of the stress-induced increase in the concentration of neuroactive steroids in rat brain by long-term administration of mirtazapine but not of fluoxetine.
Journal of psychopharmacology (Oxford, England), Volume: 16, Issue: 2		2002
Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats.
Synapse (New York, N.Y.), Volume: 43, Issue: 1		2002
A review of the pharmacological and clinical profile of mirtazapine.
CNS drug reviews,Fall, Volume: 7, Issue: 3		2001
Prevention of the stress-induced increase in frontal cortical dopamine efflux of freely moving rats by long-term treatment with antidepressant drugs.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 11, Issue: 5		2001
Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.
International clinical psychopharmacology, Volume: 10 Suppl 4		1995
Effect of chronic administration of the 6-aza analogue of mianserin (Org. 3770) and its enantiomers on behaviour and changes in noradrenaline metabolism of olfactory-bulbectomized rats in the "open field" apparatus.
Neuropharmacology, Volume: 25, Issue: 3		1986
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (20)

ArticleYear
Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies.
Clinical pharmacology and therapeutics, Volume: 111, Issue: 6		2022
In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease.
Journal of veterinary internal medicine, Volume: 32, Issue: 6		2018
Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Journal of affective disorders, Volume: 227		2018
Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
Biochemical pharmacology, Jan-01, Volume: 93, Issue: 1		2015
Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression.
Journal of clinical psychopharmacology, Volume: 32, Issue: 5		2012
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
Drug metabolism and disposition: the biological fate of chemicals, Volume: 40, Issue: 2		2012
Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study.
Veterinary journal (London, England : 1997), Volume: 192, Issue: 2		2012
Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats.
Journal of veterinary pharmacology and therapeutics, Volume: 34, Issue: 4		2011
Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, Aug-13, Volume: 52, Issue: 15		2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, Volume: 36, Issue: 7		2008
Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Clinical pharmacology and therapeutics, Volume: 81, Issue: 5		2007
Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study.
Therapeutic drug monitoring, Volume: 27, Issue: 4		2005
Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.
Journal of clinical psychopharmacology, Volume: 24, Issue: 6		2004
Population pharmacokinetic analysis of mirtazapine.
European journal of clinical pharmacology, Volume: 60, Issue: 7		2004
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Journal of medicinal chemistry, Feb-26, Volume: 47, Issue: 5		2004
Pharmacokinetics of mirtazapine and lithium in healthy male subjects.
Journal of psychopharmacology (Oxford, England), Volume: 14, Issue: 2		2000
Clinical pharmacokinetics of mirtazapine.
Clinical pharmacokinetics, Volume: 38, Issue: 6		2000
Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations.
Pharmaceutical research, Volume: 14, Issue: 1		1997
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Onset of Action (3)

ArticleYear
[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].
L'Encephale, Volume: 34, Issue: 1		2008
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Journal of clinical psychopharmacology, Volume: 23, Issue: 4		2003
Onset of action of antidepressants: results of different analyses.
Human psychopharmacology, Volume: 17 Suppl 1		2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (12)

ArticleYear
Design of mirtazapine solid dispersion with different carriers' systems: optimization, in vitro evaluation, and bioavailability assessment.
Drug delivery and translational research, Volume: 13, Issue: 9		2023
Optimization of mirtazapine loaded into mesoporous silica nanostructures via Box-Behnken design:
Drug delivery, Volume: 29, Issue: 1		2022
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
A fast, sensitive and simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. Application to a comparative bioavailability study.
Biomedical chromatography : BMC, Volume: 26, Issue: 11		2012
Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation.
Archives of pharmacal research, Volume: 34, Issue: 11		2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, Feb-11, Volume: 53, Issue: 3		2010
Cortisol metabolism in depressed patients and healthy controls.
Neuroendocrinology, Volume: 90, Issue: 3		2009
QSAR model for drug human oral bioavailability.
Journal of medicinal chemistry, Jun-29, Volume: 43, Issue: 13		2000
Clinical pharmacokinetics of mirtazapine.
Clinical pharmacokinetics, Volume: 38, Issue: 6		2000
Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Journal of affective disorders, Volume: 51, Issue: 3		1998
The clinical relevance of preclinical data: mirtazapine, a model compound.
Journal of clinical psychopharmacology, Volume: 17 Suppl 1		1997
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (94)

ArticleYear
Estradiol enhances the mirtazapine effects on the expression of cocaine-induced locomotor sensitization in female rats.
Behavioural pharmacology, 09-01, Volume: 34, Issue: 6		2023
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
International journal of molecular sciences, Jul-06, Volume: 24, Issue: 13		2023
Progressive multifocal leukoencephalopathy 10 years following transplant: 5HT receptor antagonism as an adjunct to immune reconstitution.
BMJ case reports, Dec-13, Volume: 15, Issue: 12		2022
Mirtazapine attenuates the cocaine-induced locomotor sensitization in male and female C57BL/6J and BALBA/cJ mouse.
Pharmacology, biochemistry, and behavior, Volume: 222		2023
Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial.
International clinical psychopharmacology, 01-01, Volume: 38, Issue: 1		2023
Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence.
International clinical psychopharmacology, 03-01, Volume: 37, Issue: 2		2022
Mirtazapine-induced decrease in cocaine sensitization is enhanced by environmental enrichment in rats.
Pharmacology, biochemistry, and behavior, Volume: 208		2021
Mirtazapine reduces the expression of cocaine-induced locomotor sensitization in male and female Wistar rats.
Hormones and behavior, Volume: 125		2020
No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review.
Acta psychiatrica Scandinavica, Volume: 141, Issue: 5		2020
Methods for constructing treatment episodes and impact on exposure-outcome associations.
European journal of clinical pharmacology, Volume: 76, Issue: 2		2020
Antidepressants Reduced Risk of Mortality in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan.
The Journal of clinical endocrinology and metabolism, 10-01, Volume: 104, Issue: 10		2019
Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
The lancet. Psychiatry, Volume: 6, Issue: 7		2019
Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal.
Journal of psychopharmacology (Oxford, England), Volume: 33, Issue: 5		2019
Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2.
International clinical psychopharmacology, Volume: 34, Issue: 2		2019
Other Antidepressants.
Handbook of experimental pharmacology, Volume: 250		2019
The role of mirtazapine in patients with fibromyalgia: a systematic review.
Rheumatology international, Volume: 38, Issue: 12		2018
Mirtazapine attenuates nicotine-seeking behavior in rats.
Journal of psychopharmacology (Oxford, England), Volume: 32, Issue: 9		2018
Synergistic interactions between mirtazapine and prazosin prevent the induction and expression of behavioral sensitization to cocaine in rats.
Physiology & behavior, Oct-15, Volume: 180		2017
Dose- and time-dependent effects of mirtazapine on the expression of cocaine-induced behavioral sensitization in rats.
Psychiatry research, Volume: 254		2017
Mirtazapine attenuates cocaine seeking in rats.
Journal of psychiatric research, Volume: 92		2017
Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats.
Progress in neuro-psychopharmacology & biological psychiatry, Jul-04, Volume: 68		2016
Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan.
Trials, Oct-14, Volume: 16		2015
Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters.
The American journal of psychiatry, Volume: 172, Issue: 10		2015
Mirtazapine-induced acute angle closure.
Indian journal of ophthalmology, Volume: 63, Issue: 6		2015
Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression.
The Journal of clinical psychiatry, Volume: 76, Issue: 4		2015
Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients.
Pharmacopsychiatry, Volume: 47, Issue: 6		2014
Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats.
Journal of oral & facial pain and headache,Winter, Volume: 28, Issue: 1		2014
Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients?
Pharmacoepidemiology and drug safety, Volume: 22, Issue: 12		2013
Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers.
Human psychopharmacology, Volume: 28, Issue: 3		2013
Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, Mar-15, Volume: 69, Issue: 6		2012
Adjunct mirtazapine for negative symptoms of schizophrenia.
Pharmacotherapy, Volume: 31, Issue: 10		2011
A fatal case of simultaneous ingestion of mirtazapine, escitalopram, and valproic acid.
Journal of analytical toxicology, Volume: 35, Issue: 7		2011
Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol.
Trials, May-11, Volume: 12		2011
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
International journal of clinical practice, Volume: 65, Issue: 3		2011
Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype.
Psychopharmacology, Volume: 215, Issue: 2		2011
Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team.
Psychiatria Danubina, Volume: 22 Suppl 1		2010
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Journal of clinical psychopharmacology, Volume: 30, Issue: 4		2010
Prescribing a sedative antidepressant for patients at work or on sick leave under conditions of routine care.
Pharmacopsychiatry, Volume: 43, Issue: 1		2010
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
Journal of neural transmission (Vienna, Austria : 1996), Volume: 116, Issue: 7		2009
Antidepressant switching among adherent patients treated for depression.
Psychiatric services (Washington, D.C.), Volume: 60, Issue: 5		2009
[Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center].
Gan to kagaku ryoho. Cancer & chemotherapy, Volume: 36, Issue: 4		2009
Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 19, Issue: 7		2009
Racemic intrathecal mirtazapine but not its enantiomers acts anti-neuropathic after chronic constriction injury in rats.
Brain research bulletin, Apr-06, Volume: 79, Issue: 1		2009
Impact of the WHO depression guideline on patient care by psychiatrists: a randomized controlled trial.
European psychiatry : the journal of the Association of European Psychiatrists, Volume: 23, Issue: 6		2008
Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors.
Human psychopharmacology, Volume: 23, Issue: 4		2008
Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain.
Neuroscience letters, Mar-05, Volume: 433, Issue: 1		2008
A case of mirtazapine-induced spontaneous orgasms in a female patient.
Journal of psychopharmacology (Oxford, England), Volume: 23, Issue: 1		2009
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Human psychopharmacology, Volume: 21, Issue: 3		2006
Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.
Journal of clinical psychopharmacology, Volume: 26, Issue: 1		2006
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?
Psychopharmacology, Volume: 181, Issue: 3		2005
Tissue distribution of mirtazapine and desmethylmirtazapine in a case of mirtazapine poisoning.
Forensic science international, Jan-27, Volume: 156, Issue: 2-3		2006
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Archives of general psychiatry, Volume: 61, Issue: 11		2004
Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial.
Human psychopharmacology, Volume: 19, Issue: 7		2004
Population pharmacokinetic analysis of mirtazapine.
European journal of clinical pharmacology, Volume: 60, Issue: 7		2004
Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection.
Therapeutic drug monitoring, Volume: 26, Issue: 3		2004
Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants.
Epilepsy & behavior : E&B, Volume: 4, Issue: 6		2003
Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
Current medical research and opinion, Volume: 19, Issue: 8		2003
Benefits of different drug formulations in psychopharmacology.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 13 Suppl 3		2003
Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine.
Journal of clinical psychopharmacology, Volume: 23, Issue: 5		2003
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients.
Biological psychiatry, Oct-01, Volume: 54, Issue: 7		2003
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Journal of clinical psychopharmacology, Volume: 23, Issue: 4		2003
Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.
Expert review of anticancer therapy, Volume: 2, Issue: 4		2002
Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'?
International clinical psychopharmacology, Volume: 17, Issue: 6		2002
The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms.
Brain research bulletin, Sep-30, Volume: 58, Issue: 6		2002
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
The Journal of clinical psychiatry, Volume: 63, Issue: 9		2002
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Journal of pain and symptom management, Volume: 23, Issue: 5		2002
First report of mirtazapine-induced arthralgia.
European psychiatry : the journal of the Association of European Psychiatrists, Volume: 16, Issue: 8		2001
Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold.
The Annals of pharmacotherapy, Volume: 35, Issue: 10		2001
A review of the pharmacological and clinical profile of mirtazapine.
CNS drug reviews,Fall, Volume: 7, Issue: 3		2001
Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens.
Journal of clinical psychopharmacology, Volume: 20, Issue: 5		2000
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 10, Issue: 1		1999
Depressed in-patients respond differently to imipramine and mirtazapine.
Pharmacopsychiatry, Volume: 32, Issue: 3		1999
Care of the sexually active depressed patient.
The Journal of clinical psychiatry, Volume: 60 Suppl 17		1999
Sexual functioning in depressed outpatients taking mirtazapine.
Depression and anxiety, Volume: 9, Issue: 4		1999
Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Journal of affective disorders, Volume: 51, Issue: 3		1998
Suicide attempts with mirtazapine overdose without complications.
Biological psychiatry, Nov-01, Volume: 44, Issue: 9		1998
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
The Journal of clinical psychiatry, Volume: 59, Issue: 6		1998
Safety of mirtazapine in overdose.
The Journal of clinical psychiatry, Volume: 59, Issue: 5		1998
Mirtazapine, an antidepressant.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, Jan-01, Volume: 55, Issue: 1		1998
A risk-benefit assessment of mirtazapine in the treatment of depression.
Drug safety, Volume: 17, Issue: 4		1997
Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations.
Pharmaceutical research, Volume: 14, Issue: 1		1997
Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission.
Naunyn-Schmiedeberg's archives of pharmacology, Volume: 355, Issue: 1		1997
A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 5, Issue: 4		1995
A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients.
Psychopharmacology, Volume: 127, Issue: 3		1996
Double-blind study of mirtazapine and placebo in hospitalized patients with major depression.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 4, Issue: 2		1994
Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.
International clinical psychopharmacology, Volume: 10, Issue: 1		1995
Pharmaco-EEG study of 6-azamianserin (ORG 3770): dissociation of EEG and pharmacologic predictors of antidepressant activity.
Psychopharmacology, Volume: 78, Issue: 1		1982
A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery.
Acta psychiatrica Scandinavica, Volume: 71, Issue: 4		1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (6)

ArticleYear
A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities.
Burns : journal of the International Society for Burn Injuries, Volume: 46, Issue: 5		2020
Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone.
Journal of affective disorders, Volume: 219		2017
Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.
South Dakota medicine : the journal of the South Dakota State Medical Association, Volume: 67, Issue: 4		2014
Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.
European journal of clinical pharmacology, Volume: 56, Issue: 5		2000
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Volume: 10, Issue: 1		1999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]